MILLER CHRISTOPHER PAUL (US)
DARWISH IHAB S (US)
WHAT IS CLAIMED IS: 1. A compound of Formula I: or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein: A1 is CH or N; A2 is CH or N; A3 is N or CR3; A4 is C and is a double bond, or A4 is CH and is a single bond, or A4 is N and is a single bond; L is a covalent bond or a linking moiety; R1 is a nuclear receptor-targeting epitope; R2 is hydrogen, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, or C1-6 alkoxy; R3 is hydrogen; or R2 and R3 together with the atoms to which they are attached form a 5- or 6-membered heterocyclyl or 5- or 6-membered heteroaryl; R4 is hydrogen, C6-12 aryl, or 5- to 12-membered heteroaryl, wherein the C6-12 aryl or 5- to 12- membered heteroaryl is optionally substituted with one or more R6; R5 is hydrogen, halo, or C1-6 alkyl; each R6 is independently halo, cyano, nitro, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -OR10, -OC(O)R10, -C(O)OR10, -SR10, -NR10R11, -NR10C(O)R11, -C(O)NR10R11, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl; and each R10 and R11 is independently hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, or 5- to 12-membered heteroaryl, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxyl, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl, wherein any hydrogen atom of the moiety in the brackets is replaced with attachment to L-R1. 2. The compound of claim 1, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the compound is not a compound selected from the compounds in Table 1A, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof. 3. The compound of claim 1 or 2, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A1 is CH. 4. The compound of claim 1 or 2, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A1 is N. 5. The compound of any one of claims 1-4, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A2 is CH. 6. The compound of any one of claims 1-4, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A2 is N. 7. The compound of any one of claims 1-6, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A3 is CR3 and R3 is hydrogen. 8. The compound of any one of claims 1-6, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A3 is N. 9. The compound of any one of claims 1-8, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A4 is C. 10. The compound of any one of claims 1-8, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A4 is CH. 11. The compound of any one of claims 1-8, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein A4 is N. 12. The compound of any one of claims 1-11, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R2 is C1-6 alkyl. 13. The compound of any one of claims 1-11, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R2 is methyl. 14. The compound of any one of claims 1-11, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R2 is ethyl. 15. The compound of any one of claims 1-14, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R4 is hydrogen. 16. The compound of any one of claims 1-15, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R5 is hydrogen. 17. The compound of any one of claims 1-15, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R5 is halo. 18. The compound of any one of claims 1-15, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R5 is fluoro. 19. The compound of any one of claims 1-18, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the compound if of Formula IA: . 20. The compound of any one of claims 1-18, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the compound if of Formula IB: . 21. The compound of any one of claims 1-18, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the compound if of Formula IC: 22. The compound of any one of claims 1-18, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the compound is of Formula ID: . 23. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 binds to an estrogen receptor. 24. The compound of any one of claims 1-23, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 binds to a glucocorticoid receptor. 25. The compound of any one of claims 1-24, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 binds to a progesterone receptor 26. The compound of any one of claims 1-25, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 binds to an androgen receptor. 27. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is of Formula IIA: wherein: the wavy bond represents the point of connection to L; R30 is hydrogen, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one or more R100 as valency permits; R40 is hydrogen, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one or more R100 as valency permits; each of R50 and R51 is independently halo, cyano, nitro, -OR170, -SR170, -NR170R180, C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl; wherein each C1-12 alkyl, C1-12 haloalkyl, C2-12 alkenyl, or C2-12 alkynyl is independently optionally substituted with one or more halo, hydroxyl or amino as valency permits; each R100 is independently oxo, halo, cyano, nitro, -OR170, -SR170, -SF5, -NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R170, -C(=O)OR170, -OC(=O)OR170, -OC(=O)R170, -C(=O)NR170R180, -OC(=O)NR170R180, -NR170C(=O)NR170R180, -S(=O)1-2R170, -S(=O)1-2NR170R180, -NR170S(=O)1-2R180, -NR170S(=O)1-2NR170R180, -NR170C(=O)R180, or -NR170C(=O)OR180, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl, as valency permits; and each of R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits, or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino. 28. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 29. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is of Formula IIB: , wherein: the wavy bond represents the point of connection to L; R60 is hydrogen, -OR101, -NR101R102, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R101, -C(=O)OR101, -OC(=O)R101, -OC(=O)NR101R102, -C(=O)NR101R102, -NR101C(=O)R102, -NR101C(=O)OR102, each optionally independently substituted with one or more R100 as valency permits; R80 is hydrogen, -OR101, -NR101R102, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R101, -C(=O)OR101, -OC(=O)R101, -OC(=O)NR101R102, -C(=O)NR101R102, -NR101C(=O)R102, -NR101C(=O)OR102, each optionally independently substituted with one or more R100 as valency permits; R81 is hydrogen, -OR101, -NR101R102, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R101, -C(=O)OR101, -OC(=O)R101, -OC(=O)NR101R102, -C(=O)NR101R102, -NR101C(=O)R102, -NR101C(=O)OR102, each optionally independently substituted with one or more R100 as valency permits; or R80 and R81 are taken together with the atom to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino; R82 is hydrogen, -OR101, -NR101R102, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R101, -C(=O)OR101, -OC(=O)R101, -OC(=O)NR101R102, -C(=O)NR101R102, -NR101C(=O)R102, -NR101C(=O)OR102, each optionally independently substituted with one or more R100 as valency permits; each of R101 and R102 is independently hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, or 5- to 12-membered heteroaryl, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxyl, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl, as valency permits; each R100 is independently oxo, halo, cyano, nitro, -OR170, -SR170, -SF5, -NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, -C(=O)R170, -C(=O)OR170, -OC(=O)OR170, -OC(=O)R170, -C(=O)NR170R180, -OC(=O)NR170R180, -NR170C(=O)NR170R180, -S(=O)1-2R170, -S(=O)1-2NR170R180, -NR170S(=O)1-2R180, -NR170S(=O)1-2NR170R180, -NR170C(=O)R180, or -NR170C(=O)OR180, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl, as valency permits; and each of R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits, or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino. 30. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 31. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 32. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 33. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is of Formula IIC: wherein: W is O, S, or NH; each is independently a double bond or a single bond; each of R61 and R62 is independently hydrogen, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl, wherein each C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, or C3-12 cycloalkyl is optionally independently substituted with one or more R100 as valency permits; each R100 is independently oxo, halo, cyano, nitro, -OR170, -SR170, -SF5, -NR170R180, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, 5- to 12-membered heteroaryl, - -NR170C(=O -NR170C(=O)R180, or -NR170C(=O)OR180, each independently optionally substituted with one or more substituents selected from the group consisting of halo, cyano, nitro, hydroxyl, amino, C1-12 alkoxy, C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, 5- to 12-membererd heterocyclyl, C6-12 aryl, and 5- to 12-membered heteroaryl, as valency permits; and each of R170 and R180 is independently hydrogen or C1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits, or R170 and R180 are taken together with the atoms to which they are attached to form heterocyclyl optionally substituted by halo or C1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino. 34. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 35. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is of Formula IID: wherein: the wavy bond refers to the point of connection to L; a is attached to ring a and bond b is attached to ring b; Ra and Rb are each independently -CH3 or -CH2CH3; or Ra and Rb together with the atom to which they are attached form a C3-5 cycloalkyl, oxiranyl, oxetanyl, or tetrahydrofuranyl; A and A' are each independently O or S; E, E1, E2, and E3 are each independently CRc or N, and each Rc is independently hydrogen, halo, CN, or methyl; E4 is CF, CH or N; Q1 is a bond, CH2, C=O, or (C=O)NH; Q2 is NH, O, S, CH2, NH(C=O), C(=O)NH, or C=O; R44, R45 and R46 are each independently hydrogen, CN, or C1-2 alkyl; t is 0, 1, 2, 3 or 4; each of Re and Rf is independently halo, cyano, C1-4 alkyl, or C1-4 haloalkyl; R41 is halo, CN, or NO2; R42 is halo, CH3, CH2F, CHF2, or CF3; or R41 and R42 together form a wherein the broken lines indicate bonds to ring a; R43 is hydrogen, halo, C1-2 alkyl, C2 alkenyl, NO2, CF3; or R42 and R43 together form a or , wherein each is a single or double bond, and wherein the broken lines indicate bonds to ring a. 36. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 37. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 38. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 39. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 40. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 41. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is . 42. The compound of any one of claims 1-22, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein R1 is derived from progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, testosterone, 19- nortestosterone, progesterone, andarine, cortisol, prednisone, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB- 4124, Proellex, Progenta), or an analog thereof. 43. The compound of any one of claims 1-42, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein L is of formula: -(La)q-, wherein: each La is independently -NR110-, -O-, -S(O)0-2-, -NR110C(O)-, -C(O)NR110-, -NR110C(O)NR110-, -NR110S(O)2-, -S(O)2NR110-, -NR110S(O)2NR110-, -CR120=N-NR110-, -NR110-N=CR120-, -C(O)-, -OC(O)-, -OC(O)O-, -C(O)O-, C1-12 alkylene, C2-12 alkenylene, C2-12 alkynylene, C6-12 arylene, C3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, and 5- to 12- membered heterocyclyl; each R110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and q is an integer from 0 to 20. 44. The compound of any one of claims 1-42, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein L is of the formula: -Y10-(CHR130)n’-Y20-(CHR140)n''-Y30-(CHR150)m''-Y40- wherein: each of Y10, Y20, Y30, and Y40 are independently a bond, - -, -O-, -S(O)0-2-, -NR110C(O)-, -C(O)NR110-, -NR110C(O)NR110-, -NR110S(O)2-, -S(O)2NR110-, -NR110S(O)2NR110-, -CR120=N-NR110-, -NR110-N=CR120-, -C(O)-, -OC(O)-, -OC(O)O-, -(CH2CH2O)1-5-, -C(O)O-, C1-12 alkylene, C2-12 alkenylene, C2-12 alkynylene, C6-12 arylene, C3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each R110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R130 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R140 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R150 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and n', n'', and m'' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8. 45. The compound of any one of claims 1-42, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein L is Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 ,n ^y- Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 46. The compound of any one of claims 1-42, or stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein L is n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 , n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 n ^y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 wherein the “*”and the wavy or dashed line represent a covalent bond. n ^ y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 47. The compound of any one of claims 1-46, or tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the linking moiety does not comprise a heteroarylene. 48. The compound of any one of claims 1-47, or tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein the linking moiety does not comprise a pyridylene (e.g., ^^^ 49. The compound of any one of claims 1-48, or tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, wherein -L-R1 does not comprise , wherein Raa is hydrogen, halo, C1-4 alkyl, or C1-4 haloalkyl; and Rbb is hydrogen or C1-4 alkyl. 50. A compound as provided in Table 1, or tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof. 51. A pharmaceutical composition comprising a compound of any one of claims 1-50, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 52. A method of treating cancer, comprising administering an effective amount of the compound of clams 1-50, or the pharmaceutical composition of claim 51 to an individual in need thereof. 53. The method of claim 52, wherein the cancer is liver cancer, melanoma, Hodgkin’s disease, non- Hodgkin’s lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms’ tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi’s sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, n ^ y-2633819 Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, trophoblastic neoplasms, or prostatic carcinoma. n ^ y-2633819 |
. 5 In certain embodiments, R 1 is: . In certain embodiments, R 1 is: . In certain embodiments, R a and R b are each independently CH 3 or CH 2 CH 3 . In certain embodiments, R a and R b together with the atom to which they are attached form a C3-5 cycloalkyl, oxiranyl, 5 oxetanyl, or tetrahydrofuranyl. In certain embodiments, A is O. In certain embodiments, A is S. In certain embodiments, A is O. In certain embodiments, A is S. In certain embodiments, E, E 1 , E 2 , and E 3 , are each independently CR c . In certain embodiments, E and E 1 are each independently CR c , and E 2 and E 3 are each N. 10 In certain embodiments, E is CR c , and each R c is independently hydrogen, halo, CN, or methyl. In certain embodiments, E is N. In certain embodiments, E is CH. In certain embodiments, E 1 is CR c , and each R c is independently hydrogen, halo, CN, or methyl. In certain embodiments, E 1 is N. In certain embodiments, E 1 is CH. In certain embodiments, E 2 is CR c , and each R c is independently hydrogen, halo, CN, or methyl. In 15 certain embodiments, E 2 is N. In certain embodiments, E 2 is CH. In certain embodiments, E 3 is CR c , and each R c is independently hydrogen, halo, CN, or methyl. In certain embodiments, E 3 is N. In certain embodiments, E 3 is CH. In certain embodiments, E 4 is CF. In certain embodiments, E 4 is CH. In certain embodiments, E 4 is N. 20 In certain embodiments, D is a bond. In certain embodiments, D is CH 2 . In certain embodiments, D is C=O. In certain embodiments, D is (C=O)NH. In certain embodiments, Dƍ is NH. In certain embodiments, Dƍ is O. In certain embodiments, Dƍ is S. In certain embodiments, D' is CH 2 . In certain embodiments, Dƍ is NH(C=O). In certain embodiments, Dƍ is C(=O)NH. In certain embodiments, D¶ƍ is C=O. In certain embodiments, R' is hydrogen. In certain embodiments, R' is CN. In certain embodiments, R' is C1-2 alkyl. In certain embodiments, R” is hydrogen. In certain embodiments, R” is CN. In certain embodiments, R” is C1-2 alkyl. 5 In certain embodiments, R” is hydrogen. In certain embodiments, R” is CN. In certain embodiments, R” is C1-2 alkyl. In certain embodiments, t is 0. In certain embodiments, t is 1. In certain embodiments, t is 2. In certain embodiments, t is 3, In certain embodiments, t is 4. In certain embodiments, at least one R e is independently halo. In certain embodiments, each R e is 10 independently halo. In certain embodiments, at least one R e is independently cyano. In certain embodiments, at least one R e is independently C 1-4 alkyl. In certain embodiments, at least one R e is independently C 1-4 haloalkyl. In certain embodiments, R 41 is halo. In certain embodiments, R 41 is CN. In certain embodiments, R 41 is NO 2 . 15 In certain embodiments, R 42 is halo. In certain embodiments, R 42 is CH 3 . In certain embodiments, R 42 is CH 2 F. In certain embodiments, R 42 is CHF 2 . In certain embodiments, R 42 is CF 3 . In certain embodiments, R 41 and R 42 together form a . In certain embodiments, R 41 and R 42 together form a . In certain embodiments, R 41 and R 42 together form a . In certain embodiments, R 41 and R 42 together form a H . 20 In certain embodiments, R 43 is hydrogen. In certain embodiments, R 43 is halo. In certain embodiments, R 43 is C 1-2 alkyl. In certain embodiments, R 43 is C 2 alkenyl. In certain embodiments, R 43 is NO 2 . In certain embodiments, R 43 is CF 3 . In certain embodiments, R 42 and R 43 together form a , wherein each is a single or double bond. In certain embodiments, R 42 and R 43 together form a , wherein each is a single or double bond. In certain embodiments, R42 and R43 together form a , wherein each is a single or double bond. In certain embodiments, R 1 is: . 5 In certain embodiments, R 1 is: . In certain embodiments, R 1 is: . In certain embodiments, R 1 is: 10 . In certain embodiments, R 1 is . In certain embodiments, R 1 is . In certain embodiments, R 1 is of Formula IIE: 5 wherein: the wavy bond refers to the point of connection to L; A'' and A''' are each independently O or S; R a and R b are each independently CH 3 or CH 2 CH 3 ; or R a and R b together with the atom to which they are attached form a C3-5 cycloalkyl, oxirane, oxetane, or tetrahydrofuran; 10 B, B 10 , B 2 , B 3 , Bƍ, B 1ƍ , B 2ƍ , and B 3ƍ are each independently CR c or N; each R c is independently hydrogen, fluoro, CN, or methyl; D is NH, O, S, CH 2 , or C=O; X'' is CN, halo, or NO 2 ; Y'' is CH 3 , CH 2 R d , CHF 2 , or CF 3 ; 15 R d is halo; Z'' is hydrogen, C 1-2 alkyl, C 2 alkenyl, or NO 2 ; or X'' and Y'' together form a , , , wherein the broken lines indicate bonds to the ring; or Y'' and Z'' together form a , is a single or double bond, and 20 wherein the broken lines indicate In certain embodiments, R 1 is: wherein: R 30 is hydrogen, C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl, wherein 5 each C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl is optionally independently substituted with one to five R 100 as valency permits; R 40 is hydrogen, C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl, wherein each C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl is optionally independently substituted with one to five R 100 as valency permits; 10 each R 50 is independently halo, cyano, nitro, -OR 170 , -SR 170 , -NR 170 R 180 , C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, or C 2-12 alkynyl; wherein each C 1-12 alkyl, C 1-12 haloalkyl, C 2-12 alkenyl, or C 2-12 alkynyl is independently optionally substituted with one to five halo, hydroxyl or amino as valency permits; R 60 is hydrogen, C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl, wherein each C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, or C 3-12 cycloalkyl is optionally independently substituted with one to five R 100 15 as valency permits; each R 100 is independently oxo, halo, cyano, nitro, -OR 170 , -SR 170 , -SF 5 , -NR 170 R 180 , C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, heteroaryl, -C(=O)R 170 , -C(=O)OR 170 , 20 -C=NOR 17 , wherein each C 1-12 alkyl, C 2-12 alkenyl, C 2-12 alkynyl, C3-10 cycloalkyl, heterocyclyl, aryl, and heteroaryl of R 100 are independently optionally substituted with one or more halo or C 1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino as valency permits; each R 170 and R 180 is independently hydrogen or C 1-12 alkyl optionally substituted with oxo, halo, hydroxyl or amino as valency permits; or R 170 and R 180 are taken together with the atoms to which they are 25 attached to form heterocyclyl optionally substituted by halo or C 1-12 alkyl optionally substituted by oxo, halo, hydroxyl or amino. A'' and A''' are each independently O or S; R a and R b are each independently CH 3 or CH 2 CH 3 ; or R a and R b together with the atom to which they are attached form a C 3-5 cycloalkyl, oxirane, oxetane or tetrahydrofuran; B, B 10 , B 2 , B 3 , Bƍ, B 1ƍ , B 2ƍ and B 3ƍ are each independently CR c or N; each R c is independently hydrogen, fluoro, CN, or methyl; D'' is NH, O, S, CH 2 or C=O; X'' is CN, halo, or NO 2 ; 5 Y'' is CH 3 , CH 2 R d , CHF 2 , or CF 3 ; R d is halo; Z''' is H, C 1-2 alkyl, C 2 alkenyl, or NO 2 ; or X'' and Y'' together form a , , , where the broken lines indicate bonds to form a fused ring; 10 single or double bond and where the broken lines indicate bonds to form a fused ring; Z' is CH or N. In certain embodiments, R 1 is: 15
5 bond refers to the point of connection to L. In certain embodiments, R 1 is:
5 , , ,
In certain embodiments, R 1 is: 5 , or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or an analog thereof, where the wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. In certain embodiments, R 1 is derived from, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, testosterone, 19-nortestosterone, progesterone, andarine, cortisol, 10 prednisone, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB-4124, Proellex, Progenta), or an analog thereof. In certain embodiments, R 1 is derived from, progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, 15 bazedoxifene, ospemifene, megestrol acetate, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof. In certain embodiments, the compound comprises at least one nuclear steroid receptor-targeting epitope independently comprises an epitope derived from:
5
or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or an analog thereof, wherein one or more atoms are replaced by a direct covalent bond to L. 5 In certain embodiments, R 1 comprises a nuclear receptor-targeting epitope derived from:
5
5 , , , , , , or a tautomer, stereoisomer or a mixture of stereoisomers thereof or an analog thereof, wherein at least one hydrogen atom is replaced by a direct covalent bond to L. These and other selective androgen receptor modulator (SARMs) which can be used as a nuclear 5 steroid receptor-targeting epitope in R 1 described herein can be found in US 6,462,038, US 6,777,427, WO2001/027086, WO2004/013104, WO2004/000816, WO2004/0113309, US2006/0211756, US2006/0063819, US2005/245485, US2005/250741, US2005/277681, WO2006/060108, WO2004/041277, WO2003/034987, US2006/0148893, US2006/0142387, WO2005/000795, WO2005/085185, WO2006/133216, WO2006/044707, WO2006/124447, WO2007/002181, WO2005/108351, 10 WO2005/115361, and US2006/0160845. In certain embodiments, R 1 is a selective estrogen receptor modulator (SERM). In certain embodiments, R 1 comprises an epitope derived from anordrin, bazedoxifene, broparestrol (Acnestrol), clomifene (Clomid), cyclofenil (Sexovid), lasofoxifene (Fablyn), ormeloxifene (Centron, Novex, Novex-DS, Sevista), ospemifene (Osphena, deaminohydroxytoremifene), raloxifene (Evista), tamoxifen (Nolvadex), 15 toremifene (Fareston; 4-chlorotamoxifen), acolbifene, afimoxifene (4-hydroxytamoxifen; metabolite of tamoxifen), elacestrant, enclomifene ((E)-clomifene), endoxifen (4-hydroxy-N-desmethyltamoxifen; metabolite of tamoxifen), zuclomifene ((Z)-clomifene), bazedoxifene, arzoxifene, brilanestrant, clomifenoxide (clomiphene N-oxide; metabolite of clomifene), droloxifene (3-hydroxytamoxifen), etacstil, fispemifene, GW-7604 (4-hydroxyetacstil), idoxifene (pyrrolidino-4-iodotamoxifen), levormeloxifene ((L)- 20 ormeloxifene), miproxifene, nafoxidine, nitromifene (CI-628), panomifene, pipendoxifene (ERA-923), trioxifene, keoxifene, LY117018, onapristone, fareston (toremifine citrate), or zindoxifene (D-16726), or an analog thereof. In certain embodiments, the SERM is classified structurally as a triphenylethylene (tamoxifen, clomifene, toremifene, droloxifene, idoxifene, ospemifene, fispemifene, afimoxifene, etc., or an analog 25 thereof), a benzothiophene (raloxifene, arzoxifene, etc., or an analog thereof), an indole (bazedoxifene, zindoxifene, pipendoxifene, etc., or an analog thereof), a tetrahydronaphthalene (lasofoxifene, nafoxidine, etc., or an analog thereof), or a benzopyran (acolbifene, ormeloxifene, levormeloxifene, etc., or an analog thereof). In certain embodiments, R 1 is a selective estrogen receptor downregulator (SERD). In certain 30 embodiments, the compound comprises at least one nuclear steroid receptor-targeting epitope independently comprises an epitope derived from fulvestrant, brilanestrant (ARN-810), etacstil (GW5638), AZD9496, giredestrant (GDC-9545), or GW7604. In certain embodiments, R 1 is a selective progesterone receptor modulator (SPRM). In certain embodiments, B comprises an epitope derived from ulipristal acetate, asoprisnil (J867), mifepristone, telapristone (CDB-4124, Proellex, Progenta), or an analog thereof. In certain embodiments, R 1 comprises an epitope derived from, estrogen, estetrol, estriol, estrone, 5 progesterone, enobosarm, bicalutamide, apalutamide, testosterone, dihydrotestosterone, estradiol, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, bazedoxifene, ospemifene, megestrol acetate, estramustine, abiraterone, LGD-2941, BMS-564929, ostarine, or an analog thereof. In certain embodiments, at least one nuclear steroid receptor-targeting epitope is an androgen receptor-targeting epitope, and comprises: 10
, or a tautomer, stereoisomer or a mixture of stereoisomers thereof or an analog thereof, where the wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. 5 In certain embodiments, at least one nuclear steroid receptor-targeting epitope is an androgen receptor-targeting epitope, and comprises: 10
or a tautomer, stereoisomer or a mixture of stereoisomers thereof or an analog thereof, where the wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. 5 In certain embodiments, at least one nuclear steroid receptor-targeting epitope is an estrogen receptor-targeting epitope, and comprises:
or a tautomer, stereoisomer or a mixture of stereoisomers thereof, or an analog thereof, where the wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. 5 In certain embodiments, at least one nuclear steroid receptor-targeting epitope is an estrogen receptor-targeting epitope, and comprises:
or a tautomer, stereoisomer, or a mixture of stereoisomers thereof, or an analog thereof, where the 5 wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. In certain embodiments, at least one nuclear steroid receptor-targeting epitope comprises: 10
5
5 or a tautomer, stereoisomer or a mixture of stereoisomers thereof or an analog thereof, where the wavy line indicates the point of attachment to the nuclear payload, optionally via a linking moiety. In certain embodiments, the nuclear steroid receptor-targeting epitope is not, or does not contain, a peptide, protein, nanoparticle or antibody. Linking moiety 10 The “linking moiety” of any compounds described herein can be biocleavable (e.g., acid labile) or non-biocleavable. Linking moieties can be linear, branched, saturated, unsaturated, all-carbon or heteroatomic. Linking moieties can also contain one or more rings that are fused, saturated, unsaturated, as well as be all-carbon or heteroatomic. In certain embodiments, the linking moiety is a non-biocleavable linking moiety. In certain embodiments, the linking moiety is a biocleavable linking moiety. In certain15 embodiments, a nuclear payload is bonded to one nuclear steroid receptor-targeting epitope via a non- biocleavable linking moiety and one or more nuclear steroid receptor-targeting epitope(s) via a biocleavable linking moiety. In certain embodiments, the biocleavable linking moiety is an acid-labile linking moiety. In some embodiments, the linking moiety comprises a hydrazone linkage. It is contemplated that any linking moiety can be used in the compounds described herein, provided 20 that it does not significantly interfere with or disrupt the desired binding of the nuclear payload or the nuclear receptor-targeting epitope. In some embodiments, the linking moiety (L) is alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene; wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, may optionally comprise an arylene, heteroarylene, cycloalkylene or heterocycloalkylene; and further wherein each alkylene, heteroalkylene, alkenylene, heteroalkenylene, alkynylene, heteroalkynylene, arylene, heteroarylene, cycloalkylene or heterocycloalkylene is independently optionally substituted with one to five substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 alkoxy, and 5 C 1-4 haloalkyl. In the linkers shown, where not directionality is specified, none is intended. Where not specified, either end of the linker can be bonded to R 1 or a PARP-binding portion of the compound. In certain embodiments, L is of formula: -(L a ) q -, 10 wherein: each L a is independently -NR 110 S(O)2-, -S(O)2NR 110 -, -NR -OC(O)O-, -C(O)O-, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C6-12 arylene, C 3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene, each independently optionally 15 substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, and 5- to 12- membered heterocyclyl; each R 110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; 20 each R 120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and q is an integer from 0 to 20. In certain embodiments, L is of the formula: -Y 10 -(CHR 130 ) n’ -Y 20 -(CHR 140 ) n'' -Y 30 -(CHR 150 ) m'' -Y 40 - 25 wherein: each of Y 10 , Y 20 , Y 30 , and Y 40 are independently a bond, - , -O-, -S(O) 0-2 -, -NR 110 C(O)-, -C(O)NR 110 -, -NR 110 C(O)NR 110 -, -NR 110 S(O) 2 -, -S(O) 2 NR 110 -, -NR 110 S(O) 2 NR 110 -, -CR 120 =N-NR 110 -, -NR 110 -N=CR 120 -, -C(O)-, -OC(O)-, -OC(O)O-, -(CH 2 CH 2 O) 1-5 -, -C(O)O-, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C 6-12 arylene, C 3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- 30 membered heteroarylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each R 110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 130 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; 5 each R 140 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 150 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and n', n'', and m'' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8. 10 In certain embodiments, L is of the formula: -Y 10 -(CHR 130 )n’-Y 20 -(CHR 140 )n''-Y 30 -(CHR 150 )m''-Y 40 - wherein: each of Y 10 , Y 20 , Y 30 , and Y 40 are independently a bond, -NR 110 -, -O-, -S(O)0-2-, -NR 110 C(O)-, -C(O)NR 110 -, -NR 110 C(O)NR 110 -, -NR 110 S(O)2-, -S(O)2NR 110 -, -NR 110 S(O)2NR 110 -, -CR 120 =N-NR 110 -, 15 -NR 110 -N=CR 120 -, -C(O)-, -OC(O)-, -OC(O)O-, -(CH 2 CH 2 O)1-5-, -C(O)O-, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C6-12 arylene, C 3-12 cycloalkylene, or 5- to 12-membered heterocyclylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each R 110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, 20 C6-12 aryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 120 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C 6-12 aryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 130 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; 25 each R 140 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 150 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and n', n'', and m'' are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8. 30 In certain embodiments, L is of the formula: wherein: each of L 2 , L 3 , and L 4 is independently a bond, C 1-12 alkylene, -NHC(=O)-, -C(=O)NH-, -C(=O)-O-, -O-C(=O) -, or C=O; 5 each of R 200 and R 201 is independently halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, and 5- to 12-membered heterocyclyl; and each of s and s' is independently 0, 1, 2, 3, or 4. In certain embodiments, the linking moiety is of the Formula: ; 10 wherein ring C is a 3- to 12- membered cycloalkylene or 3- to 12- membered heterocyclylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each of Y 50 and Y 60 are independently a bond, -NR 110 -, -O-, -S(O)0-2-, -NR 110 C(O)-, -C(O)NR 110 -, 15 -NR 110 C(O)NR 110 -, -NR 110 S(O)2-, -S(O)2NR 110 -, -NR 110 S(O)2NR 110 -, -CR 120 =N-NR 110 -, -NR 110 -N=CR 120 -, -C(O)-, -OC(O)-, -OC(O)O-, -(CH 2 CH 2 O)1-5-, -C(O)O-, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C6-12 arylene, C 3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, or C 1-4 haloalkoxy; 20 each R 110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 120 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and wherein the “*”and the wavy line represent a covalent bond. 25 In certain embodiments, each C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C 6-12 arylene, C 3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene of Y 50 and Y 60 is independently optionally substituted with one to five substituents independently selected from halo, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, or C 1-4 haloalkoxy. In certain embodiments, the linking moiety is of the Formula: ; wherein ring C is a 3- to 12- membered cycloalkylene or 3- to 12- membered heterocyclylene, each independently optionally substituted with one or more substituents independently selected from oxo, halo, 5 C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each of Y 50 and Y 60 are independently a bond, -NR 110 -, -O-, -S(O)0-2-, -NR 110 C(O)-, -C(O)NR 110 -, -NR 110 C(O)NR 110 -, -NR 110 S(O)2-, -S(O)2NR 110 -, -NR 110 S(O)2NR 110 -, -CR 120 =N-NR 110 -, -NR 110 -N=CR 120 -, -C(O)-, -OC(O)-, -OC(O)O-, -(CH 2 CH 2 O)1-5-, -C(O)O-, C 1-12 alkylene, C 2-12 alkenylene, C 2-12 alkynylene, C6-12 arylene, C 3-12 cycloalkylene, 5- to 12-membered heterocyclylene, or 5- to 12- membered heteroarylene, 10 each independently optionally substituted with one or more substituents independently selected from oxo, halo, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, or C1-4 haloalkoxy; each R 110 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, C6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; each R 120 is independently hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, 15 C 6-12 aryl, 5- to 12-membered heteroaryl, C 3-12 cycloalkyl, or 5- to 12-membered heterocyclyl; and wherein the “*”and the wavy line represent a covalent bond. In certain embodiments, L comprises a non-biocleavable moiety. In certain embodiments, L comprises an optionally substituted alkylene having 4-7 chain atoms, optionally substituted 4-7-membered heterocyclylene, or optionally substituted heteroalkylene having 4-7 20 chain atoms. In certain embodiments, L comprises an optionally substituted heterocyclylene or optionally substituted heteroalkylene. In certain embodiments, L comprises an optionally substituted heterocyclylene and optionally substituted heteroalkylene. In certain embodiments, L is optionally substituted C4-10 atom heteroalkylene. 25 In certain embodiments, L is a 1-12 chain atom alkylene or 2-12 chain atom heteroalkylene linking moiety, containing 0-3 optionally substituted cycloalkylene, 0-3 optionally substituted heterocyclylene, 0-3 optionally substituted heteroarylene, 0-3 optionally substituted arylene, and 0-2 C=O. In certain embodiments, L is a 1-12 chain atom alkylene or 2-12 chain atom heteroalkylene linking moiety, containing 0-3 cycloalkylene, 0-3 heterocyclylene, 0-3 heteroarylene, 0-3 arylene, and 0-2 C=O. In certain 30 embodiments, L is a 1-12 chain atom alkylene or 2-12 chain atom heteroalkylene linking moiety, containing 1-3 cycloalkylene, heterocyclylene, heteroarylene, or arylene rings, and 0-2 C=O. In certain embodiments, L is a 4-12 chain atom alkylene or 4-12 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from NH, O, or S, and optionally one C=O. In certain embodiments, L is a 4-11 chain atom alkylene or 4-11 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from 5 NH, O or S, and optionally one C=O. In certain embodiments, L is a 4-10 chain atom alkylene or 4-10 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from NH, O or S, and optionally one C=O. In certain embodiments, L is a 4-9 chain atom alkylene or 4-9 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from NH, O or S, and optionally one C=O. In certain embodiments, L is a 4-8 chain atom alkylene 10 or 4-8 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from NH, O or S, and optionally one C=O. In certain embodiments, L is a 4-7 chain atom alkylene or 4-7 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently selected from NH, O or S, and optionally one C=O. In certain embodiments, L is a 4-6 chain atom alkylene or 4-6 chain atom heteroalkylene linking moiety containing CH 2 and up to 2 heteroatoms each independently 15 selected from NH, O or S, and optionally one C=O. As used herein, “chain atoms” include only those atoms making up the linking chain, and do not include hydrogen atoms or any substituent on an atom in the chain. By way of example, each of the following are linking moieties comprising 5 chain atoms: In certain embodiments, the linking moiety (L) is of the formula: 20 25 n ^ y-2633819 5 10 n ^ y-2633819 5 10 , n ^ y-2633819 5 10 n ^ y-2633819 5 n ^ y-263 5 , , wherein the “*”and the wavy or dashed line represent a covalent bond. It is understood that either * or the wavy or dashed line can be connected to A 1 . In certain embodiments, the linking moiety (L) is of the formula: 10 n ^ y-2633819 5 10 n ^ y-2633819 5 n ^ y-2633819 5 n ^ y-2633819 ine represent a covalent bond to R 1 . It is understood that either * or the wavy or dashed line can be connected to A 1 . In certain embodiments, the linking moiety (L) is of the formula: 5 10 15 n ^ y-2633819 5 “*”and the wavy line represent a covalent bond. It is understood that either * or the wavy or dashed line can be connected to R 1 . In certain embodiments, L is , , s is 1, 2, or 3; sƍ is 0 or 1; 10 G 1 , G 2 , G 3 , and G 4 are each independently CH or N; and Lƍ and LƎ are each independently selected from a bond, CH 2 , CH 2 CH 2 , NHC(O), or C=O. In certain embodiments, , wherein Lƍ and L” are each independently selected from a bond, CH 2 , CH 2 CH 2 , NHC(O), or C=O; G 1 , G 2 , G 3 , and G 4 are each independently CH or N; and s is 1, 2, or 3. In certain embodiments, s is 1 or 2. In certain 15 embodiments, s is 1. In certain embodiments, s is 2. In certain embodiments, s is 3. In certain embodiments, , wherein Lƍ and L” are each independently selected from a bond, CH 2 , CH 2 CH 2 , NHC(O), or C=O; and s is 1, 2, or 3. In certain embodiments, s is 1 or 2. In certain embodiments, s is 1. In certain embodiments, s is 2. In certain embodiments, s is 3. n ^ y-2633819
5
5 , In certain embodiments, L is , wherein Lƍ and L” are each independently selected from a bond, CH 2 , CH 2 CH 2 , or C=O; s is 1, 2, or 3. In certain embodiments, s is 1 or 10 2. In certain embodiments, s is 1. In certain embodiments, s is 2. In certain embodiments, s is 3. In certain embodiments, , wherein Lƍ and L” are each independently selected from a bond, CH 2 , CH 2 CH 2 , or C=O; and s’ is 0 or 1. In certain embodiments, s’ is 0. In certain embodiments, sƍ is 1. 5 , . , . 10 , . In certain embodiments, Lƍ is a bond. In certain embodiments, Lƍ is CH 2 . In certain embodiments, Lƍ is CH 2 CH 2 . In certain embodiments, Lƍ is C=O. 5 , In certain embodiments, L” is a bond. In certain embodiments, L” is CH 2 . In certain embodiments, 10 L” is CH 2 CH 2 . In certain embodiments, L” is C=O.
. In certain embodiments, Lƍ is a bond. In certain embodiments, Lƍ is CH 2 . In certain embodiments, Lƍ is CH 2 CH 2 . In certain embodiments, Lƍ is C=O. 5 . In certain embodiments, L” is a bond. In certain embodiments, L” is CH 2 . In certain embodiments, L” is CH 2 CH 2 . In certain embodiments, L” is C=O. In certain embodiments, the linking moiety L is of the formula:
5 10
5 10
5 o r ; where the “*”and the wavy line represent a covalent bond. It is understood that either * or the wavy or dashed line can be connected to R 1 . In certain embodiments, wherein the wavy 10 lines represent a covalent bond. It is understood that either end can be connected to R 1 . . Also provided is a compound as provided in Table 1, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof. Table 1
In certain embodiments, the compound is not a compound selected from Table 1A, or a tautomer, stereoisomer, mixture of stereoisomers, hydrate, solvate, isotopically enriched analog, or pharmaceutically acceptable salt thereof. Table 1A
Methods of Treatment Provided herein are compounds which can be used to treat, prevent, and/or delay the onset and/or development of cancer. Accordingly, in certain embodiments, provided is a method for the treatment of 5 cancer, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound or composition described herein. Certain embodiments provide a method of potentiation of cytotoxic cancer therapy in a subject in recognized need of such treatment comprising administering to the subject a therapeutically acceptable amount of a compound or composition described herein. It is contemplated that a patient having any cancer may benefit from being treated with the compounds and compositions described herein. Accordingly, in certain embodiments, the cancer is liver cancer, melanoma, Hodgkin’s disease, non-Hodgkin’s lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, 5 lung carcinoma, Wilms’ tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head neck carcinoma, osteogenic sarcoma, 10 pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi’s sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, trophoblastic neoplasms, prostatic carcinoma, glioma, breast cancer, or prostate cancer. In certain embodiments, the cancer is bladder cancer, a blood 15 cancer, such as leukemia (e.g., chronic leukemia, chronic lymphocytic leukemia (CLL, etc.) or lymphoma (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, low grade lymphoma, high grade lymphoma), lung cancer (e.g., small cell lung cancer), breast cancer, fallopian tube cancer, glioblastoma multiforme, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer, testicular cancer, skin cancer (e.g., melanoma) or uterine cancer. In certain embodiments, the cancer is 20 bladder cancer, breast cancer, fallopian tube cancer, ovarian cancer, prostate cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer. In certain embodiments, the cancer is chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenström macroglobulinemia, polycythemia vera, trophoblastic neoplasms, and ovarian carcinoma. 25 In certain embodiments, the compounds and compositions as described herein are tailored to target cancers which overexpress a specific receptor, such as, but not limited to, androgen receptors, estrogen receptors, progesterone receptors, and/or glucocorticoid receptors by including an epitope which targets that specific nuclear receptor. The epitope can be derived from a steroid hormone or any non-steroidal drug which targets that particular receptor. 30 In certain embodiments, provided is a method of treating or preventing an androgen receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one androgen receptor-targeting epitope to an individual in need thereof. Specific cancers which are contemplated to be treated by such methods include, but are not limited to, prostate, breast, triple negative breast cancer, 35 bladder, or liver cancer. Also provided is a method of treating or preventing metastatic castration-resistant prostate cancer (mCRPC), comprising administering an effective amount of a compound or composition as described herein, or a pharmaceutically acceptable salt or solvate thereof, to an individual in need thereof. In certain embodiments, provided is a method of treating or preventing an androgen receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically 5 acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one androgen receptor-targeting epitope to an individual in need thereof. In certain embodiments, the cancer is prostate, breast, triple negative breast cancer, bladder, or liver cancer. In certain embodiments, the androgen receptor- targeting epitope comprises an androgen receptor agonist, a selective androgen-receptor modulator (SARM), an androgen receptor antagonist, a selective estrogen receptor modulator (SERM), an estrogen receptor 10 antagonist, a progestin, or an estrogen. In certain embodiments, the androgen receptor-targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, estramustine, ketoconazole, abiraterone, darolutamide, or an analog thereof. In certain embodiments, the androgen receptor-targeting epitope comprises enobosarm, bicalutamide, flutamide, nilutamide, enzalutamide, tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, 15 estramustine, ketoconazole, abiraterone, or an analog thereof. In certain embodiments, the nuclear payload comprises a PARP inhibitor. In certain embodiments, provided is a method of treating or preventing an estrogen and/or progesterone receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically acceptable salt or solvate thereof, comprising at least one nuclear payload and at least 20 one estrogen and/or progesterone receptor-targeting epitope to an individual in need thereof. Specific cancers which are contemplated to be treated by such methods include, but are not limited to, breast, uterine, or ovarian cancer. In certain embodiments, provided is a method of treating or preventing a glucocorticoid receptor overexpressing cancer, comprising administering an effective amount of a compound, or a pharmaceutically 25 acceptable salt or solvate thereof, comprising at least one nuclear payload and at least one glucocorticoid receptor-targeting epitope to an individual in need thereof. Specific cancers which are contemplated to be treated by such methods include, but are not limited to, breast, uterine, or ovarian cancer. Specific cancers which are contemplated to be treated by such methods include, but are not limited to, prostate, possibly breast, uterine, ovarian. 30 Compositions Compositions, including pharmaceutical compositions, of any of the compounds detailed herein are embraced by this disclosure. Thus, provided herein are pharmaceutical compositions comprising a compound of the disclosure, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical compositions provided herein may take a form suitable 35 for oral, buccal, parenteral (e.g., intravenous, intramuscular, infusion or subcutaneous injection), nasal, topical or rectal administration, or a form suitable for administration by inhalation. Kits Kits for use to achieve anti-cancer effects comprising a compound or composition described herein are provided. In certain embodiments, the kit comprises a unit dose of a compound or composition described herein and instructions for administering the same. In certain aspects, the kit further comprises a 5 second drug suitable for anti-cancer therapy, or instructions for co-administering an additional anti-cancer therapy (such as radiation or gene therapy). In another aspect, kits for use to achieve anti-cancer effects comprise a low dose (e.g., less than about 500 mg/day, or less than about 400 mg/day, or less than about 300 mg/day, or less than about 200 mg/day) of a compound or composition described herein and a second drug suitable for anti-cancer therapy. In yet another variation, kits for use to achieve anti-cancer effects comprise 10 a high dose (e.g., greater than about 500 mg/day) of a compound or composition as described herein and a second drug suitable for anti-cancer therapy. Methods of Manufacturing a Medicament In a further aspect of the disclosure, use of the compounds and compositions described herein in the manufacture of a medicament is provided. In particular, the manufacture of a medicament for use in the 15 treatment of cancer, or diseases or conditions which can be mediated, at least in part, by blocking DNA repair and/or transcription activation, such as by inhibition of PARP, are provided. Further, pharmaceutical compositions of a compound described herein are also intended for use in the manufacture of a medicament for use in treatment of diseases or conditions which can be mediated, at least in part, by inhibition of PARP. EXAMPLES 20 The disclosure is further illustrated by the following examples. The examples below are non- limiting are merely representative of various aspects of the disclosure. Solid and dotted wedges within the structures herein disclosed illustrate relative stereochemistry, with absolute stereochemistry depicted only when specifically stated or delineated. Where it is desired to obtain a particular enantiomer of a compound, this may be accomplished from 25 a corresponding mixture of enantiomers using any suitable conventional procedure for separating or resolving enantiomers. Thus, for example, diastereomeric derivatives may be produced by reaction of a mixture of enantiomers, e.g., a racemate, and an appropriate chiral compound. The diastereomers may then be separated by any convenient means, for example by crystallization and the desired enantiomer recovered. In another resolution process, a racemate may be separated using chiral High Performance Liquid 30 Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described. Exemplary protocols for specific compounds exemplified herein are shown in the following schemes. Scheme I illustrates a general methods which can be employed for the synthesis of compounds described herein, where each of A 1 , A 2 , A 3 , A 4 , R 2 , R 4 , R 5 , L, and R 1 are each independently as defined herein, and LG is a leaving group (e.g., hydroxy, alkoxy, halo, etc.). Scheme I 5 In Scheme I, compounds of formula C-1 can be prepared from suitably substituted compound of formula A-1 by coupling with a suitable suitably substituted compound of formula B-1. Coupling of compound C-1 with an appropriately substituted compound of formula C provides compound D, which can then be taken on to provide a compound of formula I by coupling with a suitable L-R 1 moiety, either 10 convergently or sequentially (i.e., either an L-R 1 moiety or first a precursor for L followed by R 1 ). Upon each reaction completion, each of the intermediate or final compounds can be recovered, and optionally purified, by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like. Exemplary methods for the preparation of compounds of formula A-1 can be found in the literature (see, e.g., WO 2021/013735). 15 Additionally, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in Wuts, P. G. M., Greene, T. W., & Greene, T. W. (2006). Greene's protective groups in organic synthesis. Hoboken, N.J., Wiley-Interscience, and 20 references cited therein. For example, protecting groups for alcohols, such as hydroxy, include silyl ethers (including trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tri-iso-propylsilyloxymethyl (TOM), and triisopropylsilyl (TIPS) ethers), which can be removed by acid or fluoride ion, such as NaF, TBAF (tetra-n- butylammonium fluoride), HF-Py, or HF-NEt 3 . Other protecting groups for alcohols include acetyl, removed by acid or base, benzoyl, removed by acid or base, benzyl, removed by hydrogenation, 25 methoxyethoxymethyl ether, removed by acid, dimethoxytrityl, removed by acid, methoxymethyl ether, removed by acid, tetrahydropyranyl or tetrahydrofuranyl, removed by acid, and trityl, removed by acid. Examples of protecting groups for amines include carbobenzyloxy, removed by hydrogenolysis p- methoxybenzyl carbonyl, removed by hydrogenolysis, tert-butyloxycarbonyl, removed by concentrated strong acid (such as HCl or CF 3 COOH), or by heating to greater than about 80 °C, 9- 30 fluorenylmethyloxycarbonyl, removed by base, such as piperidine, acetyl, removed by treatment with a base, benzoyl, removed by treatment with a base, benzyl, removed by hydrogenolysis, carbamate group, removed by acid and mild heating, p-methoxybenzyl, removed by hydrogenolysis, 3,4-dimethoxybenzyl, removed by hydrogenolysis, p-methoxyphenyl, removed by ammonium cerium(IV) nitrate, tosyl, removed by concentrated acid (such as HBr or H 2 SO 4 ) and strong reducing agents (sodium in liquid ammonia or sodium naphthalenide), troc (trichloroethyl chloroformate), removed by Zn insertion in the presence of acetic acid, 5 and sulfonamides (Nosyl & Nps), removed by samarium iodide or tributyltin hydride. Nomenclature was derived from ChemDraw Professional v18.2 and/or Chemdraw Professional v 21. If there are any structural ambiguities based on nomenclature, the corresponding structure shown in the scheme (and context of the synthetic scheme) should be referred to. SYNTHETIC EXAMPLES 10 Preparation of 6-chloro-N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cycl ohexyl)pyridazine-3- carboxamide (Int-A) Step-1: Preparation of tert-butyl ((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)carb amate (Int-1) 15 To a stirred solution of (rel-trans)-4-aminocyclohexan-1-ol (SM-2, 10 g, 46.5 mmol, 1.0 eq.) in DMF (100 mL) under nitrogen atmosphere was added NaH (4.08 g, 102 mmol, 2.2 eq.) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 30 min. To this reaction mixture was added 2- chloro-4-fluoro-3-methylbenzonitrile (SM-1, 7.86 g, 46.51 mmol, 1.0 eq.) portion wise over a period of 10 min at room temperature and stirred for 3h. Progress of the reaction was monitored by TLC. After 20 completion of the reaction, ice cold water (100 mL) was added and the solid precipitate formed was filtered and dried to afford Int-1 (15 g, 88%). 1H NMR (400 MHz, DMSO-d6)δ7.73(d,J = 8.31 Hz, 1H), 7.22 (d, J = 8.80 Hz, 1H), 6.82 (s, 1H), 4.37 - 4.55 (m, 2H), 2.21 (s, 3H), 1.98 - 2.11 (m, 2H), 1.76 - 1.88 (m, 2H), 1.42 - 1.51 (m, 4H), 1.38 (s, 9H). LCMS: 309 [M-56+H] + . Step-2: Preparation of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chloro-3-methylbenzonit rile Hydrochloride (Int-2) To a flask charged with Int-1 (15 g), 4M HCl in 1,4-dioxane (75 mL) was added at 0 °C. The resulting mixture was allowed to warm up to RT and stir for 16h. After completion of the reaction, volatiles 5 were evaporated under reduced pressure and the resulting residue was triturated with diethyl ether (2 x 80 mL) and filtered to afford Int-2 (15 g, crude) which was used in the next step as is. 1H NMR (400 MHz, DMSO-d 6 ) δ 8.30(brs s, 3H), 7.75 (d,J = 8.80 Hz, 1H), 7.28 (d, J = 8.80 Hz, 1H), 4.44 - 4.55 (m, 1H), 3.00 - 3.15 (m, 1H), 2.21 (s, 3H), 2.07 - 2.15 (m, 2H), 1.97 - 2.06 (m, 2H), 1.41 - 1.63 (m, 4H). LCMS: 264.75 [M+H] + . 10 Step-3: Preparation of 6-chloro-N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cycl ohexyl)pyridazine- 3-carboxamide (Int-A) To A mixture of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chloro-3-methylbenzonit rile hydrochloride (Int-2, 15 g, 56.9 mmol, 1.0 eq.) and 6-chloropyridazine-3-carboxylic acid (SM-3, 9 g, 56.9 mmol, 1.0 eq.) in DMF (100 mL) were added HATU (32.4 g, 85.44 mmol, 1.5 eq.) and DIPEA (49 mL, 284 mmol, 5.0 eq.) 15 at 0 °C. Resulting reaction mixture was then allowed to stir at RT for 16h. Progress of the reaction was monitored by TLC. After reaction completion, volatiles were evaporated under reduced pressure and the residue was diluted with water (500 mL) and extracted with ethyl acetate (3 x 300 mL). The combined organic extract was washed with water (400 mL) and brine (400 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product which was purified by column 20 chromatography eluting with 60-80% ethyl acetate in hexane to afford Int-A (6 g, 27%). 1H NMR (400 MHz, DMSO-d 6 ) δ 9.12(d,J = 8.31 Hz, 1H), 8.22 (d, J = 8.80 Hz, 1H), 8.10 (d, J = 8.80 Hz, 1H), 7.77 (d, J = 8.80 Hz, 1H), 7.27 (d, J = 8.80 Hz, 1H), 4.43 - 4.57 (m, 1H), 3.85 - 4.01 (m, 1H), 2.23 (s, 3H), 2.08 - 2.17 (m, 2H), 1.86 - 1.96 (m, 2H), 1.64 - 1.77 (m, 2H), 1.49 - 1.62 (m, 2H). LCMS: 405.2 [M+H] + .
Preparation of 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B) Step-1: Preparation of ethyl 6-formyl-5-nitronicotinate (Int-1) A flask was charged with ethyl 6-methyl-5-nitronicotinate (SM-1, 50 g, 0.23 mol, 1.0 eq.), SeO 2 5 (39.6 g, 0.35 mol, 1.5 eq.) in 1,4-dioxane (250 mL, 5 vol) was allowed to stir under a nitrogen atmosphere at 110 °C until TLC indicated complete consumption of starting material. The reaction mixture was then cooled to ambient temperature, filtered through celite. The filtrate was concentrated under reduced pressure, purified by flash column over silica gel (60-120 mesh) eluting with 50-60 % ethyl acetate in hexane. The pure fractions combined and the solvent was evaporated under reduced pressure to obtain ethyl 6-formyl-5- 10 nitronicotinate (Int-1, 48 g, 90%). 1H NMR (400 MHz, DMSO-6d 6 ) δ10.21 (s, 1H), 9.44 ( d, , 8.89 (d, J = 1.47 Hz, 1H), 4.42 (q, J = 7.01 Hz, 2H), 1.37 (t, J = 7.01 Hz, 3H). LCMS: 225.0 [M+H] + . Step-2: Preparation of ethyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate (Int-2) To a suspension of NaH (12.85 g, 0.32 mol, 2.0 eq., 60%) in dry THF (180 mL, 5 vol) was added a 15 solution of ethyl 2-(diethoxyphosphoryl)butanoate (SM-2, 60 g, 0.48 mol, 1.5 eq.) in dry THF (180 mL, 5 vol) dropwise at 0 °C under argon atmosphere, warmed up and stirred at 40 °C for 15 min. The reaction mixture was then cooled down to -78 °C and a solution of ethyl 6-formyl-5-nitronicotinate (Int-1, 36 g, 0.32 mol, 1.0 eq.) in dry THF (180 mL, 5 vol) was added dropwise at -78 °C under argon atmosphere and stirring was continued under argon atmosphere at same temperature until TLC indicated complete consumption of 20 starting material. After reaction completion, the mixture was quenched with saturated ammonium chloride solution (500 mL), extracted with ethyl acetate (2 x 500 mL), combined organic layer washed with brine solution (300 mL) and dried over sodium sulfate. The organic layer was filtered, concentrated under reduced pressure and the resulting crude product was purified by flash column (silica gel) eluting with 20-30 % ethyl acetate in hexane. The pure fractions were combined and concentrated under reduced pressure to obtain 5 ethyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate (Int-2, 40 g, 77%) (E and Z isomers were observed). LCMS: 323.2 [M+H] + . Step-3: Preparation of ethyl 7-ethyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxy late (Int-3) A flask was charged with ethyl (E)-6-(2-(ethoxycarbonyl)but-1-en-1-yl)-5-nitronicotinate (Int-2, 40 10 g, 0.12 mmol, 1.0 eq.), 10% Pd/C (12 g, 30% w/w) and EtOAc (400 mL, 10 vol). The reaction mixture was then allowed to stir under hydrogen atmosphere (100 psi) at ambient temperature until TLC indicated complete consumption of starting material. The reaction mixture was then filtered through celite, the filtrate concentrated under reduced pressure and the residue was diluted with 4M HCl in 1,4-dioxane (200 mL, 5 vol) and allowed to stir for 2h at ambient temperature. After reaction completion, the reaction mixture was15 concentrated under reduced pressure, triturated with diethyl ether (100 mL), filtered and dried to get ethyl 7- ethyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxyla te (Int-3, 22 g, 73%). LCMS: 249.2 [M+H] + . Step-4: Preparation of ethyl 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate (Int-4) A flask was charged with ethyl 7-ethyl-6-oxo-5,6,7,8-tetrahydro-1,5-naphthyridine-3-carboxy late 20 (Int-3, 60 g, 0.24 mol, 1.0 eq.), SeO 2 (39.9 g, 0.36 mol, 1.5 eq.) and AcOH (600 mL, 10 vol) and the reaction mixture was allowed to stir under a nitrogen atmosphere at 110 °C until TLC indicated complete consumption of starting material. The reaction mixture was then cooled to ambient temperature, quenched with saturated ammonium bicarbonate solution, and extracted with ethyl acetate (2 x 1L). The combined organic layer was washed with brine solution (500 mL) and dried over sodium sulfate, filtered, and 25 concentrated under reduced pressure to give ethyl 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3- carboxylate (Int-4, 25 g, 42%). 1H NMR (400 MHz, DMSO-d 6 ) δ 12.04(brs,1H),8.86(s,1H),8.12(d,J = 3.91 Hz, 1H), 7.79 (s, 1H), 4.36 (q, J = 7.34 Hz, 2H), 2.55 (q, J = 7.17 Hz, 2H), 1.33 (t, J = 7.09 Hz, 2H), 1.15 (t, J = 7.09 Hz, 3H). LCMS: 247.2 [M+H] + . Step-5: Preparation of 3-ethyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (Int-5) To a solution of ethyl 7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridine-3-carboxylate (Int-4, 7 g, 28.45 mmol, 1.0 eq.) in dry THF (350 mL, 50 vol) was added a solution of 2M LiAlH 4 in THF (28.4 mL, 56.8 mmol, 2.0 eq.) at 0 °C under nitrogen atmosphere. The resulting reaction mixture was allowed to stir under 5 nitrogen atmosphere at ambient temperature until TLC indicated complete consumption of starting material. The reaction mixture was then quenched with sodium sulfate solution, filtered and evaporated under reduced pressure to give 3-ethyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (Int-5, 4.1 g, 70%). LCMS: 205.1 [M+H] + . Step-6: Preparation of 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B) 10 A flask was charged with 3-ethyl-7-(hydroxymethyl)-1,5-naphthyridin-2(1H)-one (Int-5, 4 g, 19.60 mmol, 1.0 eq.), SOCl2 (14 g, 117 mmol, 6.0 eq.), DMF (0.4 mL, 0.1 vol, catalytic amount) and DCM (120 mL, 30 vol) and the reaction mixture was allowed to stir under nitrogen atmosphere at ambient temperature until TLC indicated complete consumption of starting material. The reaction mixture was then diluted with water (100 mL) and extracted with DCM (2 x 200 mL). The combined organic layer was washed with 15 saturated bicarbonate solution (100 mL), brine solution (100 mL), dried over sodium sulfate and concentrated under reduced pressure to give 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 2 g, 46%). 1H NMR (400 MHz, DMSO-d6)δ12.23(br, s, 1H)8.556(s,1H),7.90(s,1H),7.82(s,1H),4.94(s, 2H), 2.55 (d, J = 7.34 Hz, 2H), 1.17 (t, J = 7.34 Hz, 3H). LCMS: 223.0 [M+H] + . 20 Preparation of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int-C) Step-1: Preparation of tert-butyl 4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)p iperazine- 1-carboxylate (Int-1) A flask was charged with 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 2.4 g, 9.30 mmol, 1.0 eq.), tert-butyl piperazine-1-carboxylate (SM-1, 1.7 g, 9.30 mmol, 1.0 eq.), DIPEA (8.5 mL, 46.5 5 mmol, 5.0 eq.), KI (166 mg, 1.8 mmol, 0.2 eq.) and acetonitrile (24 mL, 10 vol) and the reaction mixture was stirred under nitrogen atmosphere at 80 °C until TLC indicated complete consumption of starting material. The reaction mixture was then cooled to ambient temperature, concentrated under reduced pressure, diluted with water (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with brine solution (100 mL), dried over sodium sulfate, filtered and concentrated under 10 reduced pressure. The crude obtained was purified by flash column over silica gel eluting with 0-3% MeOH in DCM. The pure fractions were combined and concentrated under reduced pressure to give tert-butyl 4- ((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)pip erazine-1-carboxylate (Int-1, 1.7 g, 50%). 1H NMR (400 MHz, DMSO-d6^^į^^^^^^^^V^^^+^^^^^^^^^G^^J = 1.17 Hz, 1H), 7.74 (s, 1H), 7.58 (s, 1H), 3.58 (s, 2H), 3.33 (s, 4H), 2.50 (d, J = 1.57 Hz, 2H), 2.34 (t, J = 4.30 Hz, 4H), 1.39 (s, 9H), 1.17 (t, J = 15 7.43 Hz, 3H). LCMS: 373.3 [M+H] + . Step-2: Preparation of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int- C) A flask was charged with tert-butyl 4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl) piperazine-1-carboxylate (Int-1, 1.7 g, 4.56 mmol, 1.0 eq.), HCl (17 mL, 10 vol, 4 M in 1,4-dioxane) and 20 DCM (17 mL, 10 vol) and the reaction mixture was stirred under nitrogen atmosphere at ambient temperature until TLC indicated complete consumption of starting material. The reaction mixture was then concentrated under reduced pressure, triturated with diethyl ether (50 mL), filtered and dried to give 3-ethyl- 7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int-C, 1.37 g, 97%). 1H NMR (400 MHz, DMSO-d 6 ^^į^^^^^^^^EU^V^^^+^^^^^^^^^EU^V^^^+^^^^^^^^^V^^^+^^^ ^^^^^^V^^^+^^^^^^^^ 25 (s, 1H), 4.56 (br s, 2H), 3.43 - 3.54 (m, 8H), 2.57 (q, J = 7.17 Hz, 2H), 1.18 (t, J = 7.34 Hz, 3H). LCMS: 273.2 [M+H] + . Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2-thioxoimidazolidin-1- yl)-2-fluorobenzoic acid (Int-D) Step-1: Preparation of 4-((2-carboxypropan-2-yl)amino)-2-fluorobenzoic acid (Int-1) 5 To a stirred solution of 4-bromo-2-fluorobenzoic acid (SM-1, 10.0 g, 45.66 mmol, 1.0 eq.) in DMF (100 mL, 10 vol) and water (10 mL, 1 vol), 2-amino-2-methylpropanoic acid (SM-2, 14.1 g, 136.98 mmol, 3.0 eq.), N,N-dimethylglycine (2.35 g, 22.83 mmol, 0.5 eq.), K 2 CO 3 (31.5 g, 228.3 mmol, 5.0 eq.), Cu powder (575 mg, 9.13 mmol, 0.2 eq.) and copper iodide (1.73 g, 9.13 mmol, 0.2 eq.) were added at room temperature. The reaction mixture stirred at 110 °C until TLC indicated complete consumption of SM-1. The 10 reaction mixture was then diluted with ice cold water (500 mL) and acidified with 6 N HCl (pH ~4) and extracted with ethyl acetate (2 x 1L). The combined organic layer was washed with brine solution (300 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure, recrystallized with DCM, filtered and dried to obtain 4-((2-carboxypropan-2-yl)amino)-2-fluorobenzoic acid (Int-1, 6.2 g, 56%). 1H NMR (400 MHz, DMSO-d 6 ^^į^^^^^^^^EU^V^^^+^^^^^^^^^W^^J = 8.79 Hz, 1H), 6.96 (s, 1H), 6.33 (dd,15 J = 8.79, 1.85 Hz, 1H), 6.15 (dd, J = 14.57, 1.62 Hz, 1H), 1.44 (s, 6H). LCMS: 242.15 [M+H] + . Step-2: Preparation of methyl 2-fluoro-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)benzo ate (Int-2) To a stirred solution of 4-((2-carboxypropan-2-yl)amino)-2-fluorobenzoic acid (Int-1, 6.2 g, 25.72 mmol, 1.0 eq.) in DMF (70 mL, 10 vol), MeI (3.1 mL, 51.45 mmol, 2.0 eq.), K2CO3 (53.1 g, 385.5 mmol, 15.0 eq.) were added at room temperature. The reaction mixture was allowed to stir at ambient temperature 20 until TLC indicated complete consumption of starting material. The reaction mixture was then diluted with ice cold water (500 mL) and the resulting precipitate was filtered and dried to obtain methyl 2-fluoro-4-((1- methoxy-2-methyl-1-oxopropan-2-yl)amino)benzoate (Int-2, 4.82 g, 69%). 1H NMR (400 MHz, DMSO-d6^^į^^^^^^^W^^J = 8.80 Hz, 1H), 7.11 (s, 1H), 6.29 (dd, J = 8.80, 2.45 Hz, 1H), 6.14 (dd, J = 14.67, 1.96 Hz, 1H), 3.74 (s, 3H), 3.63 (s, 3H), 1.48 (s, 6H). LCMS: 270.10 [M+H] + . Step-3: Preparation of methyl 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoate (Int-3) To a stirred solution of methyl 2-fluoro-4-((1-methoxy-2-methyl-1-oxopropan-2-yl)amino)benzo ate (Int-2, 4.8 g, 17.84 mmol, 1.0 eq.) in DMSO (7.2 mL, 1.5 vol), 4-isothiocyanato-2- 5 (trifluoromethyl)benzonitrile (SM-3, 8.5 g, 37.59 mmol, 2.1 eq.) was added at room temperature. The reaction mixture stirred at 90 °C until TLC indicated complete consumption of starting material. The reaction mixture was then diluted with ice cold water (500 mL) and extracted with ethyl acetate (2 x 1 L). The combined organic layer was washed with brine solution (300 mL), dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude obtained was purified by column (silica gel, 100-200 10 mesh), eluting with 20-30% ethyl acetate in hexane. The pure fractions were combined and concentrated under reduced pressure to obtain methyl 4-(3-(4-cyano-3-(trifluoromethyl)-phenyl)-5,5-dimethyl-4-oxo -2- thioxoimidazolidin-1-yl)-2-fluorobenzoate (Int-3, 5 g, 60%). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.41 (d, J = 8.31 Hz, 1H), 8.29 (d, J = 1.47 Hz, 1H), 8.06 - 8.11 (m, 2H), 7.51 (dd, J = 11.25, 1.96 Hz, 1H), 7.41 (dd, J = 8.31, 1.96 Hz, 1H), 3.90 (s, 3H), 1.55 (s, 6H). 15 LCMS: 466.50 [M+H] + . Step-4: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-D) A flask was charged with methyl 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoate (Int-3, 3 g, 6.45 mmol, 1.0 eq.), MeOH:THF:H2O (1:1:1, 30 mL, 20 10 vol) and LiOH (810 mg, 19.35 mmol, 3.0 eq.) at ambient temperature under argon atmosphere. The reaction mixture was stirred at ambient temperature until TLC indicated complete consumption of starting material. The reaction mixture was concentrated under reduced pressure, diluted with water (10 mL), acidified with citric acid (pH ~3) and filtered the resulting precipitate and dried to obtain 4-(3-(4-cyano-3- (trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazol idin-1-yl)-2-fluorobenzoic acid (Int-D, 2.6 g, 25 89%). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.40 (d, J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.94 (t, J = 8.07 Hz, 1H), 7.36 (d, J = 10.76 Hz, 1H), 7.29 (d, J = 8.31 Hz, 1H), 1.54 (s, 6H). LCMS: 452.20 [M+H] + . Preparation of 6-(methylamino)hexan-1-ol trifluoroacetate (Int-E) 30 Step-1: Preparation of tert-butyl (6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (Int-1) A stirred solution of tert-butyl (6-hydroxyhexyl)carbamate (SM-1 (1.0 g, 4.60 mmol, 1 eq.) in dichloromethane (10 mL) was cooled to 0 °C followed by addition of triethylamine (0.83 mL, 5.98 mmol, 1.3 eq.) and tert-butyldimethylsilyl chloride (TBDMS, 765 mg, 5.06 mmol, 1.1 eq.). The reaction mixture 5 was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After complete consumption of SM-1, the reaction mixture was diluted with ice cold water (100 mL) and extracted with DCM (2 x 100 mL). The combined organic extract was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Int-1 (1.65 g, crude). 1H NMR (400 MHz, CDCl 3 ) δ 4.50 (br s, 1H), (t, J = (t, 6.60 Hz, 2H), 3.11 (d, J = 6.36 Hz, 2H), 10 1.40 - 1.57 (m, 15H), 1.30 - 1.39 (m, 2H), 0.87 - 0.95 (m, 9H), 0.03 - 0.13 (m, 6H). LCMS: 332.38 [M+H] + . Step-2: Preparation of tert-butyl (6-((tert-butyldimethylsilyl)oxy)hexyl)(methyl)carbamate (Int-2) A stirred solution of tert-butyl (6-((tert-butyldimethylsilyl)oxy)hexyl)carbamate (Int-1, 1.5 g, 4.53 mmol, 1 eq.) in DMF (10 mL) was added sodium hydride (283 mg, 6.79 mmol, 1.5 eq.) at 0 °C followed by addition of iodomethane (0.56 mL, 9.06 mmol, 2 eq.). The reaction mixture was allowed to warm up to room 15 temperature and stir for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with ice cold water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain Int-2 (1.38 g, crude). 1H NMR (400 MHz, CDCl3)= δ 3.61 (t, J 6.60 Hz, 2H), 3.18 - 3.10 (m, J = 5.38 Hz, 2H), 2.83 (s, 20 3H), 1.40 - 1.56 (m, 17H), 1.20 - 1.40 (m, 6H), 0.82 - 0.94 (m, 9H). Step-3: Preparation of 6-(methylamino)hexan-1-ol trifluoroacetate (Int-E) A stirred solution of tert-butyl (6-((tert-butyldimethylsilyl)oxy)hexyl)(methyl)carbamate (Int-2, 1.1 g, 3.18 mmol, 1 eq.) in dichloromethane (15 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (5 mL). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of 25 the reaction was monitored by TLC. After complete consumption of Int-2, volatiles were evaporated and the crude obtained was filtered and washed with diethyl ether (2 x 50 mL) to afford Int-E (1.21 g, crude). 1H NMR (400 MHz, CDCl 3 ) δ 8.26- 8.46 (m, 2H), 4.34 (t, J = 6.50 Hz, 2H), 2.95 - 3.10 (m, 3H), 2.75 (t, J = 5.00 Hz, 2H), 1.66 - 1.80 (m, 4H), 1.43 (d, J = 2.88 Hz, 4H). Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-hydroxyhexyl)(methy l)amino)phenyl)-13- methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-c yclopenta[a]phenanthren-17-yl acetate (Int-F) 5 Step-1: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate (Int-1) To a stirred solution of SM-1 (10 g, 21 mmol, 1.0 eq.) in methanol (150 mL) and THF (150 mL) were added KOAc (20.6 g, 210 mmol, 10 eq.) and iodine (13.1 g, 105 mmol, 5 eq.) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 3h. Progress of the reaction was monitored 10 by TLC. After completion of the reaction, the reaction mixture was quenched with sodium thiosulfate (Na 2 S 2 O 3 ) solution (50 g in 30 mL water) and extracted with ethyl acetate (2 x 200 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford Int-1 (8.0 g, 82%). 1H NMR (400 MHz, DMSO-d 6 ) δ11.91(brs,1H),6.91(d,J = 8.31 Hz, 2H), 6.44 (d, J = 8.31 Hz, 15 2H), 5.67 (s, 1H), 4.37 (m, 1H), 2.75 (s, 2H), 2.61 (d, J = 4.40 Hz, 3H), 2.30 - 2.40 (m, 1H), 2.07 - 2.16 (s, 5H), 1.99 (s, 6H), 1.63 - 1.77 (m, 2H), 1.21 - 1.45 (m, 5H), 0.86 (t, J = 6.60 Hz, 1H), 0.16 - 0.28 (m, 3H). LCMS: 462.28 [M+H] + . Step-2: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-hydroxyhexyl)(methy l)amino)phenyl)- 13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1 H-cyclopenta[a]phenanthren-17-yl acetate20 (Int-F) To a solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate (Int-9, 4 g, 8.67 mmol, 1.0 eq.) and 6-bromohexan-1-ol (SM-2, 7.81 g, 43.38 mmol, 5 eq.) in ethanol (40 mL) and water (40 mL) was added NaHCO3 (7.37 g, 86.76 mmol, 10 eq.) at room temperature. The reaction mixture was heated 25 to 80 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through a pad of celite bed and washed with ethyl acetate (40 mL). The filtrate was concentrated under reduced pressure, diluted with water (120 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 70% ethyl acetate in heptane to afford Int-F (2.6 g, 53%). 1H NMR (400 MHz, DMSO-d 6 ) δ6.98(d,J = 7.89 Hz, 2H), 6.58 (d, J = 7.89 Hz, 2H), 5.67 (br s, 1H), 4.24 - 4.51 (m, 2H), 3.36 (d, J = 5.70 Hz, 2H), 3.23 (d, J = 6.58 Hz, 2H), 2.69 - 2.86 (m, 4H), 2.55 (s, 5 3H), 2.29 - 2.44 (m, 1H), 2.05 - 2.26 (m, 5H), 1.87 - 2.04 (m, 6H), 1.63 - 1.77 (m, 2H), 1.34 - 1.49 (m, 6H), 1.27 (br s, 6H), 0.23 (br s, 3H). LCMS: 562.40 [M+H] + . Preparation of tert-butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (Int-G) Step-1: Preparation of tert-butyl 4-((1-((Benzyloxy)carbonyl)piperidin-4-yl)methyl)piperazine- 1-10 carboxylate (Int-1) To a stirred solution of benzyl 4-formylpiperidine-1-carboxylate (SM-1, 2.00 g, 8.08 mmol, 1.0 eq.) and tert-butyl piperazine-1-carboxylate (SM-1, 1.50 g, 8.08 mmol, 1.0 eq.) in dichloromethane (20 mL) was added sodium triacetoxyborohydride (1.71 g, 8.08 mmol, 1.0 eq.) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 16h. Progress of the reaction was monitored by TLC. After 15 completion of the reaction, the reaction mixture was diluted with saturated aq. NaHCO3 (40 mL) and extracted with DCM (2 x 40 mL). The combined organic extract was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 60% ethyl acetate in heptane to afford Int-1 (2 g, 59%). 1H NMR (400 MHz, DMSO-d6) δ 7.35(s,5H),5.05(s,2H),3.81- 4.06 (m, 2H), 3.24 - 3.29 (m, 20 4H), 2.68 - 3.06 (m, 2H), 2.26 (br s, 3H), 2.11 (d, J = 6.36 Hz, 2H), 1.60 - 1.88 (m, 4H), 1.38 (s, 9H), 0.96 (d, J = 11.25 Hz, 2H). LCMS: 418.53 [M+H] + . Step-2: Preparation of tert-butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate (Int-G) A solution of tert-butyl 4-((1-((benzyloxy)carbonyl)piperidin-4-yl)methyl)piperazine- 1-carboxylate (Int-1, 3.6 g, 8.6 mmol, 1.0 eq.) and 10% Pd/C (300 mg, 30% w/w) in ethanol (40 mL) was allowed to stir 25 under H2 atmosphere at 200 psi and room temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through a pad of celite bed, washed with ethanol (100 mL) and the filtrate was concentrated under reduced pressure to afford Int-G (2.00 g, 83%). 1 H NMR (400 MHz, DMSO-d6)δ3.28(s,4H),3.14(d,J = 12.23 Hz, 2H), 2.71 (t, J = 11.98 Hz, 2H), 2.26 (d, J = 4.40 Hz, 4H), 2.11 (d, J = 6.36 Hz, 2H), 1.76 (d, J = 12.72 Hz, 2H), 1.39 (s, 9H), 1.10 - 1.25 (m, 4H). LCMS: 284.32 [M+H] + . Preparation of 4-(((1r,4r)-4-aminocyclohexyl)(methyl)amino)-2-chlorobenzoni trile trifluoroacetate 5 (Int-A1) Step-1: Preparation of tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)amino)cyclohexyl)carbama te (Int- 1) To a stirred solution of 2-chloro-4-fluorobenzonitrile (SM-1, 4 g, 25 mmol, 1.0 eq.) in DMSO (40 10 mL), tert-butyl ((1r,4r)-4-aminocyclohexyl)carbamate (SM-1, 5.5 g, 25 mmol, 1.0 eq.) and K2CO3 (7.1 g, 51 mmol, 2 eq.) were added at room temperature. The reaction mixture was allowed to stir at 90 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (200 mL) and extracted with ethyl acetate (2 x 400 mL). The combined organic extract was washed with water (200 mL), brine (200 mL), dried over anhydrous sodium sulfate, filtered, and 15 concentrated under vacuum. The crude obtained was purified by combi flash column eluting with 64% ethyl acetate in heptane to afford tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)amino)cyclohexyl)carbama te (Int-1, 7.1 g, 78%). 1H NMR (400 MHz, DMSO-d 6 ) δ 7.48 (d,J = 8.80 Hz, 1H), 6.86 (d, J = 6.85 Hz, 1H), 6.80 (d, J = 6.85 Hz, 1H), 6.75 (s, 1H), 6.59 (d, J = 8.80 Hz, 1H), 3.20-3.23 (m, 2H), 1.91 (d, J = 11.25 Hz, 2H), 1.79 (d, 20 J = 10.76 Hz, 2H), 1.38 (s, 9H), 1.13 - 1.33 (m, 4H). Step-2: Preparation of tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl ) carbamate (Int-2) To a stirred solution of tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)amino)cyclohexyl)carbama te (Int-1, 5.5 g, 15 mmol, 1.0 eq.) in DMF (25 mL) under nitrogen atmosphere, NaH (63%, 500 mg, 21 mmol, 25 1.3 eq.) was added portion wise at 0 °C. The reaction mixture was allowed warm up to room temperature and stir for 30 min, cooled down to 0 °C and added methyl iodide (1.1 mL, 21 mmol, 1.3 eq.) dropwise at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction was quenched with water (150 mL) and extracted with ethyl acetate (2 x 200 mL). The organic layer was concentrated under reduced 30 pressure and the crude obtained was purified by combi flash column eluting with 15% ethyl acetate in heptane to afford tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl )carbamate (Int- 2, 3.2 g, 55%). LCMS: 364.2 [M+H] + . Step-3: Preparation of 4-(((1r,4r)-4-aminocyclohexyl)(methyl)amino)-2-chlorobenzoni trile 5 trifluoroacetate (Int-A1) To a stirred solution of tert-butyl ((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohexyl )- carbamate (Int-2, 1.1 g, 3 mmol, 1.0 eq.) in DCM (10 mL) under nitrogen atmosphere was added TFA (10 mL, 10 vol) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the volatiles were 10 evaporated under reduced pressure and the residue was triturated with diethyl ether (20 mL), filtered and dried under vacuum to afford 4-(((1r,4r)-4-aminocyclohexyl)(methyl)amino)-2-chlorobenzoni trile trifluoroacetate (Int-A1, 852 mg, 74%). LCMS: 264.1 [M+H] + . Preparation of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chloro-3-methylbenzonit rile hydrochloride (Int-15 A2) Step-1: Preparation of tert-butyl ((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)carb amate (Int-1) To a stirred solution of 2-chloro-4-fluoro-3-methylbenzonitrile (SM-1, 20 g, 93 mmol, 1.0 eq.) in20 DMF (200 mL), NaH (60%, 8.1 g, 204.6 mmol, 2.2 eq.) was added at room temperature followed by tert- butyl ((1r,4r)-4-hydroxycyclohexyl)carbamate (SM-2, 15.7 g, 93 mmol, 1.0 eq.). The reaction mixture was allowed to stir at ambient temperature for 3h. Progress of the reaction was monitored by TLC. After consumption of the starting material, the reaction mixture was diluted with ice cold water (500 mL) and the precipitate was filtered, washed with water (500 mL), diethyl ether (500 mL) and dried to afford tert-butyl25 ((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)carb amate (Int-1, 32 g, 94%). 1H NMR (400 MHz, DMSO-d6 δ 7.74 (d, J = 8.80 Hz, 1H), 7.22 (d, J = 8.80 Hz, 1H), 6.84 (d, J = 7.34 Hz, 1H), 4.39 - 4.52 (m, 1H), 3.32 (s, 1H), 2.21 (s, 3H), 2.03 (d, J = 9.78 Hz, 2H), 1.81 (d, J = 10.27 Hz, 2H), 1.28 - 1.52 (m, 13H). LCMS: 309.16 [M+H-56] + . Step-2: Preparation of 4-(((1r,4r)-4-aminocyclohexyl)oxy)-2-chloro-3-methylbenzonit rile hydrochloride (Int-A2) To a stirred solution of tert-butyl ((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)carbamate (Int-1, 5 g, 13.73 mmol, 1.0 eq.) in 1,4-dioxane (50 mL) under 5 nitrogen atmosphere was added HCl (4M in 1,4-dioxane, 25 mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the volatiles were evaporated under reduced pressure and the residue was triturated with diethyl ether (50 mL), filtered and dried under vacuum to afford 4-(((1r,4r)-4- aminocyclohexyl)oxy)-2-chloro-3-methylbenzonitrile hydrochloride (Int-A2, 3.7 g, 89%). 10 Preparation of 7-(bromomethyl)-8-fluoro-3-methylquinoxalin-2(1H)-one (Int-A3) Step-1: Preparation of 1-bromo-2,4-difluoro-3-nitrobenzene (Int-1) To a solution of H 2 SO 4 (10 mL), TFA (50 mL) was added dropwise at 0 °C under argon atmosphere followed by portion wise addition of 1,3-difluoro-2-nitrobenzene (SM-1, 5.0 g, 31.46 mmol, 1.0 eq.) and 15 then NBS (6.15 g, 34.58 mmol, 1.1 eq.) while maintaining the temperature at 0 °C. The reaction mixture was allowed to warm up to ambient temperature and stir for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 x 250 mL). The combined organic layer was washed with saturated bicarbonate solution (150 mL), brine solution (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under 20 reduced pressure. The crude obtained was purified by flash column and the pure fractions were combined and concentrated under reduced pressure to afford 1-bromo-2,4-difluoro-3-nitrobenzene (Int-1, 3.3 g, 89%). 1H NMR (400 MHz, DMSO-d6) δ 8.17 (d, J = 9.29 Hz, 1H), 7.54 (d, J = 9.54 Hz, 1H). Step-2: Preparation of methyl (4-bromo-3-fluoro-2-nitrophenyl)alaninate (Int-2) To a solution of 1-bromo-2,4-difluoro-3-nitrobenzene (Int-1, 4.6 g, 19.32 mmol, 1.0 eq.) in DMF (46 mL), methyl alaninate hydrochloride (SM-2, 3.2 g, 23.19 mmol, 1.2 eq.), DIPEA (8.4 mL, 48.31 mmol, 2.5 eq.) were added under argon atmosphere at ambient temperature. The resulting reaction mixture was allowed to stir at ambient temperature for 5h. Progress of the reaction was monitored by TLC. After 5 completion of the reaction, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 x 250 mL). The combined organic layer was washed with water (150 mL), brine solution (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude obtained was purified by flash column and the pure fractions were combined and concentrated under reduced pressure to afford methyl (4-bromo-3-fluoro-2-nitrophenyl)alaninate (Int-2, 6.0 g, 96%). 10 LCMS: 321.11 [M+H] + . Step-3: Preparation of methyl (2-Amino-4-bromo-3-fluorophenyl)alaninate (Int-3) To a solution of methyl (4-bromo-3-fluoro-2-nitrophenyl)alaninate (Int-2, 6.0 g, 18.75 mmol, 1.0 eq.) in MeOH:H2O (96 mL, 15:1), Zn powder (9.75 g, 150 mmol, 8.0 eq.), NH4Cl (8 g, 150 mmol, 8.0 eq.) were added at 0 °C and the resulting reaction mixture was allowed to warm up to ambient temperature and 15 stir for 6h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through celite pad, washed with MeOH (100 mL) and concentrated under reduced pressure. The obtained residue was diluted with water (200 mL), extracted with ethyl acetate (2 x 250 mL) and the combined organic layer was washed with water (150 mL), brine solution (150 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford methyl (2-amino-4- 20 bromo-3-fluorophenyl)alaninate (Int-3, 6.0 g, crude). Step-4: Preparation of 7-bromo-8-fluoro-3-methyl-3,4-dihydroquinoxalin-2(1H)-one (Int-4) To a solution of methyl (2-amino-4-bromo-3-fluorophenyl)alaninate (Int-3, 6.0 g, 20.61 mmol, 1.0 eq.) in 1,4-dioxane (60 mL), HCl (4M in 1,4-dioxane, 60 mL) was added at 0 °C. The resulting reaction mixture was allowed to warm up to ambient temperature and stir for 2 h. Progress of the reaction was 25 monitored by TLC. After consumption of starting material, the reaction mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether (40 mL), filtered and dried to afford 7- bromo-8-fluoro-3-methyl-3,4-dihydroquinoxalin-2(1H)-one (Int-4, 5.0 g, crude). 1H NMR (400 MHz, DMSO-d 6 )δ10.42(s,1H),7.40(s,1H),7.28(s,1H),7.15(s,1H), 3.73-3.85 (m, 1H), 1.13 - 1.28 (m, 3H). LCMS: 259.1 [M+H] + . 30 Step-5: Preparation of 7-bromo-8-fluoro-3-methylquinoxalin-2(1H)-one (Int-5) To a solution of 7-bromo-8-fluoro-3-methyl-3,4-dihydroquinoxalin-2(1H)-one (Int-4, 1.0 g, 3.86 mmol, 1.0 eq.) in DCM (10 mL), DDQ (1.0 g, 4.63 mmol, 1.2 eq.) was added at 0 °C and the resulting reaction mixture was allowed to warm up to ambient temperature and stir for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with DCM (100 mL), washed with saturated bicarbonate solution (50 mL), water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford 7-bromo-8-fluoro-3- 5 methylquinoxalin-2(1H)-one (Int-5, 800 mg, crude). LCMS: 257.14 [M+H] + . Step-6: Preparation of methyl 5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxaline-6-carboxylate (Int-6) To a solution of 7-bromo-8-fluoro-3-methylquinoxalin-2(1H)-one (Int-5, 1.0 g, 3.8 mmol, 1.0 eq.) in MeOH (10 mL), Pd(dppf)Cl 2 .DCM (158 mg, 0.19 mmol, 0.05 eq.) and TEA (1 mL, 7.7 mmol, 2.0 eq.) 10 were added at RT in an autoclave and the resulting reaction mixture was allowed to stir at 80 °C under CO atmosphere for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through celite pad, washed with MeOH (50 mL) and concentrated under reduced pressure. The crude obtained was purified by flash column and the pure fractions were combined and concentrated under reduced pressure to afford methyl 5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxaline- 15 6-carboxylate (Int-6, 800 mg, 87%). 1H NMR (400 MHz, DMSO-d6)δ12.64(s,1H),7.54- 7.70 (m, 2H), 3.89 (s, 3H), 2.45 (s, 3H). LCMS: 237.3 [M+H] + . Step-7: Preparation of 8-fluoro-7-(hydroxymethyl)-3-methylquinoxalin-2(1H)-one (Int-7) To a solution of methyl 5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxaline-6-carboxylate (Int-6, 5.0 20 g, 21.18 mmol, 1.0 eq.) in THF (50 mL), LAH (21.1 mL, 42.2 mmol, 2.0 eq, 2M) solution was added at 0 °C under argon atmosphere and the resulting reaction mixture was allowed to warm up to ambient temperature and stir for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was cooled to 0 °C, quenched with saturated NH 4 Cl solution, filtered through celite pad and washed with MeOH (100 mL). The combined filtrate was concentrated under reduced pressure to afford 8- 25 fluoro-7-(hydroxymethyl)-3-methylquinoxalin-2(1H)-one (Int-7, 4 g, 91%). LCMS: 209.35 [M+H] + . Step-8: Preparation of 7-(bromomethyl)-8-fluoro-3-methylquinoxalin-2(1H)-one (Int-A3) A flask was charged with 8-fluoro-7-(hydroxymethyl)-3-methylquinoxalin-2(1H)-one (Int-7, 1.0 g, 4.8 mmol, 1.0 eq.) and a cold solution of 47% HBr (50 mL) under argon atmosphere. The resulting reaction 30 mixture was allowed to warm up to room temperature and stir at 80 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, cooled to 0 °C, quenched with saturated NaHCO3 solution (pH ~7) and extracted with DCM (2 x 200 mL). The combined organic layer was washed with water (150 mL), brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 7-(bromomethyl)-8- fluoro-3-methylquinoxalin-2(1H)-one (Int-A3, 200 mg, 15%). 5 1 H NMR (400 MHz, DMSO-d 6 )δ12.38- 12.68 (m, 1H), 7.50 (d, J = 8.31 Hz, 1H), 7.34 (t, J = 7.58 Hz, 1H), 4.78 (s, 2H), 2.40 (s, 3H). LCMS: 270.80 [M+H] + . Preparation of 3-ethyl-7-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)-1 ,5-naphthyridin-2(1H)-one trifluoroacetate (Int-C1) 10 Step-1: Preparation of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (Int-1) To a solution of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int-C, 2 g, 7.35 mmol, 1 eq.) in MeOH (20 mL) were added tert-butyl 4-formylpiperidine-1-carboxylate (SM-1, 1.56 g, 7.35 mmol, 1 eq.) and glacial acetic acid (0.2 mL) at room temperature, stirred for 1h and then 15 NaCNBH 3 (2.37 g, 36.7 mmol, 5 eq.) was added at 0 °C. Progress of the reaction was monitored by TLC. The reaction mixture was allowed to warm up to room temperature and stir for 16h, quenched with water (100 mL) and extracted with DCM (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine solution (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude obtained was purified by silica gel flash column. The pure fractions were combined and20 evaporated under reduced pressure to afford tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (Int-1, 2 g, 82%). 1H NMR (400 MHz, CDCl 3 )δ11.28- 11.56 (m, 1H), 8.49 (s, 1H), 7.86 (s, 1H), 7.70 (s, 1H), 4.03 – 4.13 (br s, 2H), 3.73 (s, 2H), 3.50 (s, 1H), 3.17 (q, J = 7.34 Hz, 2H), 2.70 – 2.74 (m, 8H), 1.75 – 1.79 (m, 3H), 1.45 (s, 9H), 1.34 (m, 6H), 1.09 - 1.23 (m, 2H). LCMS: 470.58 [M+H] + . 25 Step-2: Preparation of 3-ethyl-7-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)-1 ,5-naphthyridin-2(1H)- one trifluoroacetate (Int-C1) To a solution of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (Int-1, 1.2 g, 2.55 mmol, 1 eq.) in DCM (12 mL), TFA (6 mL, 5 vol) was added at room temperature and the solution was allowed to stir for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure and the resulting solid was filtered, washed with diethyl ether (20 mL) and dried to afford 3-ethyl-7-((4-(piperidin-4-ylmethyl)piperazin-1-yl)methyl)-1 ,5-naphthyridin-2(1H)-one trifluoroacetate (Int-C1, 1.5 g, 82%). 5 1 H NMR (400 MHz, DMSO-d 6 )δ12.01(s,1H),8.45(s,1H),8.31(br, s, 1H,7.77(s,1H,7.62 (s, 1H), 3.85 - 4.08 (m, 2H), 3.28 (d, J = 12.23 Hz, 2H), 3.05 - 3.18 (m, 4H), 2.77 - 2.92 (m, 4H), 2.54 - 2.60 (m, 2H), 1.98 (s, 2H), 1.83 (d, J = 13.69 Hz, 2H), 1.23 - 1.37 (m, 2H), 1.18 (m, 6H). Preparation of 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid (Int-E1) 10 Step-1: Preparation of tert-butyl 4-(6-(Methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylate (Int-1) To a Stirred solution of methyl 5-bromopyridine-2-carboxylate (SM-1, 200 mg, 0.92 mmol, 1.0 eq.) and tert-butyl piperazine-1-carboxylate (SM-2, 258 mg, 1.31 mmol, 1.5 eq.) in toluene (10 mL) was added cesium carbonate (60 mg, 1.8 mmol, 2 eq.) followed by BINAP (5.70 mg, 0.09 mmol, 0.1 eq.) and Pd 2 dba 3 (8.40 mg, 0.092 mmol, 0.1 eq.) under N 2 atmosphere at room temperature. Progress of the reaction was 15 monitored by TLC. The reaction mixture was stirred at 100 °C for 10h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 50% EtOAc in heptane to afford Int-1 (130 mg). 20 LCMS: 322.2 [M+H] + . Step-2: Preparation of 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid (Int-E1) A flask was charged with tert-butyl 4-(6-(methoxycarbonyl)pyridin-3-yl)piperazine-1-carboxylate (Int-1, 250 mg, 0.78 mmol, 1 eq.), MeOH:THF:H2O (1:1:1, 15 mL) and LiOH (93 mg, 3.87 mmol, 5 eq.) at ambient temperature under argon atmosphere. The reaction mixture was stirred at ambient temperature until 25 TLC indicated complete consumption of starting material. The reaction mixture was concentrated under reduced pressure, diluted with water (10 mL), acidified with citric acid (pH ~3), filtered the resulting solid and dried to obtain 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid (Int-E1, 90 mg, 39%). 1H NMR (400 MHz, DMSO-d 6 ) δ 11.74 - 12.86 (br s, 1H), 8.34 (s, 1H), 7.86 (d, J = 8.80 Hz, 1H), 7.34 (d, J = 8.31 Hz, 1H), 3.45 (s, 4H), 3.35 (s, 4H), 1.41 (s, 9H). LCMS: 308.32 [M+H] + . Example S1. Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(4-((7- ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperaz ine-1-carbonyl)piperidin-1- yl)pyridazine-3-carboxamide (Compound No.1) 5 Step-1: Preparation of ethyl 1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexy l)carbamoyl)- pyridazin-3-yl)piperidine-4-carboxylate (Int-1) To a stirred solution of 6-chloro-N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cycl ohexyl)- pyridazine-3-carboxamide (Int-A, 7 g, 17 mmol, 1.0 eq.) and ethyl piperidine-4-carboxylate (SM-1, 4 g, 25 mmol, 1.5 eq.) in DMF (70 mL) was added potassium carbonate (5.86 g, 42 mmol, 2.5 eq.) at room 10 temperature. The reaction mixture was allowed to stir at 80 °C for 12h. Progress of the reaction was monitored by TLC. After reaction completion, the reaction mixture was diluted with ice cold water (300 mL), stirred for 10 min and the precipitated solid was filtered and dried to afford Int-1 (6.0 g, 66%). 1H NMR (400 MHz, DMSO-d6)δ8.57(d, J = 7.82 Hz, 1H), 7.80 (d, J = 9.29 Hz, 1H), 7.75 (d, J = 8.80 Hz, 1H), 7.35 (d, J = 9.78 Hz, 1H), 7.24 (d, J = 8.80 Hz, 1H), 4.44 - 4.55 (m, 1H), 4.30 - 4.41 (m, 2H), 15 4.00 - 4.11 (m, 2H), 3.80 - 3.92 (m, 1H), 3.08 - 3.23 (m, 2H), 2.64 - 2.76 (m, 1H) 2.22 (s, 3H), 2.05 - 2.15 (m, 2H), 1.85 - 1.97 (m, 4H), 1.44 - 1.71 (m, 6H), 1.17 (t, J = 7.34 Hz, 3H). LCMS: 526.2 [M+H] + . Step-2: Preparation of 1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)carbamoyl)pyridazin-3-yl)piperidine -4-carboxylic acid (Int-2) To a solution of ethyl 1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexy l)carbamoyl)- 20 pyridazin-3-yl)piperidine-4-carboxylate (Int-1, 6.0 g, 11.5 mmol, 1.0 eq.) in THF (20 mL) and water (5 mL) was added LiOH.H 2 O (2.49 g, 57.9 mmol, 5.0 eq.) at 0 °C and the resulting mixture was allowed to stir for 5 h. Progress of the reaction was monitored by TLC. Volatiles were then removed under reduced pressure, diluted with water (80 mL) and acidified with 1 N aq. HCl until pH 3 and extracted with ethyl acetate (3 x 80 mL). The combined organic extract was washed with water (200 mL), brine (200 mL), dried over 25 anhydrous sodium sulfate, filtered, and concentrated under vacuum to afford Int-2 (5.4 g, 94%). LCMS: 498.37 [M+H] + . Step-3: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(4-((7-ethyl-6- oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazine-1-ca rbonyl)piperidin-1-yl)pyridazine-3- carboxamide 5 To a stirred solution of 1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)carbamoyl)-pyridazin-3-yl)piperidin e-4-carboxylic acid (Int-2, 250 mg, 0.503 mmol, 1.0 eq.) in DMF (3 mL) were added HATU (286 mg, 0.754 mmol, 1.5 eq.) and DIPEA (0.43 mL, 2.515 mmol, 5.0 eq.) at 0 °C and the reaction mixture was stirred for 5 min. To this mixture was added 3- ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int-C, 136 mg, 0.503 mmol, 1.0 10 eq.) at 0 °C and the reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC. Upon reaction completion, the mixture was diluted with water (60 mL) and extracted with EtOAc (2 x 60 mL). The combined organic extract was washed with water (60 mL), brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product which was purified by flash chromatography eluting with 1-4% methanol in dichloromethane to afford the 15 title compound (600 mg, 28%). 1H NMR (400 MHz, DMSO-d6)δ11.87(s,1H),8.58(brd, J = 8.00 Hz, 1H), 8.38 (s, 1H), 7.73 - 7.83 (m, 3H), 7.61 (s, 1H), 7.35 (br d, J = 9.51 Hz, 1H), 7.26 (br d, J = 8.88 Hz, 1H), 4.47 (br d, J = 13.38 Hz, 3H), 3.82 - 3.94 (m, 1H), 3.53 - 3.64 (m, 4H), 3.46 (br s, 2H), 2.96 - 3.15 (m, 3H), 2.52 - 2.58 (m, 2H), 2.29 - 2.46 (m, 3H), 2.24 (s, 3H), 2.07 - 2.15 (m, 2H), 1.90 (br d, J = 7.88 Hz, 2H), 1.48 - 1.76 (m, 9H), 1.18 20 (br t, J = 7.32 Hz, 3H). LCMS: 752.4 [M+H] + . HPLC purity 93.8%.
Example S2. Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(1-((7- ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperid ine-4-carbonyl)piperazin-1- yl)pyridazine-3-carboxamide (Compound No.4) 5 Step-1: Preparation of tert-butyl 4-(6-(((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)carbamoyl)-pyridazin-3-yl)piperazin e-1-carboxylate (Int-1) To a stirred solution of 6-chloro-N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cycl ohexyl)- pyridazine-3-carboxamide (Int-A, 900 mg, 2.2 mmol, 1.0 eq.) and tert-butyl piperazine-1-carboxylate (SM- 1, 622 mg, 3.3 mmol, 1.5 eq.) in DMF (10 mL) was added potassium carbonate (760 mg, 5.5 mmol, 2.5 eq.) 10 at room temperature. The reaction mixture was allowed to stir at 80 °C for 16h. Progress of the reaction was monitored by TLC. After consumption of the starting material, the reaction mixture was diluted with ice cold water (60 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extract was washed with water (40 mL), brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product which was purified by flash chromatography eluting with 30-35% ethyl acetate in 15 heptane to afford Int-1 (700 mg, 57%). 1H NMR (400 MHz, DMSO-d6^^į^^^^^^^G^^J = 7.83 Hz, 1H), 7.82 (dd, J = 36.19, 10.27 Hz, 2H), 7.24-7.39 (m, 2H), 4.45 - 4.59 (m, 1H), 3.84 - 3.96 (m, 1H), 3.74-3.69 (m, 4H), 3.50-3.44 (m,4H), 2.24 (s, 3H), 2.12 (d, J = 10.76 Hz, 2H), 1.90 (d, J = 10.76 Hz, 2H), 1.49 - 1.74 (m, 4H), 1.43 (s, 9H). LCMS: 555.53 [M+H] + . Step-2: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(piperazin-1- yl)pyridazine-3-carboxamide (Int-2) 5 To a solution of tert-butyl 4-(6-(((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)carbamoyl)-pyridazin-3-yl)piperazin e-1-carboxylate (Int-1, 700 mg, 1.2 mmol, 1 eq.) in 1,4-dioxane (7.0 mL) was added 4M HCl in1,4-dioxane (3.5 mL) at 0 °C and the resulting mixture was allowed to stir for 1h at RT. After consumption of starting material, the volatiles were evaporated under reduced pressure and the resulting residue was triturated with diethyl ether (2 x 20 mL), filtered and dried to 10 afford Int-2 (560 mg, crude) which was used as is in the next step. 1H NMR (400 MHz, DMSO-d6)δ9.11(s,1H),8.65(dd,J = 15.16, 8.31 Hz, 1H), 7.77 (d, J = 8.31 Hz, 1H), 7.33 - 7.49 (m, 1H), 7.26 (d, J = 8.80 Hz, 1H), 4.51 (s, 1H), 3.94 (s, 1H), 3.72 (s, 2H), 3.57 (s, 2H), 3.47 (s, 2H), 3.18 - 3.28 (m, 2H), 2.24 (s, 3H), 2.12 (d, J = 9.78 Hz, 2H), 1.90 (d, J = 10.27 Hz, 2H), 1.49 - 1.74 (m, 4H), 1.43 (s, 1H). LCMS: 455.36 [M+H] + . 15 Step-3: Preparation of tert-butyl 4-(4-(6-(((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cycloh exyl)- carbamoyl)pyridazin-3-yl)piperazine-1-carbonyl)piperidine-1- carboxylate (Int-3) To a stirred solution of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(piperazin- 1-yl)pyridazine-3-carboxamide (Int-2, 560 mg, 1.1 mmol, 1.0 eq.) and 1-(tert-butoxycarbonyl)piperidine-4- carboxylic acid (SM-2, 262 mg, 1.1 mmol, 1.0 eq.) in DMF (6 mL) were added HATU (652 mg, 1.6 mmol, 20 1.5 eq.) and DIPEA (0.6 mL, 3.4 mmol, 3.0 eq.) at 0 °C and the reaction mixture was allowed to stir at room temperature for 24h. Progress of the reaction was monitored by TLC. After starting material consumption, the reaction mixture was diluted with water (30 mL) and extracted with 10% methanol in DCM (3 x 30 mL). The combined organic extract was washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product which was purified by flash 25 column chromatography eluting with 30-45% EtOAc in heptane to afford Int-3 (420 mg, 55%). 1H NMR (400 MHz, DMSO-d 6 )δ8.63(d,J = 8.31 Hz, 1H), 7.72 - 7.88 (m, 2H), 7.29 (s, 2H), 4.55 (s, 1H), 3.82 - 3.97 (m, 3H), 3.53 - 3.79 (m, 8H), 2.70 - 2.91 (m, 3H), 2.22 (s, 3H), 2.10 (d, J = 9.78 Hz, 2H), 1.88 (d, J = 4.89 Hz, 2H), 1.50 - 1.70 (m, 5H), 1.30 - 1.47 (m, 9H), 1.19 - 1.26 (m, 3H). LCMS: 666.64 [M+H] + . 30 Step-4: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(piperidine-4- carbonyl)piperazin-1-yl)pyridazine-3-carboxamide hydrochloride (Int-4) To a solution of Int-3 (420 mg, 0.63 mmol, 1 eq.) in 1,4-dioxane (5 mL) was added 4M HCl in 1,4- dioxane (2 mL) at 0 °C and then allowed to stir for 2h at RT. After consumption of the starting material, the volatiles were evaporated under reduced pressure and the remaining residue was triturated with diethyl ether (2 x 20 mL) to afford Int-4 (250 mg, crude). 5 )δ8.83(d,J = 7.82 Hz, 1H), 8.63 (d, J = 7.83 Hz, 1H), 8.52 (s, 1H), 7.89 (d, J = 9.78 Hz, 1H), 7.41 (d, J = 9.29 Hz, 1H), 7.26 (d, J = 8.80 Hz, 1H), 4.51 (s, 1H), 3.89 (d, J = 4.89 Hz, 1H), 3.70 (s, 4H), 3.57 (s, 4H), 3.28 (d, J = 11.25 Hz, 2H), 2.86 - 3.07 (m, 2H), 2.24 (s, 3H), 2.12 (d, J = 10.27 Hz, 1H), 1.90 (s, 2H), 1.69 - 1.86 (m, 4H), 1.49 - 1.68 (m, 2H), 1.20 - 1.31 (m, 4H). LCMS: 566.3 [M+H] + . 10 Step-5: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(1-((7-ethyl-6- oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperidine-4-ca rbonyl)piperazin-1-yl)pyridazine-3- carboxamide To a stirred solution of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4- (piperidine-4-carbonyl)piperazin-1-yl)pyridazine-3-carboxami de hydrochloride (Int-4, 250 mg, 0.45 mmol, 15 1.0 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one 100 mg, 0.45 mmol, 1 eq.) in DMF (2.5 mL) was added DIPEA (0.24 mL, 1.3 mmol, 3 eq.) at room temperature. The reaction mixture was allowed to stir at 80 °C for 6h. Progress of the reaction was monitored by TLC. After consumption of starting material, the reaction mixture was diluted with ice cold water (60 mL) and extracted with EtOAc (3 x 30 mL). The combined organic extract was washed with water (30 mL), brine (30 mL), dried over 20 anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product obtained was purified by flash chromatography eluting with 4-6% methanol in dichloromethane to afford the title compound (75 mg, 22%). 1H NMR (400 MHz, DMSO-d 6 )δ11.82(s,1H),8.63(d,J = 7.82 Hz, 1H), 8.36 (s, 1H), 7.86 (d, J = 9.29 Hz, 1H), 7.71 - 7.80 (m, 2H), 7.61 (s, 1H), 7.36 (d, J = 9.78 Hz, 1H), 7.26 (d, J = 8.80 Hz, 1H), 4.51 (s, 25 1H), 3.89 (d, J = 8.31 Hz, 1H), 3.75 (s, 2H), 3.67 (s, 4H), 3.58 (s, 4H), 2.83 (d, J = 9.78 Hz, 2H), 2.66 (s, 1H), 2.24 (s, 3H), 2.10 (s, 4H), 1.48 - 1.71 (m, 9H), 1.23 (s, 3H), 1.18 (t, J = 7.34 Hz, 3H). LCMS: 751.8 [M+H] + . HPLC purity 96.1%. Example S3. Preparation of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(4-(4- ((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)pip erazine-1-carbonyl)piperazin-1- yl)pyridazine-3-carboxamide (Compound No.7) 5 Step-1: Preparation of methyl 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridazine-3-carbox ylate (Int- 1) To a stirred solution of methyl 6-chloropyridazine-3-carboxylate (SM-1, 5 g, 29.06 mmol, 1.0 eq.) in 1,4-dioxane (50 mL), tert-butyl piperazine-1-carboxylate (SM-2, 5.4 g, 29.06 mmol, 1.0 eq.) and DIPEA (16 mL, 87 mmol, 3 eq.) were added at room temperature. The reaction mixture was allowed to stir at 90 °C 10 for 18h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (200 mL) and the resulting precipitate was filtered, washed with water (50 mL) and pentane (50 mL) and dried to obtain methyl 6-(4-(tert-butoxycarbonyl)piperazin-1- yl)pyridazine-3-carboxylate (Int-1, 85 g, 91%). 1H NMR (400 MHz, DMSO-d6^^į^^^^^^^G^^J = 9.29 Hz, 1H), 7.28 (d, J = 9.29 Hz, 1H), 3.87 (s, 3H), 15 3.75 (s, 4H), 3.47 (s, 4H), 1.43 (s, 9H). LCMS: 323.31 [M+H] + . Step-2: Preparation of 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridazine-3-carbox ylic acid (Int-2) To a stirred solution of methyl 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridazine-3-carbox ylate (Int-1, 3.5 g, 27.9 mmol, 1.0 eq.) in MeOH:THF:H 2 O (45 mL, 1:1:1, 5 vol), LiOH.H 2 O (3.5 g, 83.7 mmol, 3.0 eq.) was added at room temperature. The reaction mixture was allowed to warm up to room temperature 5 and stir for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was acidified with citric acid solution (pH ~5) and the resulting precipitate was filtered, washed with water (50 mL) and pentane (50 mL) and dried to obtain 6-(4-(tert-butoxycarbonyl)piperazin-1- yl)pyridazine-3-carboxylic acid (Int-2, 8 g, 93%). 1H NMR (400 MHz, DMSO-d 6 )δ7.85(d,J = 9.29 Hz, 1H), 7.29 (d, J = 9.29 Hz, 1H), 3.68 - 3.74 10 (m, 4H), 3.47 (s, 4H), 1.43 (s, 9H). LCMS: 309.27 [M+H] + . Step-3: Preparation of tert-butyl 4-(6-(((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cycl ohexyl)- carbamoyl)pyridazin-3-yl)piperazine-1-carboxylate (Int-3) To a stirred solution of 6-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyridazine-3-carbox ylic acid (Int- 2, 3 g, 9.74 mmol, 1.0 eq.) in DMF (30 mL), 4-(((1r,4r)-4-aminocyclohexyl)(methyl)amino)-2- 15 chlorobenzonitrile trifluoroacetate (Int-A1, 2.5 g, 9.74 mmol, 1.0 eq.), DIPEA (5.28 mL, 29.2 mmol, 3.0 eq.) and HATU (5.5 g, 14.55 mmol, 1.5 eq.) were added at room temperature. The reaction mixture was allowed to stir at ambient temperature under argon atmosphere for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (200 mL), filtered and dried. The crude obtained was purified by combi flash column and the pure fractions20 were combined and concentrated under reduced pressure to afford tert-butyl 4-(6-(((1r,4r)-4-((3-chloro-4- cyanophenyl)(methyl)amino)cyclohexyl)carbamoyl)-pyridazin-3- yl)piperazine-1-carboxylate (Int-3, 2 g, 37%). 1H NMR (400 MHz, DMSO-d 6 )δ8.46- 8.54 (m, 1H), 7.82 - 7.88 (m, 1H), 7.59 (d, J = 8.80 Hz, 1H), 7.34 (d, J = 9.78 Hz, 1H), 6.93 (d, J = 1.96 Hz, 1H), 6.82 (d, J = 8.80 Hz, 1H), 3.70 (s, 4H), 3.46 (s, 25 4H), 2.91 (s, 2H), 2.80 - 2.87 (m, 3H), 1.91 (d, J = 7.83 Hz, 2H), 1.72 - 1.86 (m, 2H), 1.58 - 1.71 (m, 4H), 1.42 (s, 9H). Step-4: Preparation of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(piperazin- 1-yl)pyridazine-3-carboxamide trifluoroacetate (Int-4) To a stirred solution of tert-butyl 4-(6-(((1r,4r)-4-((3-chloro-4- 30 cyanophenyl)(methyl)amino)cyclohexyl)-carbamoyl)pyridazin-3- yl)piperazine-1-carboxylate (Int-3, 2 g, 3.61 mmol, 1.0 eq.) in DCM (20 mL), TFA (6 mL, 30 vol) was added at room temperature. The reaction mixture was allowed to stir at ambient temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, triturated with diethyl ether (50 mL), filtered and dried to afford N-((1r,4r)-4-((3-chloro-4- cyanophenyl)(methyl)amino)cyclohexyl)-6-(piperazin-1-yl)pyri dazine-3-carboxamide trifluoroacetate (Int- 4, 1.5 g, 73%). 1H NMR (400 MHz, DMSO-d 6 )δ8.92(brs,2H),8.54(d,J = 7.82 Hz, 1H), 7.94 (d, J = 9.29 Hz, 5 1H), 7.60 (d, J = 8.80 Hz, 1H), 7.45 (d, J = 9.29 Hz, 1H), 6.94 (s, 1H), 6.82 (d, J = 8.31 Hz, 1H), 3.70 - 3.89 (m, 4H), 3.25 (s, 4H), 2.78 - 2.99 (m, 5H), 1.92 (d, J = 8.80 Hz, 2H), 1.59 - 1.88 (m, 6H). LCMS: 454.58 [M+H] + . Step-5: Preparation of tert-butyl 4-(4-(6-(((1r,4r)-4-((3-chloro-4- cyanophenyl)(methyl)amino)cyclohexyl)-carbamoyl)pyridazin-3- yl)piperazine-1-carbonyl)piperazine- 10 1-carboxylate (Int-5) To a stirred solution of tert-butyl piperazine-1-carboxylate (SM-2, 1 g, 5.37 mmol, 1.0 eq.) in DCM (10 mL), pyridine (1 mL, 13.42 mmol, 2.5 eq.) and triphosgene solution (800 mg, 2.68 mmol, 0.5 eq.) in DCM (10 mL) were added at room temperature and the reaction mixture was allowed to stir at for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was 15 diluted with DCM (200 mL) and washed with 1N HCl solution (2 x 200 mL). The organic layer was concentrated under reduced pressure and the obtained crude was used without purification. Separately, to a solution of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(piperazin-1-yl)pyridazine- 3-carboxamide trifluoroacetate (Int-4, 1.1 g, 1.93 mmol, 1.0 eq.) in DCM (10 mL), DIPEA (1.6 mL, 9.65 mmol, 5.0 eq.), DMAP (53 mg, 0.48 mmol, 0.25 eq.) and the crude in DCM solution obtained earlier was 20 added at RT under argon atmosphere. The resulting reaction mixture was allowed to stir at room temperature for 18h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with DCM (200 mL) and washed with water (2 x 200 mL). The organic layer was dried (Na 2 SO 4 ), filtered, concentrated and the crude obtained was purified by combi flash column. The pure fractions were combined and concentrated under reduced pressure to afford tert-butyl 4-(4-(6-(((1r,4r)-4-((3-25 chloro-4-cyanophenyl)(methyl)amino)cyclohexyl)carbamoyl)pyri dazin-3-yl)piperazine-1- carbonyl)piperazine-1-carboxylate (Int-5, 1.2 g, 92%). 1H NMR (400 MHz, DMSO-d 6 )δ8.53(d,J = 8.31 Hz, 1H), 7.87 (d, J = 9.78 Hz, 1H), 7.60 (d, J = 8.80 Hz, 1H), 7.36 (d, J = 9.29 Hz, 1H), 6.94 (s, 1H), 6.82 (d, J = 8.31 Hz, 1H), 3.76 - 3.93 (m, 2H), 3.73 (s, 4H), 3.34 - 3.38 (m, 8H), 3.17 (s, 4H), 2.85 (s, 3H), 1.92 (d, J = 9.29 Hz, 2H), 1.58 - 1.82 (m, 6H), 1.41 (s, 30 9H). LCMS: 666.95 [M+H] + . Step-6: Preparation of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(4- (piperazine-1-carbonyl)piperazin-1-yl)pyridazine-3-carboxami de trifluoroacetate (Int-6) To a stirred solution of tert-butyl 4-(4-(6-(((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)- cyclohexyl)carbamoyl)pyridazin-3-yl)piperazine-1-carbonyl)pi perazine-1-carboxylate (Int-5, 350 mg, 0.52 5 mmol, 1.0 eq.) in DCM (3.5 mL) TFA (1.05 mL, 3.0 vol) was added at room temperature. The reaction mixture was allowed to stir at ambient temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, triturated with diethyl ether (50 mL), filtered and dried to afford N-((1r,4r)-4-((3-chloro-4- cyanophenyl)(methyl)amino)cyclohexyl)-6-(4-(piperazine-1-car bonyl)piperazin-1-yl)pyridazine-3- 10 carboxamide trifluoroacetate (Int-7, (300 mg, 84 %). Step-7: Preparation of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(4-(4-((7- ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperaz ine-1-carbonyl)piperazin-1-yl)pyridazine- 3-carboxamide To a stirred solution of N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(4- 15 (piperazine-1-carbonyl)piperazin-1-yl)pyridazine-3-carboxami de trifluoroacetate (Int-7, 350 mg, 0.51 mmol, 1.0 eq.) in DMF (3.5 mL), DIPEA (0.3 mL, 1.53 mmol, 3.0 eq.) and 7-(chloromethyl)-3-ethyl-1,5- naphthyridin-2(1H)-one (Int-7, 116 mg, 0.51 mmol, 1.0 eq.) were added at room temperature. The reaction mixture was allowed to stir at 80 °C for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL) and extracted with 20 ethyl acetate (2 x 200 mL). The combined organic extract was washed with water (200 mL), brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash column and the pure fractions were combined and concentrated under reduced pressure to afford N-((1r,4r)-4-((3-chloro-4-cyanophenyl)(methyl)amino)cyclohex yl)-6-(4-(4-((7-ethyl-6- oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazine-1-ca rbonyl)piperazin-1-yl)pyridazine-3- 25 carboxamide (87 mg, 22%). 1H NMR (400 MHz, DMSO-d 6 )δ11.84(s,1H),83.53 (d,J = 7.82 Hz, 1H), 8.35 - 8.41 (m, 1H), 7.86 (d, J = 9.29 Hz, 1H), 7.74 (s, 1H), 7.56 - 7.64 (m, 2H), 7.35 (d, J = 9.29 Hz, 1H), 6.94 (s, 1H), 6.83 (d, J = 8.80 Hz, 1H), 3.72 (s, 6H), 3.61 (s, 2H), 3.32 (s, 4H), 3.22 (s, 4H), 2.85 (s, 3H), 2.52 - 2.60 (m, 2H), 2.41 (s, 4H), 1.92 (d, J = 8.80 Hz, 2H), 1.59 - 1.82 (m, 6H), 1.18 (t, J = 7.34 Hz, 3H). LCMS: 752.5 [M+H] + . Example S4. Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-((4-((5- fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)pipe razin-1-yl)methyl)piperidin-1- yl)pyridazine-3-carboxamide (Compound No.12) 5 Step-1: Preparation of methyl 6-(4-(hydroxymethyl)piperidin-1-yl)pyridazine-3-carboxylate (Int-1) To a stirred solution of methyl 6-chloropyridazine-3-carboxylate (SM-1, 5 g, 28 mmol, 1.0 eq.) and piperidin-4-ylmethanol (SM-2, 3.6 g, 31 mmol, 1.1 eq.) in acetonitrile (150 mL) was added triethylamine (6 mL, 43 mmol, 1.5 eq.) and the reaction mixture was allowed to stir at room temperature for 16h. After completion of the reaction, the volatiles were evaporated under reduced pressure and the crude obtained was10 purified by combi flash column eluting with 80% ethyl acetate in heptane to afford methyl 6-(4- (hydroxymethyl)piperidin-1-yl)pyridazine-3-carboxylate (Int-1, 5.9 g, 80%). 1H NMR (400 MHz, DMSO-d66) δ 7.79 (d, = 9.29 Hz, 1H), 7.27 (d, J = 9.78 Hz, 1H), 4.55 (s, 1H), 4.51 - 4.54 (m, 2H), 3.86 (s, 3H), 3.27 (t, J = 5.14 Hz, 2H), 3.00 (t, J = 11.98 Hz, 2H), 1.72-1.80 (m, 3H), 1.08 - 1.21 (m, 2H). LCMS: 251.95 [M+H] + . Step-2: Preparation of methyl 6-(4-formylpiperidin-1-yl)pyridazine-3-carboxylate (Int-2) To a stirred solution of methyl 6-(4-(hydroxymethyl)piperidin-1-yl)pyridazine-3-carboxylate (Int-2, 1 g, 3.98 mmol, 1.0 eq.) in DCM (50 mL) was added Dess-Martin periodinane (2.7 g, 5.97 mmol, 1.5 eq.) at 0 °C and the reaction mixture was allowed to warm up to room temperature and stir for 1h. Progress of the 5 reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with saturated solution of Na 2 S 2 O 3 (60 mL) and extracted with DCM (2 x 60 mL). The combined organic extract was washed with sat. NaHCO 3 (60 mL), brine (60 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford methyl 6-(4-formylpiperidin-1-yl)pyridazine-3-carboxylate (Int-2, 930 mg, crude). 10 1 H NMR (400 MHz, DMSO-d 6 )δ9.63(s,1H),7.82(d,J = 9.78 Hz, 1H), 7.31 (d, J = 9.78 Hz, 1H), 4.34 (d, J = 13.69 Hz, 2H), 3.86 (s, 3H), 3.23 - 3.30 (m, 2H), 2.90 - 3.11 (m, 1H), 2.64 - 2.75 (m, 1H), 1.88 - 2.03 (m, 3H), 1.45 - 1.61 (m, 2H). LCMS: 250.2 [M+H] + . Step-3: Preparation of methyl 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1- yl)pyridazine-3-carboxylate (Int-3) 15 To a stirred solution of methyl 6-(4-formylpiperidin-1-yl)pyridazine-3-carboxylate (Int-2, 900 mg, 3.61 mmol, 1.0 eq.) and tert-butyl piperazine-1-carboxylate (SM-3, 670 mg, 3.61 mmol, 1.0 eq.) in methanol (30 mL) was added triethylamine (1.5 mL, 10.83 mmol, 3 eq.) at room temperature. After 10 min, cat. Amount of acetic acid (0.4 mL) was added and the reaction mixture was allowed to stir for 1h. Sodium cyanoborohydride (450 mg, 7.22 mmol, 2.0 eq.) was then added at room temperature and allowed the 20 reaction mixture to stir for 16h. After completion of the reaction, water (100 mL) was added and the aqueous solution was extracted with DCM (2 x 100 mL). The combined organic extract was washed with water (100 mL), brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The crude obtained was purified by combi flash column eluting with 80 % ethyl acetate in heptane to afford methyl 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1-yl)pyridazine-3-carboxylate (Int-3, 25 750 mg, 50%). 1H NMR (400 MHz, DMSO-d 6 )δ7.80(d,J = 9.78 Hz, 1H), 7.26 (d, J = 9.78 Hz, 1H), 4.51 (d, J = 13.21 Hz, 2H), 3.86 (s, 3H), 3.30-3.35 (m, 4H), 3.01 (t, J = 11.74 Hz, 2H), 2.20-2.29 (m, 4H), 2.15 (d, J = 7.34 Hz, 2 H,) 1.76 - 1.91 (m, 3H), 1.39 (s, 9H), 0.99 - 1.18 (m, 2H). LCMS: 420.4 [M+H] + . Step-4: Preparation of 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1-yl)pyridazine-3- 30 carboxylic acid (Int-4) To a stirred solution of methyl 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1- yl)pyridazine-3-carboxylate (Int-3, 4 g, 9.54 mmol, 1.0 eq.) in MeOH:THF:H2O (40 mL, 1:1:1, 10 vol), LiOH.H2O (2.0 g, 47.7 mmol, 5.0 eq.) was added at room temperature. The reaction mixture was stirred at ambient temperature for 16h. After consumption of the starting material, the reaction mixture was acidified with citric acid solution (pH ~5) and the precipitate was filtered, washed with water (50 mL) and pentane (50 mL) and dried to give 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1-yl)pyridazine-3- carboxylic acid (Int-4, 3 g, 78%). 5 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.79(d,J = 8.80 Hz, 1H), 7.27 (d, J = 9.29 Hz, 1H), 4.44 (d, J = 12.72 Hz, 2H), 3.30 (s, 4H), 2.96 (t, J = 12.23 Hz, 2H), 2.29 (s, 4H), 2.15 (d, J = 6.36 Hz, 2H), 1.89 - 2.00 (m, 1H), 1.80 (d, J = 13.20 Hz, 3H), 1.39 (s, 9H), 1.10 (d, J = 8.80 Hz, 2H). LCMS: 406.39 [M+H] + . Step-5: Preparation of tert-butyl 4-((1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclo hexyl)- carbamoyl)pyridazin-3-yl)piperidin-4-yl)methyl)piperazine-1- carboxylate (Int-5) 10 To a stirred solution of 6-(4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)piperidi n-1- yl)pyridazine-3-carboxylic acid (Int-4, 750 mg, 1.85 mmol, 1.0 eq.) in DMF (7.5 mL), 4-(((1r,4r)-4- aminocyclohexyl)oxy)-2-chloro-3-methylbenzonitrile hydrochloride (Int-A2, 555 mg, 1.85 mmol, 1.0 eq.), DIPEA (0.95 mL, 5.55 mmol, 3.0 eq.) and HATU (1.05 g, 2.77 mmol, 1.5 eq.) were added under nitrogen atmosphere at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 16h. 15 After completion of the reaction, the reaction mixture was diluted with water (100 mL) and the resulting precipitate was filtered. The crude obtained was purified by flash column and the pure fractions were combined and concentrated under reduced pressure afford tert-butyl 4-((1-(6-(((1r,4r)-4-(3-chloro-4-cyano- 2-methylphenoxy)cyclohexyl)carbamoyl)pyridazin-3-yl)piperidi n-4-yl)methyl)piperazine-1-carboxylate (Int-5, 300 mg, 25%). 20 1 H NMR (400 MHz, DMSO-d6)δ8.58(d,J = 7.83 Hz, 1H), 7.73 - 7.83 (m, 2H), 7.21 - 7.36 (m, 2H), 4.47 (m, 3H), 3.88 (s, 1H), 2.99 (t, J = 12.23 Hz, 2H), 2.89 (s, 1H), 2.67 - 2.77 (m, 1H), 2.20 - 2.32 (m, 8H), 2.15 (d, J = 6.85 Hz, 4H), 1.73 - 1.95 (m, 4H), 1.46 - 1.71 (m, 4H), 1.39 (s, 9H), 1.22 - 1.32 (m, 2H), 1.08 – 1.19 (m, 2H). LCMS: 652.65 [M+H] + . Step-6: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-(piperazin-1- 25 ylmethyl)piperidin-1-yl)pyridazine-3-carboxamide trifluoroacetate (Int-6) To a stirred solution of tert-butyl 4-((1-(6-(((1r,4r)-4-(3-chloro-4-cyano-2- methylphenoxy)cyclohexyl)-carbamoyl)pyridazin-3-yl)piperidin -4-yl)methyl)piperazine-1-carboxylate (Int- 5, 300 mg, 0.53 mmol, 1.0 eq.) in DCM (3.5 mL) under nitrogen atmosphere was added TFA (1.75 mL) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 4h. Progress of the 30 reaction was monitored by TLC. After completion of the reaction, the volatiles were evaporated under reduced pressure and the residue was triturated with diethyl ether (20 mL), filtered and dried under vacuum to afford N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)-cyclohexyl)- 6-(4-(piperazin-1- ylmethyl)piperidin-1-yl)pyridazine-3-carboxamide trifluoroacetate (Int-6, 400 mg, crude). LCMS: 552.60 [M+H] + . Step-7: Preparation of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-((4-((5- fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)pipe razin-1-yl)methyl)piperidin-1- yl)pyridazine-3-carboxamide 5 To a stirred solution of N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4- (piperazin-1-ylmethyl)piperidin-1-yl)pyridazine-3-carboxamid e trifluoroacetate (Int-6, 400 mg, 0.72 mmol, 1.0 eq.) in acetonitrile (4 mL), 7-(bromomethyl)-8-fluoro-3-methylquinoxalin-2(1H)-one (Int-A3, 196 mg, 0.72 mmol, 1.0 eq.), DIPEA (0.62 mL, 3.62 mmol, 5.0 eq.) was added under nitrogen atmosphere at 0 °C. The reaction mixture was allowed to warm up and stir at 80 °C for 5h. Progress of the reaction was 10 monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude obtained was purified by flash column and the pure fractions were combined and concentrated under reduced pressure to afford N-((1r,4r)-4-(3-chloro-4-cyano-2-methylphenoxy)cyclohexyl)-6 -(4-((4-((5-15 fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl)pipe razin-1-yl)methyl)piperidin-1-yl)pyridazine- 3-carboxamide (70 mg, 13%). 1H NMR (400 MHz, DMSO-d6)δ12.37- 12.45 (m, 1H), 8.56 (d, J = 8.13 Hz, 1H), 7.74 - 7.81 (m, 2H), 7.50 (d, J = 8.25 Hz, 1H), 7.31 (d, J = 9.63 Hz, 1H), 7.21 - 7.27 (m, 2H), 4.40 - 4.55 (m, 3H), 3.82 - 3.93 (m, 1H), 3.61 (s, 2H), 2.98 (t, J = 11.76 Hz, 2H), 2.28 - 2.46 (m, 9H), 2.24 (s, 3H), 2.12 (d, J = 7.00 Hz, 20 4H), 1.72 - 1.95 (m, 5H), 1.47 - 1.70 (m, 5H), 0.98 - 1.20 (m, 3H). LCMS: 741.9 [ +H] + .
Nuvation Ref.: NUVP-0051-PCT MoFo Ref.: 19369-20051.40 Example S5. Preparation of N-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)-5-(4-((7-e thyl-6-oxo-5,6-dihydro-1,5-naphthyridin- 3-yl)methyl)piperazin-1-yl)picolinamide (Compound No.2) 5 Step-1: Preparation of tert-butyl (6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4- oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)carbamate (Int-1) To a stirred soln. of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-D, 1 g, 2.21 mmol, 1.0 eq.) and tert-butyl N-(6- aminohexyl)carbamate (SM-1, 580 mg, 2.68 mmol, 1.2 eq.) in DMF (10 mL) were added N,N- 10 diisopropylethylamine (0.80 mL, 4.41 mmol, 2 eq.) and HATU (1.26 g, 3.31 mmol, 1.5 eq.) at room temperature. Progress of the reaction was monitored by TLC. The reaction mixture was stirred at room temperature for 16h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium n ^ y-2633819 sulfate, filtered, and conc. under vacuum. The crude obtained was purified by combiflash chromatography eluting with 50% EtOAc in heptane to afford Int-1 (1.00 g, 98%). 1H NMR (400 MHz, DMSO-d 6 )δ8.50(s,1H),8.41(d,J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.75 (t, J = 7.34 Hz, 1H), 7.42 (d, J = 9.78 Hz, 1H), 7.28 - 7.36 (m, 1H), 6.77 (s, 1H), 3.25 (d, 5 J = 4.89 Hz, 2H), 2.90 (d, J = 5.87 Hz, 2H), 2.69 (s, 2H), 1.54 (s, 6H), 1.19 - 1.44 (m, 15H). LCMS: 650.45 [M+H] + . Step-2: Preparation of N-(6-aminohexyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5, 5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamide trifluoroacetate (Int-2) A flask was charged with tert-butyl (6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4- 10 oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)carba mate (Int-1, 1 g, 1.54 mmol, 1.0 eq.) in dichloromethane (50 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (1.00 mL). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After complete consumption of Int-1, the volatiles were evaporated, and the crude obtained was filtered and washed with diethyl ether (2 x 25 mL) to afford the TFA salt of Int-2 (1.00 g, 15 crude). LCMS: 550.37 [M+H] + . Step-3: Preparation of tert-butyl 4-(6-((6-(4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimet hyl-4-oxo- 2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)carbamoyl )pyridin-3-yl)piperazine-1-carboxylate (Int-3) 20 To a stirred solution of N-(6-aminohexyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5, 5-dimethyl-4- oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamide trifluoroacetate (Int-2, 1.00 g, 1.5 mmol, 0.1 eq.) and 5- (4-(tert-butoxycarbonyl)piperazin-1-yl)picolinic acid (Int-E1, 449 mg, 1.5 mmol, 1 eq.) in DMF (15 mL), N,N-diisopropylethylamine (0.52 mL, 3.00 mmol, 2 eq.) and HATU (687 mg, 1.8 mmol, 1.2 eq.) were added at room temperature. Progress of the reaction was monitored by TLC. The reaction mixture was allowed to 25 stir for 16h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 5% MeOH in DCM to afford Int-3 (760 mg, crude). 1H NMR (400 MHz, DMSO-d 6 )δ8.49(t,J = 5.38 Hz, 1H), 8.38 - 8.45 (m, 2H), 8.26 - 8.30 (m, 30 2H), 8.08 (dd, J = 8.07, 1.22 Hz, 1H), 7.84 (d, J = 8.31 Hz, 1H), 7.74 (t, J = 8.07 Hz, 1H), 7.38 - 7.44 (m, 2H), 7.32 (dd, J = 8.07, 1.71 Hz, 1H), 3.44 - 3.50 (m, 4H), 3.21 - 3.28 (m, 6H), 1.46 - 1.57 (m, 10H), 1.42 (s, 10H), 1.33 (t, J = 14.43 Hz, 5H). LCMS: 839.69 [M+H] + . Step-4: Preparation of N-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)-5-(piperaz in-1-yl)picolinamide trifluoroacetate (Int-4) A stirred solution of tert-butyl 4-(6-((6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimet hyl-4- oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)carba moyl)pyridin-3-yl)piperazine-1-carboxylate 5 (Int-3, 760 mg, 9.06 mmol, 1 eq.) in dichloromethane (20 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (0.7 mL). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After complete consumption of Int-3, the volatiles were evaporated and the crude obtained was filtered and washed with diethyl ether (2 x 25 mL) to afford the TFA salt of Int-4 (750 mg, crude). 10 1 H NMR (400 MHz, DMSO-d 6 )δ8.74(brs,2H),8.37- 8.49 (m, 3H), 8.33 (s, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.89 (d, J = 8.80 Hz, 1H), 7.75 (t, J = 7.82 Hz, 1H), 7.48 (d, J = 8.31 Hz, 1H), 7.41 (d, J = 10.76 Hz, 1H), 7.32 (d, J = 7.83 Hz, 1H), 3.54 (s, 4H), 3.27 (s, 8H), 1.54 (s, 10H), 1.34 (br s, 4H). Step-5: Preparation of N-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2-15 thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)-5-(4-((7-e thyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)picolinamide To a stirred solution of N-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)-5-(piperaz in-1-yl)picolinamide trifluoroacetate (Int-4, 700 mg, 0.822 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 182 mg, 0. 20 822 mmol, 1 eq.) in DMF (7 mL) was added K2CO3 (227 mg, 1.6 mmol, 2 eq.). Progress of the reaction was monitored by TLC. The reaction mixture was allowed to stir at room temperature for 16h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by prep. HPLC eluting with Mobile phase A: 0.1% FA in water 25 and Mobile phase B: acetonitrile to afford the title compound (180 mg, 23%). 1H NMR (400 MHz, DMSO-d 6 )δ11.84(s,1H),8.49(t,J = 5.38 Hz, 1H), 8.36 - 8.42 (m, 3H), 8.28 (dd, J = 9.44, 2.31 Hz, 2H),, 8.08 (dd, J = 8.25, 1.63 Hz, 1H), 7.83 (d, J = 8.88 Hz, 1H), 7.71 - 7.77 (m, 2H), 7.62 (d, J = 1.25 Hz, 1H), 7.37 - 7.43 (m, 2H), 7.32 (dd, J = 8.13, 1.75 Hz, 1H), 3.65 (s, 2H), 3.32 - 3.36 (m, 4H), 3.22 - 3.28 (m, 4H), 2.53 - 2.58 (m, 6H), 1.47 - 1.57 (m, 10H), 1.26 - 1.40 (m, 4H), 1.18 (t, J = 7.44 Hz, 30 3H). LCMS: 99.925.8 [M+H] + . HPLC purity 99.1%. Example S6. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(2-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin- 1-yl)ethyl)-2-fluorobenzamide (Compound No.5) 5 Step-1: Preparation of tert-butyl 4-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethyl)piperazine- 1-carboxylate (Int-1) To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-D, 500 mg, 1.10 mmol, 1 eq.) and tert-butyl 4-(2- aminoethyl)piperazine-1-carboxylate (SM-1, 280 mg, 1.2 mmol, 1.1 eq.) in DMF (2 mL) was added N,N- 10 diisopropylethylamine (0.4 mL, 2.21 mmol, 2 eq.) and HATU (632 mg, 1.66 mmol, 1.5 eq.). The reaction mixture was allowed to stir at room temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (75 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was 15 purified by combiflash chromatography eluting with 67% EtOAc in heptane to afford Int-1 (615 mg, 83%). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.47 - 8.57 (m, 2H), 8.39 (s, 1H), 8.18 (d, J = 8.31 Hz, 1H), 7.89 (t, J = 8.07 Hz, 1H), 7.53 (dd, J = 10.52, 1.22 Hz, 1H), 7.44 (d, J = 7.83 Hz, 1H), 4.19 (d, J = 5.38 Hz, 4H), 3.35 - 3.55 (m, 4H), 2.41-2.58 (br s, 4H), 1.64 (s, 6H), 1.49 (s, 9H). LCMS: 663.54 [M+H] + . Step-2: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-(2-(piperazin-1-yl)ethyl )benzamide trifluoroacetate (Int-2) A stirred solution of tert-butyl 4-(2-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo- 2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)ethyl)piperazin e-1-carboxylate (Int-1, 615 mg, 0.93 mmol, 1 5 eq.) in dichloromethane (6 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (1.0 mL). The reaction mixture was allowed to warm up to room temperature and stir for 3h. Progress of the reaction was monitored by TLC. After complete consumption of Int-1, the volatiles were evaporated and the crude obtained was triturated with n-heptane (50 mL) followed by diethyl ether (2 x 25 mL) to provide the TFA salt of Int-2 (630 mg, crude). 10 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.74 (br s, 2H), 8.54 (s, 1H), 8.41 (d, J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.83 (t, J = 8.07 Hz, 1H), 7.46 (d, J = 10.76 Hz, 1H), 7.36 (d, J = 7.83 Hz, 1H), 3.51 (s, 2H), 3.22 (s, 4H), 2.81 - 3.14 (m, 6H), 1.55 (s, 6H). LCMS: 563.51 [M+H] + . Step-3: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(2-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin-1- 15 yl)ethyl)-2-fluorobenzamide A stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-(2-(piperazin-1-yl)ethyl )benzamide trifluoroacetate (Int-2, 500 mg, 0. 889 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 200 mg, 0.889 mmol, 1 eq.) in DMF (5 mL) was added K 2 CO 3 (246 mg, 1.78 mmol, 2 eq.). The reaction mixture was allowed to stir 20 at room temperature for 4h and monitored by TLC. After completion of the reaction, the reaction mixture was diluted with ice cold water (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude obtained was purified by combiflash chromatography eluting with 6% MeOH in DCM to afford the title compound (220 mg, 33%). 25 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.82 (s, 1H), 8.34 - 8.43 (m, 3H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.78 (t, J = 7.83 Hz, 1H), 7.74 (s, 1H), 7.58 (s, 1H), 7.43 (d, J = 10.76 Hz, 1H), 7.34 (d, J = 7.82 Hz, 1H), 3.57 (s, 2H), 3.38 (d, J = 5.38 Hz, 2H), 2.52 - 2.61 (m, 6H), 2.33 (s, 6H), 1.54 (s, 6H), 1.17 (t, J = 7.34 Hz, 3H). LCMS: 749.3 [M+H] + . HPLC purity 99.3%. Example S7. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(6-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin- 1-yl)hexyl)-2-fluorobenzamide (Compound No.6) 5 Step-1: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-(6-hydroxyhexyl)benzamid e (Int-1) To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-D, 700 mg, 1.55 mmol, 1 eq.) and 6-aminohexan-1-ol (SM-1 (218 mg, 1.86 mmol, 1.2 eq.) in DMF (3 mL), N,N-diisopropylethylamine (0.54 mL, 3.1 mmol, 2 eq.) 10 and HATU (884 mg, 2.32 mmol, 1.5 eq.) were added at room temperature. The reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC. The reaction mixture was then diluted with ice cold water (50 mL) and extracted with ethyl acetate (2 x 75 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 15 65% EtOAc in heptane to afford Int-1 (450 mg, 53%). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.49 (t, J = 5.38 Hz, 1H), 8.40 (d, J = 8.26 Hz, 1H), 8.29 (d, J = 1.63 Hz, 1H), 8.08 (dd, J = 8.19, 1.69 Hz, 1H), 7.75 (t, J = 8.00 Hz, 1H), 7.42 (dd, J = 10.51, 1.75 Hz, 1H), 7.32 (dd, J = 8.13, 1.75 Hz, 1H), 4.33 (t, J = 5.13 Hz, 1H), 3.36 - 3.42 (m, 2H), 3.23 - 3.28 (m, 2H), 1.49 - 1.57 (m, 8H), 1.39 - 1.45 (m, 2H), 1.29 - 1.36 (m, 4H). LCMS: 551.31 [M+H] + . Step-2: Preparation of N-(6-chlorohexyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 ,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamide (Int-2) A solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2-thioxoimidazolidin-1- yl)-2-fluoro-N-(6-hydroxyhexyl)benzamide (Int-1, 350 mg, 0.63 mmol, 1 eq.) in DCM (4 mL) was cooled to 5 0 °C followed by addition of thionyl chloride (SOCl 2 ) dropwise and a catalytic amount of DMF (20µL). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC/LCMS. After completion of reaction, volatiles were evaporated under reduced pressure to give the crude product Int-2 (222 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.50 (s, 1H), 8.39 (dd, J = 11.49, 8.56 Hz, 2H), 8.27 (d, J = 17.12 10 Hz, 1H), 8.09 (t, J = 8.31 Hz, 1H), 7.73 (dt, J = 18.95, 8.13 Hz, 1H), 7.30 - 7.49 (m, 1H), 3.64 (t, J = 6.60 Hz, 2H), 3.26 (d, J = 5.87 Hz, 2H), 1.73 (quin, J = 6.73 Hz, 2H), 1.47 - 1.60 (m, 8H), 1.31 - 1.47 (m, 4H). LCMS: 569.29 [M+H] + . Step-3: Preparation of tert-butyl 4-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)piperazine- 1-carboxylate (Int-3) 15 A 100 mL sealed tube was charged with N-(6-chlorohexyl)-4-(3-(4-cyano-3- (trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazol idin-1-yl)-2-fluorobenzamide (Int-2, 380 mg, 0.667 mmol, 1 eq.), tert-butyl piperazine-1-carboxylate (SM-2, 150 mg, 0.801 mmol, 1.2 mmol), DIPEA (0.23 mL, 1.33 mmol, 2 eq.) and KI (111 mg, 0.667 mmol, 1 eq.) in acetonitrile (4 mL). The reaction mixture was purged with N 2 gas and allowed to stir at 80 °C for 16h. Progress of the reaction was monitored 20 by TLC. The reaction mixture was then diluted with ice cold water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product Int- 3 (350 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.49 (t, J = 5.50 Hz, 1H), 8.35 - 8.44 (m, 1H), 8.23 - 8.31 (m, 25 1H), 8.05 - 8.13 (m, 1H), 7.65 - 7.77 (m, 1H), 7.29 - 7.48 (m, 2H), 3.20 - 3.30 (m, 8H), 2.22 - 2.30 (m, 4H), 1.47 - 1.57 (m, 10H), 1.38 (s, 9H), 1.31 (br s, 4H). LCMS: 719.56 Step-4: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(piperazin-1-yl)hexyl )benzamide trifluoroacetate (Int-4) A stirred solution of tert-butyl 4-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo- 30 2-thioxoimidazolidin-1-yl)-2-fluorobenzamido)hexyl)piperazin e-1-carboxylate (Int-3, 330 mg, 0.459 mmol, 1 eq.) in dichloromethane (5 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (0.35 mL, 4.59 mmol, 10 eq.). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After complete consumption of Int-3, volatiles were evaporated under reduced pressure. The crude obtained was triturated with n-heptane (50 mL) followed by diethyl ether (2 x 25 mL) to provide the TFA salt of Int-4 (280 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 9.09 (s, 2H), 8.47 - 8.55 (m, 1H), 8.34 - 8.46 (m, 1H), 8.27 (d, J = 16.14 Hz, 1H), 8.08 (d, J = 7.34 Hz, 1H), 7.66 - 7.79 (m, 1H), 7.28 - 7.50 (m, 2H), 3.90 - 4.90 (m, 4H), 3.13 5 - 3.49 (m, 6H), 3.05 (s, 2H), 1.44 - 1.67 (m, 8H), 1.35 (s, 4H), 1.24 (s, 2H). LCMS: 619.47 [M+H] + . Step-5: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(6-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin-1- yl)hexyl)-2-fluorobenzamide To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- 10 thioxoimidazolidin-1-yl)-2-fluoro-N-(6-(piperazin-1-yl)hexyl )benzamide trifluoroacetate (Int-4, 280 mg, 0. 453 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 100 mg, 0.453 mmol, 1 eq.) in DMF (3 mL), K 2 CO 3 (125 mg, 0.91 mmol, 2 eq.) was added. Progress of the reaction was monitored by TLC. The reaction mixture was allowed to stir at room temperature for 4h, diluted with ice cold water (75 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic extract was washed with water (50 15 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude obtained was purified by prep. HPLC purification method eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the title compound (37 mg, 12%). 1H NMR (400 MHz, DMSO-d 6 ) δ 11.80 (s, 1H), 8.47 (t, J = 5.19 Hz, 1H), 8.40 (d, J = 8.25 Hz, 1H), 8.35 (d, J = 1.75 Hz, 1H), 8.29 (d, J = 1.75 Hz, 1H), 8.08 (dd, J = 8.19, 1.69 Hz, 1H), 7.71 - 7.75 (m, 2H), 20 7.57 (d, J = 1.25 Hz, 1H), 7.41 (dd, J = 10.51, 1.88 Hz, 1H), 7.32 (dd, J = 8.19, 1.81 Hz, 1H), 3.55 (s, 2H), 3.25 (d, J = 6.13 Hz, 2H), 2.53 (dd, J = 7.44, 0.94 Hz, 2H), 2.32 - 2.43 (m, 6H), 2.25 (t, J = 7.19 Hz, 2H), 1.49 - 1.56 (m, 9H), 1.38 - 1.44 (m, 2H), 1.27 - 1.34 (m, 5H), 1.17 (t, J = 7.44 Hz, 3H). LCMS: 805.5 [M+H] + . HPLC purity 99.3%.
Example S8. Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(6-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin- 1-yl)hexyl)-2-fluoro-N-methylbenzamide (Compound No.9) 5 Step-1: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-(6-hydroxyhexyl)-N-methy lbenzamide (Int-1) To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-1, 800 mg, 1.77 mmol, 1 eq.) and the trifluoroacetate salt of 6-(methylamino)hexan-1-ol (Int-E, 651 mg, 2.66 mmol, 1.5 eq.) in DMF (6 mL), N,N- 10 diisopropylethylamine (0.92 mL, 5.31 mmol, 3 eq.) and HATU (1.34 g, 3.54 mmol, 2 eq.) were added at room temperature. The reaction mixture was allowed to stir at room temperature for 16h. Progress of the reaction was monitored by TLC. The reaction mixture was then diluted with ice cold water (75 mL) and extracted with ethyl acetate (2 x 75 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to obtain Int-1 15 (1.28 g, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.40 (d, J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 7.83 Hz, 1H), 7.74 (t, J = 7.82 Hz, 1H), 7.42 (d, J = 9.78 Hz, 1H), 7.33 (d, J = 7.82 Hz, 1H), 4.24 - 4.42 (m, 2H), 3.39 - 3.52 (m, 1H), 3.10 - 3.28 (m, 1H), 2.94 - 3.02 (m, 1H), 2.68 (s, 3H), 1.54 (s, 6H), 1.20 - 1.45 (m, 8H). LCMS: 565.45 [M+H] + . 20 Step-2: Preparation of N-(6-chlorohexyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 ,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide (Int-2) A solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2-thioxoimidazolidin-1- yl)-2-fluoro-N-(6-hydroxyhexyl)-N-methylbenzamide (Int-1, 1.0 g, 1.77 mmol, 1 eq.) in DCM (20 mL) was cooled to 0 °C followed by addition of thionyl chloride (SOCl 2 ) dropwise (0.4 mL, 5.31 mmol, 3 eq.) and a catalytic amount of DMF (10 µL) and allowed to warm up to room temperature and stir for 16h. Progress of 5 the reaction was monitored by TLC/LCMS. After reaction completion, the volatiles were evaporated under reduced pressure to give the desired product Int-2 (680 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.39 - 8.41 (d, J = 7.82 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 7.82 Hz, 1H), 7.66 - 7.80 (m, 1H), 7.42 (d, J = 9.29 Hz, 1H), 7.33 (d, J = 6.85 Hz, 1H), 3.59 - 3.69 (m, 1H), 3.44 - 3.58 (m, 1H), 2.68 (s, 3H), 1.67 - 1.79 (m, 2H), 1.54 (s, 6H), 1.28 - 1.47 (m, 4H), 1.05 - 1.27 (m, 4H). 10 LCMS: 583.35 [M+H] + . Step-3: Preparation of tert-butyl 4-(6-(4-(3-(4-Cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo-2- thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamido)hexyl)pi perazine-1-carboxylate (Int-3) To a solution of N-(6-chlorohexyl)-4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5 ,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide (Int-2, 600 mg, 1.03 mmol, 1 eq.) in acetonitrile (10 15 mL), tert-butyl piperazine-1-carboxylate (SM-1, 287 mg, 1.54 mmol, 1.5 eq.), DIPEA (0.35 mL, 2.06 mmol, 2 eq.) and KI (170 mg, 1.03 mmol, 1 eq.) were added. The resulting mixture was stirred at 80 °C for 16h. Progress of the reaction was monitored by TLC. The reaction mixture was then diluted with ice cold water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced 20 pressure to obtain Int-3 (365 mg, crude). LCMS: 733.40 [M+H] + . Step-4: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-methyl-N-(6-(piperazin-1 -yl)hexyl)benzamide Trifluoroacetate (Int- 4) 25 A stirred solution of tert-butyl 4-(6-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl- 4-oxo- 2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamido)hexyl) piperazine-1-carboxylate (Int-3, 350 mg, 0.478 mmol, 1 eq.) in dichloromethane (10 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (1.0 mL). The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After complete consumption of Int-3, the volatiles were evaporated 30 and the crude obtained was triturated with diethyl ether (3 x 25 mL), filtered and dried under reduced pressure to provide Int-4 (395 mg, crude). NMR (400 MHz, DMSO-d 6 ) δ 8.97 - 9.18 (m, 2H), 8.41 (d, J = 8.31 Hz, 1H), 8.28 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.75 (t, J = 8.07 Hz, 1H), 7.43 (d, J = 10.27 Hz, 1H), 7.33 (d, J = 7.83 Hz, 1H), 4.44 - 5.37 (m, 3H), 4.27 - 4.42 (m, 1H), 3.21 - 3.45 (m, 5H), 3.03 - 3.19 (m, 2H), 2.96 - 3.03 (m, 1H), 2.85-3.01 (m, 3H), 1.45 - 1.75 (m, 9H), 1.36 (s, 4H), 1.05 - 1.17 (m, 1H). LCMS: 633.4 [ . Step-5: Preparation of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-N-(6-(4-((7-ethyl-6-oxo-5,6-dihydro -1,5-naphthyridin-3-yl)methyl)piperazin-1- 5 yl)hexyl)-2-fluoro-N-methylbenzamide To a stirred solution of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluoro-N-methyl-N-(6-(piperazin-1 -yl)hexyl)benzamide trifluoroacetate (Int-4, 350 mg, 0. 552 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 147 mg, 0.663 mmol, 1.2 eq.) in DMF (4 mL) was added K2CO3 (152 mg, 1.104 mmol, 2 eq.). Progress of the 10 reaction was monitored by TLC. The reaction mixture was then allowed to stir at room temperature for 6h, diluted with ice cold water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude obtained was purified by prep. HPLC eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the title compound (111 mg, 24%). 15 1 H NMR (400 MHz, DMSO-d6) į 11.80 (s, 1H), 8.48 (q, J = 5.34 Hz, 1H), 8.38 - 8.42 (m, 1H), 8.32 - 8.36 (m, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.25 Hz, 1H), 7.71 - 7.75 (m, 1H), 7.54 - 7.61 (m, 1H), 7.39 - 7.46 (m, 1H), 7.32 (d, J = 8.25 Hz, 1H), 3.52 - 3.57 (m, 2H), 3.48 (t, J = 7.19 Hz, 1H), 3.35 - 3.43 (m, 1H), 3.25 (d, J = 6.13 Hz, 1H), 3.13 (t, J = 7.00 Hz, 1H), 2.85-3.00 (d, 3H), 2.53 (d, J = 7.38 Hz, 2H), 2.38 (s, 4H), 2.21 - 2.29 (m, 2H), 1.47 - 1.57 (m, 8H), 1.38 - 1.46 (m, 2H), 1.32 (d, J = 3.00 Hz, 4H), 1.17 (t, = 7.44 Hz, 20 3H), 1.07 (d, J = 3.00 Hz, 2H). LCMS: 819.2 [M+H] + . HPLC purity 99.7%. Example S9. Preparation of 4-(3-(4-(4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin- 3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carbonyl)-3-flu orophenyl)-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (Compound No.10) Step-1: Preparation of tert-butyl 4-((1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo-2- thioxoimidazolidin-1-yl)-2-fluorobenzoyl)piperidin-4-yl)meth yl)piperazine-1-carboxylate (Int-1) To a stirred solution 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo- 2- thioxoimidazolidin-1-yl)-2-fluorobenzoic acid (Int-D, 557 mg, 1.23 mmol, 0.7 eq.) and tert-butyl 4- 5 (piperidin-4-ylmethyl)piperazine-1-carboxylate (Int-G, 500 mg, 1.76 mmol, 1 eq.) in DMF (5 mL), N,N- diisopropylethylamine (0.61 mL, 3.52 mmol, 2 eq.) and HATU (802 mg, 2.11 mmol, 1.2 eq.) were added at room temperature. Progress of the reaction was monitored by TLC. The reaction mixture was allowed to stir at room temperature for 16h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium 10 sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 5% MeOH in DCM to afford Int-1 (2.71 g, crude). 1H NMR (400 MHz, DMSO-d6) į 8.41 (d, J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.31 Hz, 1H), 7.59 (t, J = 7.58 Hz, 1H), 7.43 (d, J = 9.29 Hz, 1H), 7.30-7.38 (m, 1H), 4.51 (d, J = 12.72 Hz, 1H), 3.42 (d, J = 12.72 Hz, 1H), 3.35-3.26 (m, 4H), 3.13-3.05 (m, 1H), 2.86-2.78 (m, 2H), 2.26-2.31 (m, 4H), 2.18-2.14 (m, 15 2H), 1.85-1.69 (m, 2H), 1.64-1.91 (m, 2H), 1.55 (s, 6H), 1.41 (s, 9H). LCMS: 717.2 [M+H] + . Step-2: Preparation of 4-(3-(3-fluoro-4-(4-(piperazin-1-ylmethyl)piperidine-1-carbo nyl)phenyl)-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl )benzonitrile trifluoroacetate (Int-2) A stirred solution of tert-butyl 4-((1-(4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo- 2-thioxoimidazolidin-1-yl)-2-fluorobenzoyl)piperidin-4-yl)me thyl)piperazine-1-carboxylate (Int-5, 500 mg, 20 0.698 mmol, 1 eq.) in dichloromethane (10 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (1.2 mL). Progress of the reaction was monitored by TLC. The reaction mixture was allowed to warm up to room temperature and stir for 16h and the volatiles were evaporated. The crude obtained was washed with diethyl ether (2 x 25 mL) to afford the TFA salt of Int-2 (520 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) į 8.79 - 9.24 (m, 2H), 8.41 (d, J = 8.31 Hz, 1H), 8.29 (s, 1H), 8.02 - 25 8.11 (m, 1H), 7.59 (t, J = 7.58 Hz, 1H), 7.44 (d, J = 9.78 Hz, 1H), 7.34 (d, J = 8.31 Hz, 1H), 5.07 (s, 1H), 4.52 (d, J = 12.72 Hz, 1H), 3.57 (d, J = 4.40 Hz, 1H), 3.38 - 3.48 (m, 1H), 3.04 - 3.19 (m, 4H), 2.76 - 2.90 (m, 3H), 2.69 (s, 3H), 2.03 (s, 1H), 1.89 (d, J = 12.23 Hz, 1H), 1.73 (d, J = 11.25 Hz, 1H), 1.56 (s, 5H), 1.03 - 1.25 (m, 2H). LCMS: 617.56 [M+H] + . Step-3: Preparation of 4-(3-(4-(4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin- 3-yl)methyl)piperazin-30 1-yl)methyl)piperidine-1-carbonyl)-3-fluorophenyl)-4,4-dimet hyl-5-oxo-2-thioxoimidazolidin-1-yl)-2- (trifluoromethyl)benzonitrile A stirred solution of 4-(3-(3-fluoro-4-(4-(piperazin-1-ylmethyl)piperidine-1-carbo nyl)phenyl)-4,4- dimethyl-5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl )benzonitrile trifluoroacetate (Int-2, 400 mg, 0.649 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 130 mg, 0.578 mmol, 0.7 eq.) in DMF (5 mL) was added K 2 CO 3 (179 mg, 1.3 mmol, 2 eq.). Progress of the reaction was monitored by TLC. The reaction mixture was allowed to stir at room temperature for 16h, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic extract was washed with 5 water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by prep. HPLC eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the title compound (135 mg, 26%). 1H NMR (400 MHz, DMSO-d6) į 11.81 (s, 1H), 8.40 (d, J = 8.13 Hz, 1H), 8.35 (d, J = 1.75 Hz, 1H), 8.29 (d, J = 1.75 Hz, 1H), 8.08 (dd, J = 8.25, 1.63 Hz, 1H), 7.73 (s, 1H), 7.55 - 7.61 (m, 2H), 7.42 (dd, 10 J = 9.88, 1.75 Hz, 1H), 7.32 (dd, J = 8.00, 1.75 Hz, 1H), 4.50 (d, J = 12.88 Hz, 1H), 3.55 (s, 2H), 3.41 (d, J = 13.01 Hz, 1H), 3.08 (t, J = 11.94 Hz, 1H), 2.77 - 2.85 (m, 1H), 2.52 - 2.57 (m, 2H), 2.38 (s, 7H), 2.15 (t, J = 6.25 Hz, 2H), 1.81 (d, J = 11.38 Hz, 2H), 1.64 - 1.74 (m, 1H), 1.55 (s, 6H), 1.17 (t, J = 7.44 Hz, 4H), 0.98 - 1.09 (m, 2H). LCMS: 803.3 [M+H] + . Example S10. Preparation of 2-chloro-4-(3-(4-(4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naph thyridin-3-15 yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)-4,4-d imethyl-5-oxo-2-thioxoimidazolidin-1- yl)benzonitrile (Compound No.3) Step-1: Preparation of (1-(4-nitrophenyl)piperidin-4-yl)methanol (Int-1) To a stirred solution of piperidin-4-ylmethanol hydrochloride (SM-1, 30 g, 197.8 mmol, 1.0 eq.) in 20 DMF (600 mL) and 1-fluoro-4-nitrobenzene (SM-2, 33.4 g, 237.4 mmol, 1.2 eq.), K2CO3 (81.9 g, 593.5 mmol, 3.0 eq.) was added at 0 °C under argon atmosphere. The resulting reaction mixture was allowed to stir at 90 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (1L) and the resulting precipitate was filtered, washed with water (500mL) and dried under vacuum to afford (1-(4-nitrophenyl)piperidin-4-yl)methanol (Int-1, 40 g, 87%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.02 (d, J = 9.65 Hz, 2H), 6.99 (d, J = 9.21 Hz, 2H), 4.50 (t, J = 5.26 Hz, 1H), 4.05 (d, J = 13.15 Hz, 2H), 3.27 (t, J = 5.48 Hz, 2H), 2.97 (t, J = 12.06 Hz, 2H), 1.62 - 1.78 (m, 3H), 1.10 - 1.22 (m, 2H). LCMS: 237.19 [M+H] + . Step-2: Preparation of (1-(4-aminophenyl)piperidin-4-yl)methanol (Int-2) 5 To a stirred solution of (1-(4-nitrophenyl)piperidin-4-yl)methanol (Int-1, 10 g, 42.3 mmol, 1.0 eq.) in MeOH:EtOAc (1:1, 300 mL), 10% Pd/C (2 g, 20% w/w) was added at ambient temperature under argon atmosphere. The resulting reaction mixture was stirred at 100 psi under hydrogen atmosphere for 16h in an autoclave. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was filtered through a pad of celite, washed with MeOH (200 mL) and the filtrate was evaporated 10 under reduced pressure to afford (1-(4-aminophenyl)piperidin-4-yl)methanol (Int-2, 10 g, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 6.68 (d, J = 8.77 Hz, 2H), 6.47 (d, J = 8.33 Hz, 2H), 4.51 (br s, 2H), 4.43 (s, 1H), 3.28 - 3.34 (m, 4H), 2.44 (t, J = 11.62 Hz, 2H), 1.71 (d, J = 12.28 Hz, 2H), 1.40 (d, J = 4.82 Hz, 1H), 1.16 - 1.29 (m, 2H). LCMS: 207.14 [M+H] + . Step-3: Preparation of ethyl 2-((4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)amino)-2-methy lpropanoate 15 (Int-3) o a stirred solution of (1-(4-aminophenyl)piperidin-4-yl)methanol (Int-2, 10 g, 48.54 mmol, 1.0 eq.) in DMF (200 mL), ethyl 2-bromo-2-methylpropanoate (SM-3, 11.35 g, 58.25 mmol, 1.2 eq.) and K2CO3 (20.09 g, 145.63 mmol, 3.0 eq.) were added at 0 °C under argon atmosphere. Progress of the reaction was monitored by TLC. The resulting reaction mixture was allowed to stir at 80 ^ for 16h, cooled down to room 20 temperature, diluted with water (500 mL) and extracted with ethyl acetate (2 x 500 mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude obtained was purified with a flash column and the pure fractions were combined and concentrated under reduced pressure to provide ethyl 2-((4-(4- (hydroxymethyl)piperidin-1-yl)phenyl)amino)-2-methylpropanoa te (Int-3, 10 g, 64%). 25 1 H NMR (400 MHz, DMSO-d 6 ) į 6.71 (d, J = 8.33 Hz, 2H), 6.40 (d, J = 8.33 Hz, 2H), 5.28 (s, 1H), 4.43 (s, 1H), 4.05 (q, J = 6.58 Hz, 2H), 3.38 (d, J = 11.40 Hz, 2H), 3.28 (d, J = 5.26 Hz, 2H), 2.45 (t, J = 11.62 Hz, 2H), 1.71 (d, J = 11.84 Hz, 2H), 1.39 (s, 6H), 1.15 - 1.28 (m, 3H), 1.10 (t, J = 6.80 Hz, 3H). LCMS: 321.48 [M+H] + . Step-4: Preparation of 2-chloro-4-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4, 4-dimethyl-5-oxo- 30 2-thioxoimidazolidin-1-yl)benzonitrile (Int-4) To a stirred solution of ethyl 2-((4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)amino)-2- methylpropanoate (Int-3, 30 g, 93.75 mmol, 1.0 eq.) in DMSO (120 mL), 2-chloro-4- isothiocyanatobenzonitrile (SM-4, 21.8 g, 112.5 mmol, 1.2 eq.) was added at 0 °C under argon atmosphere. Progress of the reaction was monitored by TLC. The resulting reaction mixture was allowed to stir at 80 °C for 4h, cooled down to room temperature and diluted with water (500 mL). The resulting precipitate was filtered, washed with water (500 mL) and diethyl ether (300 mL) and dried under vacuum to afford 2-chloro- 5 4-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4,4-dimethy l-5-oxo-2-thioxoimidazolidin-1- yl)benzonitrile (Int-4, 35 g, 81%). 1H NMR (400 MHz, DMSO-d 6 ) į 8.17 (d, J = 7.83 Hz, 1H), 8.01 (s, 1H), 7.71 (d, J = 7.34 Hz, 1H), 7.14 (d, J = 8.31 Hz, 2H), 7.03 (d, J = 8.31 Hz, 2H), 4.41 - 4.52 (m, 1H), 3.80 (d, J = 12.23 Hz, 2H), 3.26 - 3.29 (m, 2H), 2.72 (t, J = 11.74 Hz, 2H), 1.77 (d, J = 12.23 Hz, 2H), 1.46 (s, 6H), 1.14 - 1.31 (m, 3H). 10 LCMS: 469.47 [M+H] + . Step-5: Preparation of (1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thiox oimidazolidin-1- yl)phenyl)piperidin-4-yl)methyl methanesulfonate (Int-5) To a stirred solution of 2-chloro-4-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4, 4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl)benzonitrile (Int-4, 10 g, 21.36 mmol, 1.0 eq.) in DCM (300 mL), MsCl 15 (1.81 mL, 23.5 mmol, 1.1 eq.), TEA (6 mL, 42.73 mmol, 2.0 eq.) were added at 0 °C under argon atmosphere. Progress of the reaction was monitored by TLC. The resulting reaction mixture was allowed to stir at RT for 1h, diluted with water (500 mL) and extracted with DCM (2 x 500mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to afford (1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thiox oimidazolidin-1- 20 yl)phenyl)piperidin-4-yl)methyl methanesulfonate (Int-5, 11.7 g, crude). 1H NMR (400 MHz, CDCl 3 ) į 7.75 - 7.84 (m, 1H), 7.68 (s, 1H), 7.52 (d, J = 8.33 Hz, 1H), 7.13 (d, J = 7.45 Hz, 2H), 6.99 (d, J = 7.45 Hz, 2H), 4.13 (d, = 5.26 Hz, 2H), 3.82 (d, J = 11.84 Hz, 2H), 3.03 (s, 3H), 2.77 - 2.94 (m, 2H), 1.91 (d, J = 13.15 Hz, 2H), 1.57 (s, 6H), 1.34 - 1.52 (m, 3H). LCMS: 547.46 [M+H] + . 25 Step-6: Preparation of tert-butyl 4-((1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)phenyl)piperidin-4-yl)methyl)piperaz ine-1-carboxylate (Int-6) To a stirred solution of (1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)phenyl)piperidin-4-yl)methyl methanesulfonate (Int-5, 11.7 g, 21.48 mmol, 1.0 eq.) in acetonitrile (120 mL), tert-butyl piperazine-1-carboxylate (SM-5, 4 g, 21.48 mmol, 1.0 eq.), DIPEA (7.5 30 mL, 42.96 mmol, 2.0 eq.) and KI (350 mg, 2.14 mmol, 0.1 eq.) were added at 0 °C under argon atmosphere. Progress of the reaction was monitored by TLC. The resulting reaction mixture was allowed to stir at 80 °C for 16h, cooled down to room temperature, concentrated under reduce pressure, diluted with water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude obtained was purified with flash column and the pure fraction were combined and concentrated under reduced pressure to afford tert-butyl 4-((1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-th ioxoimidazolidin- 1-yl)phenyl)piperidin-4-yl)methyl)piperazine-1-carboxylate (Int-6, 10 g, 73%). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.17 (d, J = 8.29 Hz, 1H), 8.00 - 8.03 (m, 1H), 7.71 (dd, J = 8.35, 5 1.91 Hz, 1H), 7.10 (d, J = 8.81 Hz, 2H), 6.59 (d, J = 8.94 Hz, 2H), 3.46 (dd, J = 9.08, 7.63 Hz, 1H), 3.22 – 3.42 (m, 8H), 2.91 (t, J = 8.81 Hz, 1H), 2.24 - 2.39 (m, 6H), 1.54 - 1.70 (m, 3H), 1.45 (s, 6H), 1.39 (s, 9H). LCMS: 637.80 [M+H] + . Step-7: Preparation of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl )piperidin-1- yl)phenyl)-2-thioxoimidazolidin-1-yl)benzonitrile trifluoroacetate (Int-7) 10 To a stirred solution of tert-butyl 4-((1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl)phenyl)piperidin-4-yl)methyl)piperaz ine-1-carboxylate (Int-6, 5.2 g, 8.16 mmol, 1.0 eq.) in DCM (104 mL), TFA (26 mL, 5 vol) was added at 0 °C under argon atmosphere. Progress of the reaction was monitored by TLC. The resulting reaction mixture was stirred at RT for 16h, concentrated under reduced pressure, diluted with water (100 mL) and extracted with diethyl ether (2 x 100 mL). The 15 aqueous layer was basified with saturated bicarbonate solution (200 ml, pH ~8) and the resulting solid was filtered, washed with water (500 mL) and diethyl ether (300 mL) and dried under vacuum to afford 2-chloro- 4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl)piperidi n-1-yl)phenyl)-2-thioxoimidazolidin-1- yl)benzonitrile trifluoroacetate (Int-7, 4 g, 93%). 1H NMR (400 MHz, DMSO-d 6 ) į 8.16 (d, J = 8.31 Hz, 1H), 8.01 (s, 1H), 7.71 (d, J = 8.31 Hz, 1H), 20 7.10 (d, J = 8.80 Hz, 2H), 6.59 (d, J = 8.31 Hz, 2H), 3.57 (s, 4H), 3.34 - 3.39 (m, 2H), 3.15 - 3.27 (m, 2H), 2.68 (s, 4H), 2.25 - 2.34 (m, 4H), 2.13 (d, J = 5.87 Hz, 2H), 1.55 - 1.70 (m, 2H), 1.45 (s, 6H). LCMS: 537.63 [M+H] + . Step-8: Preparation of 2-chloro-4-(3-(4-(4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naph thyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)-4,4-d imethyl-5-oxo-2-thioxoimidazolidin-1- 25 yl)benzonitrile To a stirred solution of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl )piperidin-1- yl)phenyl)-2-thioxoimidazolidin-1-yl)benzonitrile trifluoroacetate (Int-7, 4 g, 7.46 mmol, 1.0 eq.) in DMF (40 mL), 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 1.4 g, 6.71 mmol, 0.9 eq.) and DIPEA (2.6 mL, 14.92 mmol, 2.0 eq.) were added at 0 °C under argon atmosphere. Progress of the reaction 30 was monitored by TLC. The resulting reaction mixture was stirred at ambient temperature for 16h, diluted with water (200 mL), the solid residue was filtered and washed with water (500 mL), diethyl ether (300 mL), acetonitrile (100 ml), DCM (200 mL) and dried under vacuum to afford 2-chloro-4-(3-(4-(4-((4-((7-ethyl-6- oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl) methyl)piperidin-1-yl)phenyl)-4,4-dimethyl-5- oxo-2-thioxoimidazolidin-1-yl)benzonitrile (2.3 g, 42%). 1 H NMR (400 MHz, DMSO-d 6 ) į 11.79 (s, 1H), 8.33 (s, 1H), 8.14 (d, J = 8.31 Hz, 1H), 7.99 (d, J = 1.47 Hz, 1H), 7.66 - 7.73 (m, 2H), 7.56 (s, 1H), 7.08 (d, J = 8.80 Hz, 2H), 6.57 (d, J = 8.80 Hz, 2H), 3.50 - 3.58 (m, 2H), 3.43 (t, J = 8.31 Hz, 1H), 3.31 - 3.36 (m, 1H), 3.19 - 3.26 (m, 2H), 2.88 (t, J = 8.56 Hz, 1H), 2.50 - 2.56 (m, 2H), 2.19 - 2.46 (m, 10H), 2.05 - 2.17 (m, 1H), 1.52 - 1.67 (m, 3H), 1.36 - 1.49 (m, 6H), 1.12 5 - 1.24 (m, 3H). LCMS: 723.3 [M+H] + . Example S11. Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((7-ethyl-6-oxo- 5,6-dihydro- 1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)hexyl)(methyl)am ino)phenyl)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate formate (Compound No.14) 10 Step-1: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6-oxo hexyl)amino) phenyl)-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate (Int-1) To a stirred solution of Int-F (500 mg, 0.891 mmol, 1 eq.) in ethyl acetate (40 mL) was added Dess- 15 Martin periodinane (DMP, 1.1 g, 2.67 mmol, 3 eq.) portion wise at 0 °C. The reaction mixture was heated to 80 °C for 2h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with 50% aqueous Na2S2O3 solution (10 mL) and sat. NaHCO3 solution (15 mL) and the aqueous solution was extracted with ethyl acetate (2 x 25 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum 20 to afford Int-1 (450 mg, 92%). 1H NMR (400 MHz, DMSO-d 6 ) δ 9.64 (s, 1H), 6.98 (d, J = 8.31 Hz, 2H), 6.58 (d, J = 8.80 Hz, 2H), 5.67 (s, 1H), 4.39 (d, J = 5.87 Hz, 1H), 3.22 (t, J = 6.60 Hz, 2H), 2.55 - 2.80 (m, 5H), 2.51 – 2.54 (m, 2H), 2.40 (t, J = 7.09 Hz, 2H), 1.96 - 2.15 (m, 12H), 1.56-1.69 (m, 2H), 1.11 - 1.59 (m, 10H), 0.23 (s, 3H). LCMS: 560.4 [M+H] + . 25 Step 2: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((7-ethyl-6-oxo- 5,6-dihydro-1,5- naphthyridin-3-yl)methyl)piperazin-1-yl)hexyl)(methyl)amino) phenyl)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate formate ) To a solution of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int-C, 0.5 g, 1.3 mmol, 1 eq.) in methanol (10 mL) were added (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-30 (methyl(6-oxohexyl)amino)phenyl)-3-oxo-2,3,6,7,8,11,12,13,14 ,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate (Int-1, 869 mg, 1.55 mmol, 1.2 eq.), triethylamine (0.18 mL, 1.29 mmol, 1 eq.) and acetic acid (0.7 mL) at room temperature and the mixture was allowed to stir for 2h. To this reaction mixture was added NaCNBH 3 (160 mg, 2.59 mmol, 2 eq.) portion wise at 0 °C. The reaction mixture was warmed up to room temperature and allowed to stir for 16h. Progress of the reaction was 5 monitored by TLC. After completion of the reaction, cold water (50 mL) was added and extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic extract was washed with water (60 mL), brine (50 mL) and dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by prep. HPLC purification method eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the formate salt of the title compound (100 mg, 9%). 10 1 H NMR (400 MHz, DMSO-d6) į 11.81 (s, 1H), 8.36 (s, 1H), 8.13 (s, 1H), 7.75 (s, 1H), 7.61 (s, 1H), 6.92 (d, J = 8.31 Hz, 2H), 6.54 (d, J = 8.31 Hz, 2H), 5.65 (s, 1H), 4.33 (d, J = 6.36 Hz, 1H), 3.58 (s, 2H), 3.17 (s, 3H), 2.70 - 2.77 (m, 5H), 2.59 - 2.68 (m, 4H), 2.10 - 2.47 (m, 10H), 2.02 - 2.08 (m, 5H), 1.80 - 1.98 (m, 6H), 1.59 - 1.72 (m, 3H), 1.33 - 1.44 (m, 6H), 1.21 (s, 5H), 1.14 (t, J = 7.34 Hz, 3H), 0.17 (s, 3H). LCMS: 816.4 [M+H] + . HPLC purity 92.1%. 15 Example S12. Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((4-((7-ethyl-6- oxo-5,6- dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)methyl)p iperidin-1- yl)hexyl)(methyl)amino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11, 12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate (Compound No.18) 20 Step-1: Preparation of tert-butyl 4-((1-(6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-m ethyl-3- oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a]phenanthren-11- yl)phenyl)(methyl)amino)hexyl)piperidin-4-yl)methyl)piperazi ne-1-carboxylate (Int-2) To a stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6- oxohexyl)amino)phenyl)-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthren-25 17-yl acetate (Int-1, 100 mg, 0.35 mmol, 1.0 eq.) and tert-butyl 4-(piperidin-4-ylmethyl)piperazine-1- carboxylate (Int-G, 240 mg, 0.42 mmol, 1.2 eq.) in methanol (5 mL) was added catalytic amount of acetic acid (0.5 mL) at room temperature and resulting mixture was allowed to stir for 4h. To this reaction mixture, NaCNBH 3 (45 mg, 0.70 mmol, 2 eq.) was added portion wise at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. After 5 completion of the reaction, the reaction mixture was quenched with cold water (20 mL) and extracted with 10% MeOH in DCM (2 x 20 mL). The combined organic extract was washed with water (30 mL), brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was triturated with n-pentane and diethyl ether to afford Int-2 (330 mg, 93%). 1H NMR (400 MHz, DMSO-d6) į 8.68 - 8.86 (m, 1H), 6.98 (d, J = 8.31 Hz, 2H), 6.59 (d, J = 7.82 10 Hz, 2H), 5.68 (s, 1H), 4.35-4.38 (m, 1H), 3.49 - 3.55 (m, 3H), 3.46 (d, J = 9.29 Hz, 1H), 3.35 - 3.42 (m, 6H), 3.14 - 3.26 (m, 4H), 2.91 - 3.13 (m, 3H), 2.67 - 2.90 (m, 8H), 2.55 - 2.66 (m, 3H), 2.19 - 2.43 (m, 6H), 2.04 - 1.83 (m, 21H), 1.16 - 1.52 (m, 9H), 0.29 - 0.55 (m, 3H). LCMS: 414.60 [M/2+H] + . Step-2: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6-(4- (piperazin-1- ylmethyl)piperidin-1-yl)hexyl)amino)phenyl)-3-oxo-2,3,6,7,8, 11,12,13,14,15,16,17-dodecahydro-1H- 15 cyclopenta[a]phenanthren-17-yl acetate trifluoroacetate (Int-3) A stirred solution tert-butyl 4-((1-(6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-m ethyl-3- oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a]phenanthren-11- yl)phenyl)(methyl)amino)hexyl)piperidin-4-yl)methyl)piperazi ne-1-carboxylate (Int-2, 220 mg, 0.26 mmol, 1 eq.) in dichloromethane (5 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (0.41 mL, 20 20 eq.). The reaction mixture was allowed to warm up to room temperature and stir for 2h. Progress of the reaction was monitored by TLC. After complete consumption of Int-2, the volatiles were evaporated under reduced pressure. The crude obtained was washed with n-heptane and diethyl ether to afford the TFA salt of Int-3 (500 mg, crude). 1H NMR (400 MHz, DMSO-d 6 ) δ 8.68 - 8.99 (m, 2H), 7.68 - 7.73 (m, 1H), 7.48 (t, = 7.09 Hz, 25 1H), 7.24 (t, J = 6.85 Hz, 1H), 6.91 - 7.13 (m, 1H), 6.72 (s, 1H), 5.68 (s, 1H), 4.42 (d, J = 6.36 Hz, 1H), 3.49 (d, J = 10.76 Hz, 3H), 3.16 - 3.35 (m, 6H), 2.70 - 2.93 (m, 18H), 2.55 - 2.65 (m, 8H), 1.51-2.05 (m, 20H), 0.86 (t, J = 6.60 Hz, 3H). LCMS: 364.8 [M/2+H] + . Step-3: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((4-((7-ethyl-6- oxo-5,6-dihydro-1,5- naphthyridin-3-yl)methyl)piperazin-1-yl)methyl)piperidin-1-y l)hexyl)(methyl)amino)phenyl)-13-methyl-3- 30 oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a]phenanthren-17-yl acetate A stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6-(4- (piperazin-1- ylmethyl)piperidin-1-yl)hexyl)amino)phenyl)-3-oxo-2,3,6,7,8, 11,12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate trifluoroacetate (Int-3, 600 mg, 0.826 mmol, 1 eq.) and 7- (chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 130 mg, 0.578 mmol, 0.7 eq.) in acetonitrile (6 mL) was added DIPEA (0.58 mL, 3.30 mmol, 4 eq.) and the resulting reaction mixture was allowed to stir at room temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, water (30 mL) was added and extracted with ethyl acetate (2 x 30 mL). The combined organic extract was 5 washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product obtained was purified by prep. HPLC eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the title compound (45 mg, 7%). 1H NMR (400 MHz, DMSO-d 6 ) δ 11.81 (s, 1H), 8.35 (s, 1H), 7.73 (s, 1H), 7.57 (s, 1H), 6.97 (d, J = 8.33 Hz, 2H), 6.58 (d, J = 8.33 Hz, 2H), 5.68 (s, 1H), 4.39 (d, J = 6.14 Hz, 1H), 3.56 (s, 2H), 3.24 (d, J = 10 7.02 Hz, 3H), 2.81 (s, 3H), 2.54 - 2.77 (m, 8H), 2.31 - 2.43 (m, 6H), 2.06 - 2.24 (m, 8H), 2.00 (s, 4H), 1.73 - 1.97 (m, 5H), 1.62 - 1.73 (m, 5H), 1.36 - 1.60 (m, 10H), 1.18 (t, J = 7.24 Hz, 9H), 0.20 - 0.26 (m, 3H). LCMS: 913.9 [M+H] + . HPLC purity 95.1%. Example S13. Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((4-((7-ethyl-6- oxo-5,6- dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)methyl)p iperidin-1-yl)-6-15 oxohexyl)(methyl)amino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11, 12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate (Compound No.16) Step-1: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate (Int-1) 20 To a stirred solution of SM-1 (10 g, 21 mmol, 1.0 eq.) in methanol (150 mL) and THF (150 mL) were added KOAc (20.6 g, 210 mmol, 10 eq.) and iodine (13.1 g, 105 mmol, 5 eq.) at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with sodium thiosulfate (Na 2 S 2 O 3 ) solution (50 g in 30 mL water) and extracted with ethyl acetate (2 x 200 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under vacuum to afford Int-1 (8.0 g, 82%). 1H NMR (400 MHz, DMSO-d 6 ) į 11.91 (br s, 1H), 6.91 (d, J = 8.31 Hz, 2H), 6.44 (d, J = 8.31 Hz, 5 2H), 5.67 (s, 1H), 4.37 (m, 1H), 2.75 (s, 2H), 2.61 (d, J = 4.40 Hz, 3H), 2.30 - 2.40 (m, 1H), 2.07 - 2.16 (s, 5H), 1.99 (s, 6H), 1.63 - 1.77 (m, 2H), 1.21 - 1.45 (m, 5H), 0.86 (t, J = 6.60 Hz, 1H), 0.16 - 0.28 (m, 3H). LCMS: 462.28 [M+H] + . Step-2: Preparation of 6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3 -oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- 10 yl)phenyl)(methyl)amino)hexanoic acid (Int-2) To a stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3- oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a]phenanthren-17-yl acetate (Int-1, 5 g, 10.83 mmol, 1.0 eq.) and 6-bromohexanoic acid (SM-2, 10.56 g, 54.13 mmol, 5 eq.) in ethanol (50 mL) and water (50 mL) was added NaHCO3 (7.37 g, 86.76 mmol, 10 eq.) at room temperature. The reaction mixture 15 was heated to 80 °C and stirred for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (120 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic extract was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 80% ethyl acetate in heptane to afford Int-2 (0.90 g, 15%). 20 1 H NMR (400 MHz, DMSO-d 6 ) į 11.94 (br s, 1H), 6.98 (d, J = 7.83 Hz, 2H), 6.58 (d, J = 7.34 Hz, 2H), 5.67 (s, 1H),4.36 - 4.43 (m, 1H), 3.18 - 3.24 (m, 2H), 2.65 - 2.88 (m, 2H), 2.54 - 2.64 (m, 3H), 2.29 - 2.42 (m, 3H), 2.06 - 2.29 (m, 3H), 1.85 - 2.04 (m, 6H), 1.62 - 1.78 (m, 8H), 1.21 - 1.60 (m, 8H), 0.24 (s, 3H). LCMS: 576.67 [M+H] + . Step-3: Preparation of tert-butyl 4-((1-(6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-m ethyl-3-25 oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta [a]phenanthren-11- yl)phenyl)(methyl)amino)hexanoyl)piperidin-4-yl)methyl)piper azine-1-carboxylate (Int-3) To a stirred solution of 6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3 -oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- yl)phenyl)(methyl)amino)hexanoic acid (Int-2, 0.35 g, 0.61 mmol, 1 eq.) and tert-butyl 4-(piperidin-4-30 ylmethyl)piperazine-1-carboxylate (Int-G) in dichloromethane (10 mL) were added N,N- diisopropylethylamine (0.32 mL, 1.82 mmol, 3 eq.) and propylphosphonic anhydride (T3P, 0.45 mL 1.53 mmol, 2.5 eq.) at room temperature. Progress of the reaction was monitored by TLC. The reaction mixture was allowed to stir at room temperature for 16h, diluted with water (30 mL) and extracted with DCM (2 x 30 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by combiflash chromatography eluting with 70% ethyl acetate in heptane to afford Int-3 (0.25 g, 49%). 1H NMR (400 MHz, DMSO-d 6 ) į 7.95 (s, 1H), 6.97 (d, = 8.31 Hz, 2H), 6.57 (d, J = 8.31 Hz, 2H), 5 5.66 (s, 1H), 4.28 - 4.41 (m, 1H), 3.93 - 4.17 (m, 1H), 3.59 - 3.84 (m, 4H), 3.28 (s, 6H), 3.21 (t, J = 6.85 Hz, 2H), 2.87 - 3.03 (m, 4H), 2.80 (s, 2H), 2.63 - 2.76 (m, 3H), 2.52 - 2.63 (m, 4H), 2.26 (s, 7H), 2.05 - 2.18 (m, 6H), 1.99 (s, 2H), 1.85 - 1.96 (m, 2H), 1.60 - 1.83 (m, 4H), 1.42 - 1.55 (m, 4H), 1.38 (s, 9H), 1.20 - 1.32 (m, 2H), 0.77 - 1.02 (m, 3H). LCMS: 841.07 [M+H] + . Step-4: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6-oxo -6-(4-(piperazin-1-10 ylmethyl)piperidin-1-yl)hexyl)amino)phenyl)-3-oxo-2,3,6,7,8, 11,12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate trifluoroacetate (Int-4) A stirred solution of tert-butyl 4-((1-(6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-m ethyl- 3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopen ta[a]phenanthren-11- yl)phenyl)(methyl)amino)hexanoyl)piperidin-4-yl)methyl)piper azine-1-carboxylate (Int-3, 0.25 g, 0.30 15 mmol, 1 eq.) in dichloromethane (2 mL) was cooled to 0 °C followed by addition of trifluoroacetic acid (0.30 mL, 10 eq.). The reaction mixture was warmed to room temperature and stirred for 3h. Progress of the reaction was monitored by TLC. After complete consumption of the starting material, volatiles evaporated, and the crude obtained was triturated with diethyl ether to afford the TFA salt of Int-4 (0.25 g, crude). LCMS: 741.7 [M+H] + . 20 Step-5: Preparation of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-(4-((4-((7-ethyl-6- oxo-5,6-dihydro-1,5- naphthyridin-3-yl)methyl)piperazin-1-yl)methyl)piperidin-1-y l)-6-oxohexyl)(methyl)amino)phenyl)-13- methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-c yclopenta[a]phenanthren-17-yl acetate To a stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methyl(6-oxo -6-(4- (piperazin-1-ylmethyl)piperidin-1-yl)hexyl)amino)phenyl)-3-o xo-2,3,6,7,8,11,12,13,14,15,16,17- 25 dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate trifluoroacetate (Int-4, 0.25 g, 0.34 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 0.75 mg, 0.34 mmol, 1 eq.) in acetonitrile (10 mL) was added N,N-diisopropylethylamine (0.18 mL, 1.02 mmol, 3 eq.) at room temperature under inert atmosphere. The reaction mixture was stirred at 80 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (30 mL) and extracted 30 with DCM (2 x 30 mL). The combined organic extract was washed with water (50 mL), brine (50 mL) and dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by prep. HPLC eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford the title compound (30 mg, 9.6%). 1 H NMR (400 MHz, DMSO-d 6 ) į 11.81 (s, 1H), 8.34 (s, 1H), 7.73 (s, 1H), 7.57 (s, 1H), 6.97 (d, J = 8.31 Hz, 2H), 6.57 (d, J = 8.31 Hz, 2H), 5.67 (s, 1H), 4.28 - 4.41 (m, 2H), 3.78 (d, J = 12.23 Hz, 1H), 3.55 (s, 2H), 3.21 (t, J = 7.09 Hz, 2H), 2.92 (t, J = 11.98 Hz, 1H), 2.80 (s, 3H), 2.63 - 2.77 (m, 2H), 2.61 (s, 1H), 2.53 (d, J = 7.83 Hz, 3H), 2.28 - 2.42 (m, 8H), 2.19 - 2.27 (m, 3H), 2.12 - 2.18 (m, 2H), 2.09 (s, 6H), 1.99 (s, 5 4H), 1.81 - 1.96 (m, 3H), 1.60 - 1.74 (m, 6H), 1.41 - 1.51 (m, 4H), 1.31 - 1.40 (m, 2H), 1.21 - 1.30 (m, 4H), 1.17 (t, J = 7.34 Hz, 3H), 0.77 - 0.99 (m, 3H). LCMS: 928.22 [M+H] + . HPLC purity 99.8%. Example S14. Preparation of 6-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3 -oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- yl)phenyl)(methyl)amino)hexyl 4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- 10 yl)methyl)piperazine-1-carboxylate (Compound No.17) To a stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6- hydroxyhexyl)(methyl)amino)phenyl)-13-methyl-3-oxo-2,3,6,7,8 ,11,12,13,14,15,16,17-dodecahydro-1H- cyclopenta[a]phenanthren-17-yl acetate (Int-F, 500 mg, 0.89 mmol, 1 eq.) in dichloromethane (5 mL) was 15 added triethylamine (0.31 mL, 2.23 mmol, 2.5 eq.) and catalytic amount of DMAP (~1 mg, 0.025 eq.). The reaction mixture was cooled to 0 °C followed by addition of 4-nitrophenyl chloroformate (538 mg, 2.67 mmol, 3 eq.). The reaction mixture was warmed to room temperature and stirred for 2h. Progress of the reaction was monitored by TLC. After complete consumption of Int-F, an additional amount of triethylamine (0.1 mL, 0.89 mmol, 1 eq.) was added followed by 3-ethyl-7-(piperazin-1-ylmethyl)-1,5- 20 naphthyridin-2(1H)-one (Int-C, 367 mg, 1.33 mmol, 1.5 eq.) and the resulting reaction mixture was stirred at room temperature for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, water (30 mL) was added, and the aqueous mixture was extracted with DCM (2 x 30 mL). The combined organic extract was washed with water (50 mL), brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude obtained was purified by prep. HPLC 25 purification eluting with Mobile phase A: 0.1% FA in water and Mobile phase B: acetonitrile to afford Compound 17 (85 mg, 11%). 1H NMR (400 MHz, DMSO-d6) į 12.15 (s, 1H), 8.49 (s, 1H), 7.80 (s, 1H), 7.73 (s, 1H), 7.02 (d, J = 7.45 Hz, 2H), 6.57 - 6.74 (m, 2H), 5.68 (s, 1H), 4.41 (d, J = 6.14 Hz, 2H), 3.99 (t, J = 6.58 Hz, 4H), 3.21 - 3.29 (m, 3H), 2.91 - 3.18 (m, 4H), 2.84 (s, 3H), 2.57 (d, J = 7.02 Hz, 3H), 2.31 - 2.42 (m, 2H), 2.19 - 2.24 30 (m, 1H), 2.12 - 2.17 (m, 2H), 2.10 (s, 4H), 1.99 (s, 3H), 1.86 - 1.94 (m, 2H), 1.65 - 1.77 (m, 3H), 1.50 - 1.56 (m, 2H), 1.43 (d, J = 14.03 Hz, 4H), 1.26 (d, J = 17.98 Hz, 6H), 1.19 (t, J = 7.24 Hz, 5H), 0.22 (s, 3H). LCMS: 860.99 [M+H] + . HPLC purity 95.7%. Example S15. Preparation of 3-ethyl-7-((4-((1-(6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13 -methyl-3- oxo-17-(prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodec ahydro-1H-cyclopenta[a]phenanthren-11- 5 yl)phenyl)(methyl)amino)hexyl)piperidin-4-yl)methyl)piperazi n-1-yl)methyl)-1,5-naphthyridin-2(1H)- one (Compound No.19) Step-1: Preparation of (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-(methylamino )phenyl)-17- (prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-3-one (Int- 10 1) To a stirred solution of (8S,11R,13S,14S,17S)-11-(4-(dimethylamino)phenyl)-17-hydroxy -13- methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-do decahydro-3H-cyclopenta[a]phenanthren-3- one (SM-1, 5 g, 11.63 mmol, 1.0 eq.) in MeOH:THF (1:1, 50 mL), KOAc (11.4 g, 111.6 mmol, 10.0 eq.) was added followed by a solution of I2 (8.8 g, 58.15 mmol, 3.0 eq.) in THF (25 mL) dropwise at 0 °C under 15 argon atmosphere and the resulting reaction mixture was allowed to stir at 0 °C for 1h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was quenched with 5% sodium thiosulfate solution (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine solution (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue obtained was triturated with diethyl ether (2520 mL) and filtered to give (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-(methylamino )phenyl)-17- (prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro- 3H-cyclopenta[a]phenanthren-3-one (Int-1, 4 g, 82%). 1H NMR (400 MHz, DMSO-d6) į 6.99 (d, J = 7.82 Hz, 1H), 6.89 (d, J = 7.82 Hz, 1H), 6.75 (d, J = 7.82 Hz, 1H), 6.44 (d, J = 8.31 Hz, 1H), 5.64 (s, 1H), 5.41 (s, 1H), 4.18 - 4.40 (m, 1H), 2.83 - 2.92 (m, 2H), 25 2.69 - 2.80 (m, 3H), 2.52 - 2.66 (m, 2H), 2.28 - 2.45 (m, 2H), 2.04 - 2.27 (m, 3H), 1.90 - 2.04 (m, 2H), 1.72 - 1.90 (m, 3H), 1.59 (s, 2H), 1.19 - 1.37 (m, 2H), 1.09 (t, J = 6.85 Hz, 1H), 0.86 (t, J = 6.11 Hz, 1H), 0.42 (d, J = 2.93 Hz, 3H). LCMS: 416.62 [M+H] + . Step-2: Preparation of (8S,11R,13S,14S,17S)-17-hydroxy-11-(4-((6- hydroxyhexyl)(methyl)amino)phenyl)-13-methyl-17-(prop-1-yn-1 -yl)-1,2,6,7,8,11,12,13,14,15,16,17- 5 dodecahydro-3H-cyclopenta[a]phenanthren-3-one (Int-2) To a stirred solution of (8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-11-(4-(methylamino )phenyl)- 17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahyd ro-3H-cyclopenta[a]phenanthren-3-one (Int- 1, 3 g, 7.22 mmol, 1.0 eq.) in EtOH:H2O (45 mL, 2:1) were added NaHCO3 (1.8 g, 21.65 mmol, 3.0 eq.) and 6-bromohexan-1-ol (4.72 mL, 36.09 mmol, 5.0 eq.) at room temperature. The reaction mixture was stirred at 10 80 °C for 16h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine solution (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude obtained was purified by silica gel flash column and the pure fractions were combined and concentrated under reduced pressure to afford 15 (8S,11R,13S,14S,17S)-17-hydroxy-11-(4-((6-hydroxyhexyl)(meth yl)amino)phenyl)-13-methyl-17-(prop-1- yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclo penta[a]phenanthren-3-one (Int-2, 1.4 g, 37%). 1H NMR (400 MHz, DMSO-d6) į 6.97 (d, J = 8.31 Hz, 2H), 6.60 (d, J = 8.80 Hz, 2H), 5.65 (s, 1H), 5.05 - 5.11 (m, 1H), 4.26 - 4.36 (m, 2H), 3.34 - 3.41 (m, 2H), 3.15 - 3.27 (m, 2H), 2.70 - 2.89 (m, 4H), 2.53 - 20 2.67 (m, 2H), 2.28 - 2.47 (m, 2H), 2.06 - 2.28 (m, 4H), 1.92 - 2.05 (m, 2H), 1.74 - 1.86 (m, 4H), 1.55 - 1.68 (m, 2H), 1.36 - 1.53 (m, 4H), 1.29 (d, J = 2.93 Hz, 6H), 0.36 - 0.46 (m, 3H). LCMS: 516.75 [M+H] + . Step-3: Preparation of 6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(p rop-1-yn-1-yl)- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- yl)phenyl)(methyl)amino)hexanal (Int-3) 25 To a solution of (8S,11R,13S,14S,17S)-17-hydroxy-11-(4-((6-hydroxyhexyl)(meth yl)amino)phenyl)- 13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17 -dodecahydro-3H-cyclopenta[a]phenanthren- 3-one (Int-2, 1.4 g, 2.71 mmol, 1.0 eq.) in EtOAc (14 mL) was added Dess–Martin periodinane (2.3 g, 5.43 mmol, 2.0 eq.) at room temperature and the reaction mixture was stirred at 80 °C under argon atmosphere for 1h. Progress of the reaction was monitored by TLC. After completion of the reaction, the reaction 30 mixture was quenched with aq. sodium bicarbonate and aq. sodium thiosulfate solution (100 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine solution (100 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(p rop-1-yn-1-yl)- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- yl)phenyl)(methyl)amino)hexanal (Int-3, 1.6 g, crude). LCMS: 514.56 [M+H] + . Step-4: Preparation of 3-ethyl-7-((4-((1-(6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13 -methyl-3-oxo-17- 5 (prop-1-yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro- 1H-cyclopenta[a]phenanthren-11- yl)phenyl)(methyl)amino)hexyl)piperidin-4-yl)methyl)piperazi n-1-yl)methyl)-1,5-naphthyridin-2(1H)- one To a solution of 6-((4-((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(p rop-1-yn-1-yl)- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11-10 yl)phenyl)(methyl)amino)hexanal (Int-3, 1 g, 1.94 mmol, 1 eq.) in MeOH (10 mL), 3-ethyl-7-((4-(piperidin- 4-ylmethyl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one trifluoroacetate (Int-C1, 715 mg, 1.94 mmol, 1 eq.) and glacial acetic acid (0.1 mL) were added at room temperature and stirred for 2h. To this reaction mixture was added NaCNBH 3 (609 mg, 9.7 mmol, 5 eq.) at 0 °C and the reaction mixture was allowed to warm up to room temperature and stir for 16h. Progress of the reaction was monitored by TLC. 15 After completion of the reaction, the reaction mixture was quenched with water (100 mL) and extracted with DCM (2 x 200 mL). The combined organic layer was washed with water (100 mL), brine solution (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The crude obtained was purified by Prep.HPLC and the pure fractions were lyophilized to afford 3-ethyl-7-((4-((1-(6-((4- ((8S,11R,13S,14S,17S)-17-hydroxy-13-methyl-3-oxo-17-(prop-1- yn-1-yl)-2,3,6,7,8,11,12,13,14,15,16,17-20 dodecahydro-1H-cyclopenta[a]phenanthren-11-yl)phenyl)(methyl )amino)hexyl)piperidin-4- yl)methyl)piperazin-1-yl)methyl)-1,5-naphthyridin-2(1H)-one (64 mg). 1H NMR (400 MHz, DMSO-d 6 ) į 11.84 - 12.00 (m, 1H), 8.34 - 8.45 (m, 1H), 8.13 (s, 1H), 7.75 (s, 1H), 7.53 - 7.62 (m, 1H), 6.96 (d, J = 8.63 Hz, 2H), 6.52 (d, J = 8.63 Hz, 2H), 5.65 (s, 1H), 5.13 (s, 1H), 3.55 - 3.74 (m, 2H), 3.41 - 3.53 (m, 2H), 3.21 - 3.27 (m, 4H), 2.93 - 3.04 (m, 3H), 2.71 - 2.88 (m, 8H), 2.51 - 25 2.61 (m, 6H), 2.07 - 2.28 (m, 6H), 1.70 - 2.07 (m, 8H), 1.54 - 1.66 (m, 6H), 1.48 (s, 4H), 1.22 - 1.36 (m, 10H), 1.18 (t, J = 7.44 Hz, 2H), 0.41 (s, 3H). LCMS: 867.9 [M+H] + . Example S16. Preparation of 3-ethyl-7-((4-(6-(((8S,13S,14S,17S)-13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl)oxy)hexyl)piperazin- 1-yl)methyl)-1,5-naphthyridin-2(1H)-one (Compound No.21) 5 Step-1: Preparation of (8S,13S,14S,17S)-13-methyl-1,2,4,6,7,8,12,13,14,15,16,17- dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxola n]-17-ol (Int-1) To a stirred solution of (8S,13S,14S,17S)-17-hydroxy-13-methyl-1,2,6,7,8,11,12,13,14, 15,16,17- dodecahydro-3H-cyclopenta[a]phenanthren-3-one (SM-1, 1.0 g, 3.67 mmol, 1 eq.) in toluene (10 mL), PTSA (63 mg, 0.36 mmol, 0.1 eq.), ethylene glycol (SM-2, 1.12 mL, 18.35 mmol, 5 eq.) were added and 10 resulting reaction mixture allowed to stir at 100 °C for 3h. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction, the reaction was quenched with aqueous sat. NaHCO3 solution (30 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product obtained was purified by combiflash column chromatography eluting with 40% EtOAc in 15 heptane to afford Int-1 (600 mg, 52%). 1H NMR (400 MHz, DMSO-d6) į 5.47 - 5.53 (m, 1H), 4.55 (d, J = 3.29 Hz, 1H), 3.83 - 3.89 (m, 4H), 3.57 (t, J = 7.89 Hz, 1H), 2.31 - 2.44 (m, 1H), 2.16 (s, 2H), 2.03 - 2.12 (m, 3H), 1.72 - 1.94 (m, 4H), 1.59 - 1.71 (m, 4H), 1.34 - 1.45 (m, 1H), 1.00 - 1.10 (m, 3H), 0.62 (s, 3H). LCMS: 317.2 [M+H] + . Step-2: Preparation of (8S,13S,14S,17S)-17-((6-chlorohexyl)oxy)-13-methyl-1,2,4,6,7 ,8,12,13,14,15,16,17- 20 dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxola ne] (Int-2) A stirred solution of (8S,13S,14S,17S)-13-methyl-1,2,4,6,7,8,12,13,14,15,16,17- dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxola n]-17-ol (Int-1, 1.0 g, 3.16 mmol, 1 eq.) and 1-bromo-6-chlorohexane (SM-3, 3.15 g, 15.82 mmol, 5 eq.) in DMF (10 mL) was cooled to 0 °C followed by addition of NaH (1.26 g, 31.6 mmol, 10 eq.). After complete addition, the reaction mixture was allowed to stir at 50 °C for 16h. Progress of the reaction was monitored by TLC/LCMS. The reaction mixture was then quenched with cold water (20 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layer was washed with water (50 mL), brine (50 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The crude obtained was purified by combiflash column chromatography eluting with 30% 5 EtOAc in heptane to afford Int-2 (640 mg, 46%). 1H NMR (400 MHz, DMSO-d 6 ) į 5.47 (s, 1H), 3.86 (s, 4H), 3.37 - 3.45 (m, 2H), 3.28 (d, J = 4.25 Hz, 4H), 2.31 - 2.44 (m, 1H), 2.23 - 2.29 (m, 4H), 2.01 - 2.18 (m, 4H), 1.72 - 2.01 (m, 2H), 1.59 - 1.72 (m, 2H), 1.36 - 1.51 (m, 6H), 1.21 - 1.35 (m, 6H), 0.66 (s, 3H). LCMS: 435.55 [M+H] + . Step-3: Preparation of tert-butyl 4-(6-(((8S,13S,14S,17S)-13-methyl-1,2,4,6,7,8,12,13,14,15,16 ,17-10 dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxola n]-17-yl)oxy)hexyl)piperazine-1- carboxylate (Int-3) To a stirred solution of (8S,13S,14S,17S)-17-((6-chlorohexyl)oxy)-13-methyl- 1,2,4,6,7,8,12,13,14,15,16,17-dodecahydrospiro[cyclopenta[a] phenanthrene-3,2'-[1,3]dioxolane] (Int-2, 640 mg, 1.47 mmol, 1 eq.) in DMF (12 mL), N-Boc-piperazine (SM-6, 275 mg, 1.47 mmol, 1 eq.), Cs2CO3 (958 15 mg, 2.94 mmol, 2 eq.) and KI (122 mg, 0.735 mmol, 0.5 eq.) were added. The reaction mixture was allowed to stir at 80 °C for 16h. Progress of the reaction was monitored by TLC/LCMS. After completion of the reaction, the reaction mixture was diluted with ice cold water (40 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with water (30 mL), brine (30 mL), dried over anhydrous Na 2 SO 4 and concentrated under reduced pressure. The crude product was purified by combiflash column 20 chromatography eluting with 40% EtOAc in heptane to afford Int-3 (400 mg, 46%). 1H NMR (400 MHz, DMSO-d 6 ) į 5.48 (s, 1H), 3.87 (s, 4H), 3.40 (t, J = 8.55 Hz, 2H), 3.23 - 3.30 (m, 6H), 2.22 - 2.28 (m, 6H), 2.00 - 2.21 (m, 8H), 1.61 - 1.71 (m, 3H), 1.39 - 1.51 (m, 8H), 1.38 (s, 9H), 1.21 - 1.35 (m, 6H), 0.66 (s, 3H). LCMS: 585.2 [M+H] + . Step-4: Preparation of (8S,13S,14S,17S)-13-methyl-17-((6-(piperazin-1-yl)hexyl)oxy) - 25 1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]p henanthren-3-one trifluoroacetate (Int-4) To a stirred solution of tert-butyl 4-(6-(((8S,13S,14S,17S)-13-methyl-1,2,4,6,7,8,12,13,14,15,16 ,17- dodecahydrospiro[cyclopenta[a]phenanthrene-3,2'-[1,3]dioxola n]-17-yl)oxy)hexyl)piperazine-1-carboxylate (Int-3, 400 mg, 0.684 mmol, 1.0 eq.) in DCM (5 mL) under nitrogen atmosphere, TFA (1.5 mL, 10 vol) was added at 0 °C. The reaction mixture was allowed to warm up to room temperature and stir for 4h. Progress 30 of the reaction was monitored by TLC. After completion of the reaction, the volatiles were evaporated under reduced pressure and the residue was triturated with diethyl ether (30 mL) to afford Int-4 (300 mg, 79%). 1 H NMR (400 MHz, DMSO-d 6 ) į 8.98 - 9.40 (m, 2H), 5.58 (s, 1H), 3.96 - 5.28 (m, 2H), 3.31 - 3.42 (m, 5H), 2.92 - 3.14 (m, 4H), 2.86 (dt, J = 14.76, 5.19 Hz, 1H), 2.76 (dd, J = 16.01, 2.38 Hz, 1H), 1.67 – 2.48 (m, 12H), 1.19 – 1.65 (m, 14H), 0.83 (s, 3H). LCMS: 441.58 [M+H] + . Step-5: Preparation of 3-ethyl-7-((4-(6-(((8S,13S,14S,17S)-13-methyl-3-oxo- 5 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl)oxy)hexyl)piperazin-1- yl)methyl)-1,5-naphthyridin-2(1H)-one To a stirred solution of (8S,13S,14S,17S)-13-methyl-17-((6-(piperazin-1-yl)hexyl)oxy) - 1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]p henanthren-3-one trifluoroacetate (Int-4, 200 mg, 0.453 mmol, 1 eq.) and 7-(chloromethyl)-3-ethyl-1,5-naphthyridin-2(1H)-one (Int-B, 100 mg, 10 0.453 mmol, 1 eq.) in acetonitrile (2 mL), DIPEA (0.24 mL, 1.36 mmol, 3 eq.) and KI (37 mg, 0.22 mmol, 0.5 eq.) were added. The reaction mixture was allowed to stir at 80 °C for 4h. Progress of the reaction was monitored by TLC. After completion of the reaction, water (30 mL) was added, and the aqueous mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic extract was washed with water (30 mL), brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude 15 obtained was purified by combiflash column chromatography eluting with 17% MeOH in DCM to afford the title compound (45 mg, 20%). 1H NMR (400 MHz, DMSO-d 6 ) δ 11.89 (s, 1H), 9.67 - 9.88 (m, 1H), 8.39 (s, 1H), 7.74 (s, 1H), 7.56 (s, 1H), 5.57 (s, 1H), 3.57 - 3.70 (m, 2H), 3.36 - 3.48 (m, 3H), 3.26 - 3.30 (m, 1H), 2.85 (dt, J = 14.88, 5.19 Hz, 2H), 2.76 (dd, J = 16.07, 2.44 Hz, 1H), 2.52 - 2.58 (m, 2H), 2.40 - 2.47 (m, 3H), 2.34 - 2.40 (m, 2H), 20 2.27 - 2.34 (m, 3H), 2.23 (d, J = 11.13 Hz, 2H), 2.08 - 2.16 (m, 1H), 1.92 - 2.02 (m, 1H), 1.80 - 1.92 (m, 2H), 1.52 - 1.60 (m, 3H), 1.37 - 1.52 (m, 4H), 1.21 - 1.36 (m, 9H), 1.15 - 1.21 (m, 4H), 1.10 - 1.15 (m, 1H), 0.83 (s, 3H). LCMS: 627.94 [M+H] + . HPLC purity 96.8%. Example S17. Preparation 2-chloro-4-(3-(4-(4-((4-((5-fluoro-2-methyl-3-oxo-3,4-dihydr oquinoxalin-6- yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)-4,4-d imethyl-5-oxo-2-thioxoimidazolidin-1- 25 yl)benzonitrile (Compound No.22) ^
Step-1: Synthesis of (1-(4-nitrophenyl)piperidin-4-yl)methanol (Int-1) To a stirred solution of piperidin-4-ylmethanol. HCl (SM-1, 30 g, 197.8 mmol, 1.0 eq) in DMF (600 mL), 1-fluoro-4-nitrobenzene (SM-2, 33.4 g, 237.4 mmol, 1.2 eq), K 2 CO 3 (81.9 g, 593.5 mmol, 3.0 eq) were 5 added at 0 o C under argon atmosphere. The resultant reaction mixture was stirred at 90 o C for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of the starting material, the reaction mixture was cooled to room temperature and diluted with water (1 L), filtered the obtained solids and washed with water (500mL), dried under vacuum to afford (1-(4-nitrophenyl)piperidin-4-yl)methanol (Int-1, 40 g, 87%) as a pale yellow solid. MS m/z calcd. For C 12 H 16 N 2 O 3 ([M+H]+) 237.12; found 10 237.19. Step-2: Synthesis of (1-(4-aminophenyl) piperidin-4-yl) methanol (Int-2) To a stirred solution of (1-(4-nitrophenyl) piperidin-4-yl) methanol (Int-1, 10 g, 42.3 mmol, 1.0 eq) in MeOH:EtOAc (1:1, 300 mL), 10% Pd-C (2 g, 20% w/w) was added at ambient temperature under argon atmosphere. The resulting reaction mixture was stirred at 100PSI under Hydrogen atmosphere for 16 h 15 (Autoclave). Progress of the reaction was monitored by TLC. After complete consumption of the starting material, the reaction mixture was filtered through celite bed and washed with MeOH (200 mL), filtrate was evaporated under reduced pressure to afford crude (1-(4-aminophenyl) piperidin-4-yl) methanol (Int- 2, 10 g, Crude) as a pale-yellow gummy. MS m/z calcd. For C 12 H 18 N 2 O ([M+H]+) 207.15; found 207.14. Step-3: Synthesis of ethyl 2-((4-(4-(hydroxymethyl) piperidin-1-yl)phenyl)amino)-2-20 methylpropanoate (Int-3)^ To a stirred solution of (1-(4-aminophenyl) piperidin-4-yl)methanol (Int-2, 10 g, 48.54 mmol, 1.0 eq) in DMF (200 mL), ethyl 2-bromo-2-methylpropanoate (SM-3, 11.35 g, 58.25 mmol, 1.2 eq), K 2 CO 3 (20.09 g, 145.63 mmol, 3.0 eq) were added at 0 o C, under argon atmosphere. The resulting reaction mixture was stirred at 80 o C for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was cooled to room temperature and diluted with water (500 mL), extracted with ethyl acetate (2 x 500mL). The combined organic layer was washed with brine (200 mL), 5 dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain crude compound, which was purified by flash column to obtain ethyl 2-((4-(4-(hydroxymethyl)piperidin-1- yl)phenyl)amino)-2-methylpropanoate (Int-3, 10 g, 64%) as a pale yellow solid. ESI MS m/z calcd. For C18H28N2O3 ([M+H]+) 321.21; found 321.48. Step-4: Synthesis of 2-chloro-4-(3-(4-(4-(hydroxymethyl) piperidin-1-yl)phenyl)-4,4-dimethyl-5-oxo-10 2-thioxoimidazolidin-1-yl)benzonitrile (Int-4)^ To a stirred solution of ethyl 2-((4-(4-(hydroxymethyl) piperidin-1-yl)phenyl)amino)-2-methylpropanoate (Int-3, 30 g, 93.75 mmol, 1.0 eq) in DMSO (120 mL), 2-chloro-4-isothiocyanatobenzonitrile (SM-4, 21.8 g, 112.5 mmol, 1.2 eq) was added at 0 o C under argon atmosphere. The resulting reaction mixture was stirred at 80 o C for 4 h. Progress of the reaction was monitored by TLC. After complete consumption of 15 starting material, the reaction mixture was cooled to room temperature and diluted with water (500 mL) and filtered the obtained solids, washed with water (500 mL) and diethyl ether (300 mL), dried under vacuum to afford 2-chloro-4-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4, 4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)benzonitrile (Int-4, 35 g, 81%) as a pale yellow solid. ESI MS m/z calcd. For C24H25ClN4O2S ([M+H]+) 469.14; found 469.47. 20 Step-5: Synthesis of (1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thiox oimidazolidin-1- yl) phenyl) piperidin-4-yl) methyl methane sulfonate (Int-5)^ To a stirred solution of 2-chloro-4-(3-(4-(4-(hydroxymethyl)piperidin-1-yl)phenyl)-4, 4-dimethyl-5-oxo- 2-thioxoimidazolidin-1-yl)benzonitrile (Int-4, 10 g, 21.36 mmol, 1.0 eq) in DCM (300 mL), MsCl (1.81 mL, 23.5 mmol, 1.1 eq), TEA (6 mL, 42.73 mmol, 2.0 eq) were added at 0 o C under argon atmosphere. 25 The resulting reaction mixture was stirred at RT for 1 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was diluted with water (500 mL) and extracted with DCM (2 x 500mL). The combined organic layer was washed with brine (200 mL), dried over anhydrous sodium sulphate, filtered, evaporated under reduced pressure to afford crude (1-(4- (3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimida zolidin-1-yl)phenyl) piperidin-4- 30 yl)methyl methane sulfonate (Int-5, 11.7 g, Crude) as a yellow gummy semi-solid. ESI MS m/z calcd. For C25H27ClN4O4S2 ([M+H] +) 542.12; found 547.46. Step-6: Synthesis of tert-butyl 4-((1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2- thioxoimidazolidin-1-yl) phenyl)piperidin-4-yl)methyl)piperazine-1-carboxylate (Int-6)^ To a stirred solution of (1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2-thiox oimidazolidin-1- 35 yl)phenyl) piperidin-4-yl)methyl methane sulfonate (Int-5, 11.7 g, 21.48 mmol, 1.0 eq) in Acetonitrile (120 mL), tert-butyl piperazine-1-carboxylate (SM-5, 4 g, 21.48 mmol, 1.0 eq), DIPEA (7.5 mL, 42.96 mmol, 2.0 eq) and KI (350 mg, 2.14 mmol, 0.1 eq) were added at 0 o C, under argon atmosphere. The resulting reaction mixture was stirred at 80 o C for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was cooled to room temperature 5 and evaporated under reduce pressure to obtain crude compound, which was diluted with water (200 mL) and extracted with ethyl acetate (2 x 200mL). The combined organic layer was washed with brine (100 mL), dried over anhydrous sodium sulphate, filtered, and evaporated under reduced pressure to obtain crude compound, which was purified by flash column to afford tert-butyl 4-((1-(4-(3-(3-chloro-4- cyanophenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)ph enyl)piperidin-4-yl)methyl) piperazine-1- 10 carboxylate (Int-6, 10 g, 73%) as an off white solid. ESI MS m/z calcd. For C33H41ClN6O3S ([M+H]+) 637.26; found 637.80. Step-7: Synthesis of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl ) piperidin-1-yl) phenyl)-2-thioxoimidazolidin-1-yl) benzonitrile (Int-7)^^ To a stirred solution of tert-butyl 4-((1-(4-(3-(3-chloro-4-cyanophenyl)-5,5-dimethyl-4-oxo-2- 15 thioxoimidazolidin-1-yl)phenyl)piperidin-4-yl)methyl)piperaz ine-1-carboxylate (Int-6, 5.2 g, 8.16 mmol, 1.0 eq) in DCM (104 mL), TFA (26 mL, 5 vol) was added at 0 o C. under argon atmosphere. The resulting reaction mixture was stirred at RT for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was evaporated under reduced pressure to obtain crude compound, which was diluted with water (100 mL) and washed with diethyl ether (2 X 20 100 mL), the aqueous layer was basified with saturated bicarbonate solution (200 ml, pH up to ~8) and filtered the obtained solid, washed with water (500 mL) and diethyl ether (300 mL), dried under vacuum to afford 2-chloro-4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl ) piperidin-1-yl) phenyl)-2- thioxoimidazolidin-1-yl) benzonitrile (Int-7, 4 g, 93%) as an off white solid. ESI MS m/z calcd. For C 28 H 33 ClN 6 OS ([M+H]+) 537.21; found 537.63. 25 Step-8: Synthesis of 2-chloro-4-(3-(4-(4-((4-((5-fluoro-2-methyl-3-oxo-3,4-dihydr oquinoxalin-6- yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)phenyl)-4,4-d imethyl-5-oxo-2-thioxoimidazolidin-1- yl)benzonitrile ^ To a stirred solution of 2-chloro-4-(4,4-dimethyl-5-oxo-3-(4-(4-(piperazin-1-ylmethyl )piperidin-1- yl)phenyl)-2-thioxoimidazolidin-1-yl)benzonitrile (Int-7, 0.15 g, 0.27 mmol) and 7-(bromomethyl)-8- 30 fluoro-3-methyl-1H-quinoxalin-2-one (Int-A3, 0.075 g, 0.27 mmol) in DMF (1.5 mL) was added DIPEA (0.097 mL, 0.55 mmol) and stirred at room temperature for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was diluted with water (25 mL) and extracted with EtOAc (2 X 50 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to get crude compound, which was35 purified by prep-HPLC to afford 2-chloro-4-(3-(4-(4-((4-((5-fluoro-2-methyl-3-oxo-3,4- dihydroquinoxalin-6-yl)methyl)piperazin-1-yl)methyl)piperidi n-1-yl)phenyl)-4,4-dimethyl-5-oxo-2- thioxoimidazolidin-1-yl)benzonitrile (Compound No.22, 33 mg, 16%) as an off-white solid. 1H NMR (400 MHz, DMSO-d 6 ) į ppm 11.73 - 12.88 (br s, 1 H), 8.09 (d, J = 8.44 Hz, 1 H), 7.94 (d, J = 1.83 Hz, 1 H), 7.65 (dd, J = 8.31, 1.83 Hz, 1 H), 7.49 (d, J = 8.31 Hz, 1 H), 7.20 - 7.27 (m, 1 H), 7.07 (d, J = 5 8.80 Hz, 2 H), 6.55 (d, J = 9.05 Hz, 2 H), 3.61 (s, 2 H), 3.37 - 3.43 (m, 1 H), 3.13 - 3.23 (m, 2 H), 2.85 (t, J = 8.62 Hz, 1 H), 2.40 - 2.48 (m, 7 H), 2.39 (s, 3 H), 2.21 (dd, J = 8.19, 6.48 Hz, 1 H), 2.06 - 2.14 (m, 1 H), 1.58 (d, J = 6.36 Hz, 3 H), 1.41 (s, 6 H); ESI MS m/z calcd. For C 38 H 40 ClFN 8 O 2 S ([M+H]+) 727.2 found 727.2. Example S18. Preparation of 5-((4-((8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3 -oxo-10 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-11- yl)phenyl)(methyl)amino)pentyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (Compound No.23) ^ ^ Step-1: Synthesis of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate To a stirred solution of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int- 5 C, 1.0 g, 3.2 mmol, 1.0 eq) in methanol (20 mL) was added triethyl amine (323 mg, 3.5 mmol, 1.1 eq) at room temperature and stirred for 15 minutes. To this reaction mixture were added tert-butyl 4- formylpiperidine-1-carboxylate (SM-4, 760 mg, 3.5 mmol) and acetic acid (192 mg, 3.2 mmol, 1.0 eq) at room temperature and again stirred for 30 min at room temperature. To this reaction mixture was added NaCNBH3 (396 mg, 6.4 mmol, 2 eq) at 0 o C. The reaction mixture was allowed to room temperature and 10 stirred for 4 h. Progress of the reaction was monitored by TLC. After complete consumption of starting materials, solvents were evaporated under reduced pressure to obtain crude compound, which was triturated with diethyl ether (50 mL) and dried under vacuum to afford tert-butyl 4-((4-((7-ethyl-6-oxo- 5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)meth yl)piperidine-1-carboxylate (1.1 g, crude) as a colourless liquid which was used in next step without any further purification. ESI MS m/z calcd. For 15 C26H39N5O3 ([M+H] + ) 470.3; found 470.2. Step-2: Synthesis of 3-ethyl-7-((4-(piperidin-4-ylmethyl) piperazin-1-yl) methyl)-1,5-naphthyridin- 2(1H)-one hydrochloride salt To a stirred solution of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (1.1 g, 2.3 mmol, 1.0 eq) in 1,4-dioaxne (10 20 mL) was added 4M HCl in 1,4-dioxane (3.5 mL, 3.0 eq) at 0 o C. The resultant reaction mixture was allowed to room temperature and stirred for 12 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the solvents were removed under reduced pressure to get crude compound, which was washed with diethyl ether (3 X 15 mL) and dried under vacuum to afford 3- ethyl-7-((4-(piperidin-4-ylmethyl) piperazin-1-yl) methyl)-1,5-naphthyridin-2(1H)-one hydrochloride salt 25 (900 mg, 94%) as an off white solid. ESI MS m/z calcd. For C 21 H 32 ClN 5 O ([M+H] + ) 370.2; found 370.4. Step-3: Synthesis of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate To a stirred solution of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)- 13-methyl-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]p henanthren-17-yl acetate (SM-5, 10 g, 21 30 mmol, 1.0 eq) in methanol (150 mL) and THF (150 mL) were added KOAc (20.6 g, 210 mmol, 10 eq) and Iodine (13.1 g, 105 mmol, 5 eq) at 0 o C. The resultant reaction mixture was allowed to room temperature and stirred for 3 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was quenched with sodium thiosulfate (Na2S2O3) solution (50 g in 30 mL water) and extracted with ethyl acetate (2 X 200 mL). The combined organic extracts were washed with 35 brine (100 mL) and dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to afford (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14, 15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate (8.0 g, 82%) as an off-white solid, which was used in next step without any further purification. ESI MS m/z calcd. For C 29 H 35 NO 4 ([M+H] + ) 462.26; found 462.28. 5 Step-4: Synthesis of (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6-hydroxyhexyl)(methy l)amino) phenyl)- 13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1 H-cyclopenta[a] phenanthren-17-yl acetate To a solution of (8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-(4-(methylamino) phenyl)-3-oxo- 2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a] phenanthren-17-yl acetate (4 g, 8.67 mmol, 10 1.0 eq) and 6-bromohexan-1-ol (SM-6, 7.81 g, 43.38 mmol, 5 eq) in ethanol (40 mL) and water (40 mL) was added NaHCO3 (7.37 g, 86.76 mmol, 10 eq) at room temperature. The resultant reaction mixture was heated to 80 o C and stirred for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, the reaction mixture was filtered through a pad of celite bed and washed with ethyl acetate (40 mL). Filtrate was concentrated under reduced pressure to obtain crude material, which was 15 diluted with water (120 mL) and extracted with ethyl acetate (2 X 200 mL). The combined organic extracts were washed with brine (100 mL) and dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to obtain crude compound. Which was purified by Combiflash chromatography by eluting with 70% ethyl acetate in heptane to afford (8S,11R,13S,14S,17R)-17-acetyl-11-(4-((6- hydroxyhexyl)(methyl)amino) phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodec ahydro-1H- 20 cyclopenta[a] phenanthren-17-yl acetate (2.6 g, 53%) as an off-white solid. ESI MS m/z calcd. For C 35 H 47 NO 5 ([M+H] + ) 562.35; found 562.40. Step-5: Synthesis of [(8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-[4-[methyl-[5-( 4- nitrophenoxy)carbonyloxypentyl]amino]phenyl]-3-oxo-1,2,6,7,8 ,11,12,14,15,16- decahydrocyclopenta[a]phenanthren-17-yl] acetate 25 To a stirred solution of [(8S,11R,13S,14S,17R)-17-acetyl-11-[4-[5-hydroxypentyl(methy l) amino]phenyl]- 13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta [a] phenanthrene-17-yl] acetate (200 mg, 0.365 mmol, 1 eq) in DCM (10 mL) was added 4-nitrophenylchloroformate (SM-7, 114 mg, 0.547 mmol, 1.5 eq), DMAP (9 mg, 0.073 mmol, 0.2 eq) and triethyl amine (0.25 mL, 1.82 mmol, 5 eq) at 0 0 C. The resultant reaction mixture was allowed to stir at room temperature for 4 h. Progress of the reaction was 30 monitored by TLC and LCMS. After complete consumption of starting material, the reaction mixture was quenched with ice cold water (20 mL) and extracted with 10% MeOH in DCM (2 x 50 mL). The combined organic layer was washed with brine (100 mL) and dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get crude product, which was triturated with diethyl ether twice (2 x 20 mL) to afford [(8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-[4-[methyl-[5-( 4-nitrophenoxy) 35 carbonyloxypentyl]amino]phenyl]-3-oxo-1,2,6,7,8,11,12,14,15, 16-decahydrocyclopenta[a] phenanthren-17- yl] acetate (100 mg, 38% yield) as a light yellow colour solid. ESI MS m/z calcd. For C 41 H 48 N 2 O 9 ([M+2) 712.8; found 713.1.^ Step-6: Synthesis of 5-[4-[(8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3- oxo- 1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-1 1-yl]-N-methyl-anilino]pentyl 4-[[4-[(7- 5 ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl]m ethyl]piperidine-1-carboxylate To a stirred solution of [(8S,11R,13S,14S,17R)-17-acetyl-13-methyl-11-[4-[methyl-[5-( 4- nitrophenoxy)carbonyloxypentyl]amino]phenyl]-3-oxo-1,2,6,7,8 , 11,12,14,15,16- decahydrocyclopenta[a]phenanthren-17-yl] acetate (100 mg, 0.140 mmol, 1 eq) in dichloromethane (15 mL) was added 3-ethyl-7-[[4-(4-piperidylmethyl) piperazin-1-yl]methyl]-1H-1,5-naphthyridin-2- 10 one,hydrochloride (77 mg, 0.21 mmol, 1.5 eq), and DIPEA (0.12 mL, 0.701 mmol, 5 eq). The resultant reaction mixture was allowed to stir at room temperature for 16 h. Progress of the reaction was monitored by TLC and LCMS. After complete consumption of starting material, the reaction was diluted with water (20 mL) and extracted with 5% MeOH in DCM (2 x 20 mL). The combined organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure to get crude compound, which15 was purified by combiflash column chromatography and product was eluted in 100% ethyl acetate to get 5- [4-[(8S,11R,13S,14S,17R)-17-acetoxy-17-acetyl-13-methyl-3-ox o-1,2,6,7,8,11,12,14,15,16- decahydrocyclopenta[a]phenanthren-11-yl]-N-methyl-anilino]pe ntyl 4-[[4-[(7-ethyl-6-oxo-5H-1,5- naphthyridin-3-yl)methyl]piperazin-1-yl]methyl]piperidine-1- carboxylate (57 mg, 43%) as an off-white solid. 20 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.82 (br s, 1 H) 8.35 (br s, 1 H) 7.74 (s, 1 H) 7.57 (s, 1 H) 6.97 (br d, J=8.63 Hz, 2 H) 6.51 - 6.60 (m, 2 H) 5.67 (s, 1 H) 4.39 (br d, J=7.00 Hz, 1 H) 3.82 - 4.01 (m, 4 H) 3.56 (br s, 2 H) 3.23 (br t, J=7.25 Hz, 2 H) 2.81 (s, 3 H) 2.64 - 2.77 (m, 4 H) 2.54 (br s, 4 H) 2.32 - 2.42 (m, 6 H) 2.05 - 2.24 (m, 9 H) 1.85 - 2.02 (m, 6 H) 1.60 - 1.77 (m, 5 H) 1.41 - 1.59 (m, 5 H) 1.22 - 1.39 (m, 5 H) 1.17 (t, J=7.38 Hz, 3 H) 0.57 - 0.97 (m, 3 H) 0.23 (s, 3 H) LCMS: 95.82 %; ESI MS m/z calcd. For 25 C 56 H 74 F 3 N 6 O 7 ([M+H] +) 943.2; found 944.4 HPLC: 95.02 % Example S19. Preparation of N-((1r,4r)-4-((6-cyano-5-(trifluoromethyl)pyridin-3- yl)(methyl)amino)cyclohexyl)-6-(4-((4-((7-ethyl-6-oxo-5,6-di hydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidin-1-yl)pyridazine-3- carboxamide (Compound No.24) ^
Step-1: Synthesis of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate To a stirred solution of 3-ethyl-7-(piperazin-1-ylmethyl)-1,5-naphthyridin-2(1H)-one hydrochloride (Int- 5 C, 1.0 g, 3.2 mmol, 1.0 eq) in methanol (20 mL) was added triethyl amine (323 mg, 3.5 mmol, 1.1 eq) at room temperature and stirred for 15 minutes. To this reaction mixture were added tert-butyl 4- formylpiperidine-1-carboxylate (SM-4, 760 mg, 3.5 mmol) and acetic acid (192 mg, 3.2 mmol, 1.0 eq) at room temperature and again stirred for 30 min at room temperature. To this reaction mixture was added NaCNBH3 (396 mg, 6.4 mmol, 2 eq) at 0 o C. The reaction mixture was allowed to room temperature and 10 stirred for 4 h. Progress of the reaction was monitored by TLC. After complete consumption of starting materials, solvents were evaporated under reduced pressure to obtain crude compound, which was triturated with diethyl ether (50 mL) and dried under vacuum to afford tert-butyl 4-((4-((7-ethyl-6-oxo- 5,6-dihydro-1,5-naphthyridin-3-yl)methyl)piperazin-1-yl)meth yl)piperidine-1-carboxylate (1.1 g, crude) as a colourless liquid which was used in next step without any further purification. ESI MS m/z calcd. For 15 C26H39N5O3 ([M+H] + ) 470.3; found 470.2. Step-2: Synthesis of 3-ethyl-7-((4-(piperidin-4-ylmethyl) piperazin-1-yl) methyl)-1,5-naphthyridin- 2(1H)-one hydrochloride salt To a stirred solution of tert-butyl 4-((4-((7-ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3- yl)methyl)piperazin-1-yl)methyl)piperidine-1-carboxylate (1.1 g, 2.3 mmol, 1.0 eq) in 1,4-dioaxne (10 mL) was added 4M HCl in 1,4-dioxane (3.5 mL, 3.0 eq) at 0 o C. The resultant reaction mixture was allowed to room temperature and stirred for 12 h. Progress of the reaction was monitored by TLC. After 5 complete consumption of starting material, the solvents were removed under reduced pressure to get crude compound, which was washed with diethyl ether (3 X 15 mL) and dried under vacuum to afford 3- ethyl-7-((4-(piperidin-4-ylmethyl) piperazin-1-yl) methyl)-1,5-naphthyridin-2(1H)-one hydrochloride salt (900 mg, 94%) as an off white solid. ESI MS m/z calcd. For C 21 H 32 ClN 5 O ([M+H] + ) 370.2; found 370.4. Step-3: Synthesis of tert-butyl N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]amino] 10 cyclohexyl]carbamate To a stirred solution of 4-amino-2-(trifluoromethyl)benzonitrile (SM-5, 1 g, 5.372 mmol, 1.0 eq) in DMF (30 mL) were added tert-butyl N-(4-oxocyclohexyl)carbamate (SM-6, 1.37 g, 6.447 mmol, 1.2 eq) and chlorotrimethylsilane (1.71 mL, 13.431 mmol, 2.5 eq) at 0 o C . The resultant reaction mixture was stirred for 10 min at 0 o C, followed by drop wise addition of BORANE-THF complex (1 mol/L) in THF (5.37 mL, 15 5.3726 mmol, 1 eq). The resultant reaction mixture was stirred at 0 o C for 2 h, allowed to room temperature and stirred at room temperature for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting materials, the reaction mixture was diluted with ice cold water (20 mL), saturated Na 2 CO 3 solution and extracted with ethyl acetate (2 * 100 mL). The combined organic extracts were washed with water (100 mL), brine (100 mL) and dried over anhydrous sodium sulphate, filtered and 20 concentrated under reduced pressure to obtain crude compound, which was purified by reverse phase column by eluting with 0.1 % HCOOH in water, ACN to afford tert-butyl N-[4-[[6-cyano-5- (trifluoromethyl)-3-pyridyl]amino]cyclohexyl]carbamate (350 mg, 78% yield) as an off white solid. ESI MS m/z calcd. For C 18 H 23 F 3 N 4 O 2 ([M-H] +) 384.3; found 383.2. Step-4: Synthesis of tert-butyl N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl- 25 amino]cyclohexyl]carbamate To a stirred solution of tert-butyl N-[4-[[6-cyano-5-(trifluoromethyl)-3- pyridyl]amino]cyclohexyl]carbamate (300 mg, 0.780 mmol, 1.0 eq) in DMF (15 mL) under nitrogen atmosphere was added 63% of NaH (21 mg, 0.780 mmol, 1.0 eq) portion wise at 0 o C. The reaction mixture was allowed to room temperature and stirred for 30 min then added methyl iodide (0.05 mL, 30 0.780 mmol, 1.0 eq) drop wise at 0 o C. The reaction mixture was allowed to room temperature and stirred for 3h. Progress of the reaction was monitored by TLC. After completion of the reaction, cold water (10 mL) was added and extracted with ethyl acetate (2 X 20 mL). Solvents were evaporated under reduced pressure to get crude compound which was purified by combiflash column by eluting with 15% ethyl acetate in heptane in to afford tert-butyl N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl- 35 amino]cyclohexyl]carbamate (180 mg, 58% yield) as an off white solid. ESI MS m/z calcd. For C 19 H 25 F 3 N 4 O 2 ([M-H] +) 398.4; found 399.2. Step-5: Synthesis of 5-[(4-aminocyclohexyl)-methyl-amino]-3-(trifluoromethyl)pyri dine-2- carbonitrile;hydrochloride. HCl salt To a stirred solution of tert-butyl N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl- amino]cyclohexyl]carbamate (300 mg, 0.753 mmol, 1.0 eq) in DCM (10 mL) under nitrogen atmosphere 5 was added 4M hydrochloric acid (4 mol/L) in 1,4-dioxane (0.5 ml, 7.53 mmol, 4 mol/L, 10 eq) at 0 o C. The resultant reaction mixture was allowed to stir at room temperature for 16h. Progress of the reaction was monitored by TLC. After complete consumption of starting material, solvents were evaporated under reduced pressure to obtain crude material, which was washed with diethyl ether (20 mL) and dried under vacuum to afford 5-[(4-aminocyclohexyl)-methyl-amino]-3-(trifluoromethyl) pyridine-2-carbonitrile 10 hydrochloride salt (250 mg, crude) as an off white solid. ESI MS m/z calcd. For C 14 H 17 F 3 N 4 .ClH ([M-H] +) 334.7; found 334.8. Step-6: Synthesis of 6-chloro-N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methy l- amino]cyclohexyl]pyridazine-3-carboxamide To a stirred solution of 5-[(4-aminocyclohexyl)-methyl-amino]-3-(trifluoromethyl)pyri dine-2- 15 carbonitrile;hydrochloride. HCl salt (450 mg, 1.344 mmol, 1.0 eq) and 6-chloropyridazine-3-carboxylic acid (SM-7, 213 mg, 1.344 mmol, 1.0 eq) in DMF (15 mL) were added T3P (50% in ethylacetate) (0.85 mL, 2.688 mmol, 2.0 eq) and DIPEA (0.7 mL, 4.032 mmol, 3.0 eq) at room temperature and stirred for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting materials the reaction mixture was diluted with water (25 mL) and extracted with ethyl acetate (2 X 30 mL). The 20 combined organic extracts were washed with water (30 mL), brine (50 mL) and dried over anhydrous sodium sulphate. Filtered and concentrated under reduced pressure to obtain crude compound which was purified by combiflash column by eluting with 0-50% ethyl acetate in heptane to afford 6-chloro-N-[4- [[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl-amino]cycloh exyl] pyridazine-3-carboxamide (150 mg, 2 5%) as an off white solid.ESI MS m/z calcd. For C 19 H 18 ClF 3 N 6 O ([M-H] +) 438.8; found 439.31. 25 Step-15: Synthesis of N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl-amino]c yclohexyl]-6-[4-[[4- [(7-ethyl-6-oxo-5H-1,5-naphthyridin-3-yl)methyl]piperazin-1- yl]methyl]-1-piperidyl]pyridazine-3- carboxamide To a stirred solution of 6-chloro-N-[4-[[6-cyano-5-(trifluoro methyl)-3-pyridyl]-methyl- amino]cyclohexyl]pyridazine-3-carboxamide (140 mg, 0.319 mmol, 1.0 eq) in acetonitrile (10 mL) was 30 added 3-ethyl-7-[[4-(4-piperidylmethyl) piperazin-1-yl]methyl]-1H-1,5-naphthyridin-2-one (153 mg, 0.414 mmol, 1.3 eq) and K 2 CO 3 (132 mg, 0.957 mmol, 3.0 eq) at room temperature. The reaction mixture was heated to 90 o C and stirred for 16 h. Progress of the reaction was monitored by TLC. After complete consumption of starting material the reaction was cooled to room temperature and diluted with cold water (20 mL), extracted with ethyl acetate (2 X 30 mL). The combined organic layer was washed with water (30 35 mL), brine (30 mL) and dried over anhydrous sodium sulphate, filtered, and concentrated under reduced pressure to obtain crude compound, which was purified by combi-flash column by eluting with 3-5% methanol in dichloromethane to afford N-[4-[[6-cyano-5-(trifluoromethyl)-3-pyridyl]-methyl- amino]cyclohexyl]-6-[4-[[4-[(7-ethyl-6-oxo-5H-1,5-naphthyrid in-3-yl)methyl]piperazin-1-yl]methyl]-1- piperidyl]pyridazine-3-carboxamide (Compound No.24, 100 mg, 40% yield) as an off white solid. 1H NMR (400 MHz, DMSO-d 6 ^^į^SSP 11.82 (s, 1 H), 8.52 (d, J=2.75 Hz, 1 H), 8.46 (d, J=7.38 Hz, 1 H), 5 8.36 (d, J=1.75 Hz, 1 H), 7.80 (d, J=9.63 Hz, 1 H), 7.74 (s, 1 H), 7.58 (d, J=1.13 Hz, 1 H), 7.42 (d, J=2.63 Hz, 1 H), 7.33 (d, J=9.76 Hz, 1 H), 4.47 (br d, J=13.26 Hz, 2 H), 4.15 - 4.21 (m, 1 H), 4.07 (br d, J=1.25 Hz, 1 H), 3.57 (s, 2 H), 2.94 - 3.08 (m, 5 H), 2.52 - 2.58 (m, 3 H), 2.40 (br d, J=1.63 Hz, 6 H), 2.14 (br d, J=6.88 Hz, 2 H), 1.75 - 1.98 (m, 10 H), 1.56 (br d, J=8.38 Hz, 2 H), 1.16 - 1.24 (m, 3 H), 1.09 (br d, J=10.01 Hz, 2 H); LCMS: 97.51 %; ESI MS m/z calcd. For C 40 H 48 F 3 N 11 O 2 ([M+H] +) 772.8; found 772.4 HPLC: 96.64 % 10 Compound Nos.8, 11, 13, 15, and 20 were prepared similarly. Compound No.8 1H NMR (400 MHz, DMSO-d6)δ11.84(s,1H),8.34- 8.43 (m, 2H), 8.29 (s, 1H), 8.08 (d, J = 7.83 Hz, 1H), 7.74 (s, 1H), 7.58 (d, J = 6.85 Hz, 2H), 7.43 (d, J = 9.78 Hz, 1H), 7.33 (d, J = 4.40 Hz, 1H), 3.58 (d, J = 8.31 Hz, 2H), 3.37 - 3.51 (m, 5H), 3.14 (br s, 1H), 3.00 (s, 2H), 2.85 (s, 2H), 2.54 (s, 1H), 2.27 - 2.41 15 (m, 5H), 2.16 - 2.22 (m, 1H), 1.43 - 1.65 (m, 9H), 1.31 (d, J = 5.87 Hz, 2H), 1.17 (t, J = 7.34 Hz, 3H), 1.09 (d, J = 5.87 Hz, 1H); LCMS: 832.8 [ purity 96.8%. Compound No.11 (400 MHz, DMSO-d6) δ12.35- 12.46 (m, 1H), 8.46 (d, J = 8.38 Hz, 1H), 7.79 (d, J = 9.51 Hz, 1H), 7.60 (d, J = 9.01 Hz, 1H), 7.49 (d, J = 8.25 Hz, 1H), 7.31 (d, J = 9.76 Hz, 1H), 7.24 (t, J = 20 7.69 Hz, 1H), 6.94 (d, J = 2.25 Hz, 1H), 6.82 (dd, J = 9.13, 2.38 Hz, 1H), 4.45 (d, J = 13.13 Hz, 2H), 3.72 - 3.91 (m, 2H), 3.61 (s, 2H), 2.98 (t, J = 11.94 Hz, 2H), 2.85 (s, 4H), 2.32 - 2.47 (m, 9H), 2.12 (d, J = 6.88 Hz, 2H), 1.91 (d, J = 9.51 Hz, 2H), 1.59 - 1.82 (m, 9H), 1.01 - 1.14 (m, 3H). LCMS: 740.9 [M+H] + . Compound No.13 1H NMR (400 MHz, DMSO-d 6 )δ12.43(s,1H),8.58(d,J = 8.25 Hz, 1H), 7.79 (dd, J = 16.26, 25 9.13 Hz, 2H), 7.51 (d, J = 8.25 Hz, 1H), 7.34 (d, J = 9.63 Hz, 1H), 7.23 - 7.29 (m, 2H), 4.43 - 4.55 (m, 3H), 3.82 - 3.94 (m, 1H), 3.66 (s, 2H), 3.42 - 3.59 (m, 4H), 3.09 (t, J = 11.76 Hz, 2H), 2.95 - 3.04 (m, 1H), 2.44 (s, 2H), 2.41 (s, 3H), 2.36 (s, 2H), 2.24 (s, 3H), 2.08 - 2.15 (m, 2H), 1.87 - 1.94 (m, 2H), 1.48 - 1.74 (m, 8H). LCMS: 755.7 [M+H] + . Compound No.15 30 (400 MHz, DMSO-d 6 ) δ11.81(s,1H),8.46(d,J = 8.31 Hz, 1H), 8.36 (s, 1H), 8.25 (s, 1H), 7.80 (d, J = 9.29 Hz, 1H), 7.74 (s, 1H), 7.58 (s, 1H), 7.37 (s, 1H), 7.31 (d, J = 9.78 Hz, 1H), 4.46 (d, J = 12.23 Hz, 2H), 3.80 - 3.94 (m, 2H), 3.57 (s, 2H), 2.99 (t, J = 11.98 Hz, 2H), 2.90 (s, 2H), 2.52 - 2.57 (m, 3H), 2.40 (s, 7H), 2.15 (d, J = 6.36 Hz, 2H), 1.59 - 1.96 (m, 12H), 1.18 (t, J = 7.34 Hz, 3H), 1.06 - 1.14 (m, 2H). LCMS: 738.4 [M+H] + . Compound No.20 1H NMR (400 MHz, DMSO-d 6 ^^į^^^^^^^^V^^^+^^^^^^^^^G^^J = 1.63 Hz, 1H), 8.14 (s, 1H), 7.74 (s, 5 1H), 7.57 (s, 1H), 6.95 (d, J = 8.50 Hz, 2H), 6.58 (d, J = 8.88 Hz, 2H), 6.53 (s, 2H), 5.64 (s, 1H), 5.11 (s, 1H), 4.29 - 4.34 (m, 1H), 3.56 (s, 2H), 3.20 - 3.25 (m, 2H), 2.81 (s, 3H), 2.70 - 2.78 (m, 2H), 2.34 - 2.44 (m, 7H), 2.25 - 2.31 (m, 3H), 2.16 - 2.24 (m, 3H), 2.13 (s, 1H), 2.05 - 2.11 (m, 1H), 1.90 - 2.04 (m, 2H), 1.67 - 1.87 (m, 5H), 1.53 - 1.66 (m, 2H), 1.33 - 1.51 (m, 5H), 1.22 - 1.32 (m, 7H), 1.17 (t, J = 7.44 Hz, 4H). LCMS: 770.2 [M+H] + . 10 BIOLOGICAL ASSAYS Biological Example 1 AR binding assay: To assess AR binding, test compound (top dose 10 ^M, 4 fold serial dilution, 8 point dose response) and control (progesterone) were transferred to the assay plate. Cytosol from LnCaP cells was added to the plate, followed by addition of radiolabeled 3 H-R1881 at a final concentration of 1 nM. 15 The plate was sealed, and the reaction was incubated at 300 rpm at 4 °C for 24 hrs. Radioligand absorption buffer (10 mM Tris-HCl, pH 7.4; 1.5 mM EDTA; 1 mM DTT; 0.25% charcoal; 0.0025% dextran) was then added to the plate, mixed, and incubated at 4 °C for 15 minutes. The plate was then centrifuged at 3000 rpm for 30 minutes at 4 °C. The supernatant was transferred to the scint-tube and Tri-carb was used for scintillation counting. The data was analyzed using GraphPadPrism v5.0 and binding IC50 was determined as 20 the concentration where 50% inhibition of radioligand binding was observed. GR binding assay: To assess GR binding, test compound (top dose 1 ^M, 4 fold serial dilution, 8 point dose response) and control (dexamethasone) are transferred to the assay plate. Cytosol from IM-9 cells is added to the plate, followed by addition of radiolabeled 3 H-Dexamethasone at a final concentration of 1.5 nM. The plate is sealed, and the reaction incubated at 300 rpm at 4 °C for 24 hrs. Radioligand absorption 25 buffer (10 mM Tris-HCl, pH 7.4; 1.5 mM EDTA; 1 mM DTT; 0.25% charcoal; 0.0025% dextran) is then added to the plate, mixed, and incubated at 4 °C for 15 minutes. The plate is then centrifuged at 3000 pm for 30 minutes at 4 °C. The supernatant is transferred to the scint-tube and Tri-carb is used for scintillation counting. The data is analyzed using GraphPadPrism v5.0 and binding IC 50 is determined as the concentration where 50% inhibition of radioligand binding is observed. 30 PR binding assay: Progesterone PR-B receptors from human breast carcinoma T47D cells are used in modified Na 2 HPO 4 /NaH 2 PO 4 buffer pH 7.4. Compounds are screened at a range of doses (top dose 40 nM, 4 fold serial dilution, 8 point dose response) and are dispensed into the assay plate. Supernatant of 1.2 u 10 5 cells aliquot is added to the assay plate and is incubated with 0.5 nM [ 3 H]Progesterone for 20 hours at 4qC. Membranes are filtered and washed, the filters are then counted to determine [ 3 H]Progesterone specifically bound. Binding IC50 is determined as the concentration where 50% inhibition of radioligand binding is observed. ER binding assay: (5Į^ELQGLQJ^is assessed using the LanthaScreen® TR-FRET ER Alpha Competitive Binding kit from ThermoFisherScientific. In this assay, a terbium-labeled anti-GST antibody is 5 used to indirectly label GST-tagged ER Alpha-ligand binding domain (LBD) by binding to its GST tag. Competitive binding to the ER Alpha-LBD (GST) is detected by a test compound’s ability to displace a fluorescent ligand (Fluormone™ ES2 Green tracer) from the ER Alpha-LBD (GST), which results in a loss of FRET signal between the Tb-anti-GST antibody and the tracer. To assess ER binding, test compound (top dose 10 ^M, 4 fold serial dilution, 8 point dose response) and controls (e.g. estradiol) are transferred to the 10 assay plate. The Fluormone™ ES2 Green tracer (3nM final concentration with assay buffer) is added to the assay plate. This is followed by addition of a mixture of the ER Alpha-LBD (GST) and terbium anti-GST antibody. After a 2h incubation period at room temperature, the plate is read on the Envision plate reader and the TR-FRET ratio of 520:495 emissions are calculated and used to determine the IC50 from a dose response curve of the compound. 15 AR antagonism assay: To evaluate AR antagonist activity, test compound was added to the assay plate (top dose 10 ^M, 3 fold serial dilution, 10 point dose response). HEK293 cells stably expressing the full-length androgen receptor were seeded at a density of 20000 cells/well in the assay plate. The assay plate was then incubated at room temperature for 10 minutes and at 37 °C, 5% CO2 for 20 minutes. Testosterone was added to the assay plate at 1 nM final concentration and the assay plate incubated at 37 °C, 5% CO2 for 20 20 h. After the incubation period, Steady-glo was added to the assay plate and mixed at room temperature for 20 minutes on an orbital shaker, before reading out on the EnVision plate reader. GR antagonism assay: To evaluate GR antagonist activity, test compound is added to the assay plate (top dose 5 ^M, 4 fold serial dilution, 8 point dose response). HEK293 cells stably expressing the ligand binding domain of the glucocorticoid receptor are seeded at a density of 40000 cells/well in the assay 25 plate. The assay plate is then incubated at 37 °C, 5% CO 2 for 30 minutes. Dexamethasone is added to the assay plate at 1.5 nM final concentration and the assay plate incubated at 37 °C, 5% CO 2 for 20 h. After the incubation period, Dual-glo luciferase reagent is added to the assay plate and mixed at room temperature for 20 minutes on an orbital shaker, before reading out on the EnVision plate reader. 50 ^L of Stop & Glo reagent is added to assay plate, mixed at room temperature for 20 minutes, and read on the Envision plate 30 reader. PR coactivator antagonist assay: Test compound (top dose 10 ^M, 4 fold serial dilution, 8 point dose response) and/or vehicle is incubated with the 2.5 nM Progesterone Receptor (PR)-LBD and coactivator peptide for 30 minutes at RT. Determination of the amount of complex formed is read spectrofluorimetrically (excitation: 337 nm, emission: 520/490 nm). Test compound-induced inhibition of 10 35 nM progesterone-induced fluorescence response by 50 percent or more (t50%) indicates receptor antagonist activity. ER antagonism assay: To evaluate ER antagonist activity, SK-BR-3 cells are seeded at a density of 30000 cells/well in the assay plate. The assay plate is then incubated at 37 °C, 5% CO 2 for 24 h. A mixture of ERE plasmid and ER in opti-MEM media is incubated with lipofectamine 3000 in Opti-MEM media and incubated at room temperature for 15 minutes. 10 ^L of this transfection mix is added to each well of the 5 assay plate and the assay plate is incubated at 37 °C, 5% CO 2 IRU^^^^K^^^^^^Q0^ȕ-Estradiol in 10 ^L medium or 10 ^L medium (control wells) is added to corresponding wells of aVVD\^SODWH^DQG^LQFXEDWHG^DW^^^^^^^^^ CO 2 for 24 h. After the incubation period, 50 ^L of Dual-glo luciferase reagent is added to the assay plate and mixed at room temperature for 20 mins on an orbital shaker, before reading out on the EnVision plate reader. 50 ^L of Stop & Glo reagent is added to assay plate, mixed at room temperature for 20 minutes, and 10 read on the Envision plate reader. Cell viability assay: LNCap, 22Rv1, MDA-MB-436, MDA-MB-453, and IEC6 cells were seeded at a density of 500-2000 cells/well in 96 well plates, and a ‘T0’ (timepoint 0) was included along with the assay plate. The plates were then incubated at 37 °C, 5% CO2 in a cell culture incubator overnight. On the next day, the ‘T0’ plate was assayed using CellTiterGlo (Promega, Inc) according to the manufacturer’s 15 instructions. The appropriate compounds were diluted in DMSO and added to the assay plate (final DMSO concentration of 0.1-0.2%) on the next day. The assay plates were incubated for 6 days at 37 °C, 5% CO2. After the incubation period, the plates were assayed using CellTiterGlo (Promega, Inc) according to the manufacturer’s instructions and luminescence was read on the EnVision plate reader. Inhibition of the tested compounds was determined by the following formula: Inhibition rate (%) = (1– (RLU compound – RLU 20 day0) / (RLU control – RLU day0))*100%. GraphPadPrism was used to analyze the data and determine GI50/IC50 values. Data obtained for certain compounds disclosed herein in the assays described above in Biological Assay 2 are shown in Table 2 and Table 3. In Table 2, activity is provided as follows: A = IC50 ^100 nM; B = IC50 from >100 nM to ^1,000 25 nM; C = IC50 from >1,000 nM to ^10,000 nM; D = IC50 >10,000 nM; NT = Not tested. Table 2
In Table 3, activity is provided as follows: A = IC 50 ^500 nM; B = IC 50 from >500 nM to ^5,000 nM; C = IC50 from >5,000 nM to ^30,000 nM; D = IC50 >30,000 nM; NT = Not tested. Table 3